**HOW TO BEHAVE ON THE WARDS**

**Be on Time**

Most OB/GYN teams begin rounding between 6 and 7 A.M. If you are expected to “pre-round,” you should give yourself at least 10 minutes per patient that you are following to see the patient and learn about the events that occurred overnight. Like all working professionals, you will face occasional obstacles to punctuality, but make sure this is occasional. When you first start a rotation, try to show up at least 15 minutes early until you get the routine figured out.

**Dress in a Professional Manner**

Even if the resident wears scrubs and the attending wears stiletto heels, you must dress in a professional, conservative manner. Wear a *short* white coat over your clothes unless discouraged (as in pediatrics).

- **Men** should wear long pants, with cuffs covering the ankle, a long collared shirt, and a tie. No jeans, no sneakers, no short-sleeved shirts.
- **Women** should wear long pants or knee-length skirt, blouse or dressy sweater. No jeans, no sneakers, no heels greater than 1 1/2 inches, no open-toed shoes.
- **Both men and women** may wear scrubs occasionally, during overnight call or in the operating room or birthing ward. Do not make this your uniform.

**Act in a Pleasant Manner**

The rotation is often difficult, stressful, and tiring. Smooth out your experience by being nice to be around. Smile a lot and learn everyone's name. If you do not understand or disagree with a treatment plan or diagnosis, do not “challenge.” Instead, say “I'm sorry, I don't quite understand, could you please explain . . .”

Try to look interested to attendings and residents. Sometimes this stuff is boring, or sometimes you're not in the mood, but when someone is trying to teach you something, look grateful and not tortured.

Always treat patients professionally and with respect. This is crucial to practicing good medicine, but on a less important level if a resident or attending spots you being impolite or unprofessional, it will damage your grade and evaluation quicker than any dumb answer on rounds ever could. And be nice to the nurses. Really nice. Learn names; bring back pens and food from pharmaceutical lunches and give them out. If they like you, they can make your life a lot easier and make you look good in front of the residents and attendings.

**Be Aware of the Hierarchy**

The way in which this will affect you will vary from hospital to hospital and team to team, but it is always present to some degree. In general, address your questions regarding ward functioning to interns or residents. Address your medical questions to attendings; make an effort to be somewhat informed on
your subject prior to asking attendings medical questions. But please don’t ask a question just to transparently show off what you know. It’s annoying to everyone. Show off by seeming interested and asking real questions that you have when they come up.

**Address Patients and Staff in a Respectful Way**

Address patients as Sir or Ma’am, or Mr., Mrs., or Miss. Try not to address patients as “honey,” “sweetie,” and the like. Although you may feel these names are friendly, patients will think you have forgotten their name, that you are being inappropriately familiar, or both. Address all physicians as “doctor,” unless told otherwise.

**Be Helpful to Your Residents**

That involves taking responsibility for patients that you’ve been assigned to, and even for some that you haven’t. If you’ve been assigned to a patient, know everything there is to know about her, her history, test results, details about her medical problems, and prognosis. Keep your interns or residents informed of new developments that they might not be aware of, and ask them for any updates as well.

If you have the opportunity to make a resident look good, take it. If some new complication comes up with a patient, tell the resident about it before the attending gets a chance to grill the resident on it. And don’t hesitate to give credit to a resident for some great teaching in front of an attending. These things make the resident’s life easier, and he or she will be grateful and the rewards will come your way.

Volunteer to do things that will help out. So what if you have to run to the lab to follow up on a stat H&H. It helps everybody out, and it is appreciated. Observe and anticipate. If a resident is always hunting around for some tape to do a dressing change every time you round on a particular patient, get some tape ahead of time.

**Respect Patients’ Rights**

1. All patients have the right to have their personal medical information kept private. This means do not discuss the patient’s information with family members without that patient’s consent and do not discuss any patient in hallways, elevators, or cafeterias.
2. All patients have the right to refuse treatment. This means they can refuse treatment by a specific individual (you, the medical student) or of a specific type (no nasogastric tube). Patients can even refuse lifesaving treatment. The only exceptions to this rule are a patient who is deemed to not have the capacity to make decisions or understand situations—in which case a health care proxy should be sought—or a patient who is suicidal or homicidal.
3. All patients should be informed of the right to seek advanced directives on admission. This is often done by the admissions staff, in a booklet. If your patient is chronically ill or has a life-threatening illness, address the subject of advanced directives with the assistance of your attending.
More Volunteering

Be self-propelled, self-motivated. Volunteer to help with a procedure or a difficult task. Volunteer to give a 20-minute talk on a topic of your choice. Volunteer to take additional patients. Volunteer to stay late. The more unpleasant the task, the better.

Be a Team Player

Help other medical students with their tasks; teach them information you have learned. Support your supervising intern or resident whenever possible. Never steal the spotlight, steal a procedure, or make a fellow medical student look bad.

Be Honest

If you don’t understand, don’t know or didn’t do it, make sure you always say that. Never say or document information that is false (for example, don’t say “bowel sounds normal” when you did not listen).

Keep Patient Information Handy

Use a clipboard, notebook, or index cards to keep patient information, including a miniature history and physical, lab, and test results at hand.

Present Patient Information in an Organized Manner

Here is a template for the “bullet” presentation:

“This is a [age]-year-old [gender] with a history of [major history such as abdominal surgery, pertinent OB/GYN history] who presented on [date] with [major symptoms, such as pelvic pain, fever], and was found to have [working diagnosis]. [Tests done] showed [results]. Yesterday the patient [state important changes, new plan, new tests, new medications]. This morning the patient feels [state the patient’s words], and the physical exam is significant for [state major findings]. Plan is [state plan].

The newly admitted patient generally deserves a longer presentation following the complete history and physical format (see below).

Some patients have extensive histories. The whole history can and probably should be present in the admission note, but in ward presentation it is often too much to absorb. In these cases, it will be very much appreciated by your team if you can generate a good summary that maintains an accurate picture of the patient. This usually takes some thought, but it’s worth it.

Document Information in an Organized Manner

A complete medical student initial history and physical is neat, legible, organized, and usually two to three pages long (see Figure 1-1).
The main advantage to doing the OB/GYN clerkship is that you get to see patients. The patient is the key to learning, and the source of most satisfaction and frustration on the wards. One enormously helpful tip is to try to skim this book before starting your rotation. Starting OB/GYN can make you feel like you're in a foreign land, and all that studying the first two years doesn’t help much. You have to start from scratch in some ways, and it will help enormously if you can skim through this book before you start. Get some of the terminology straight, get some of the major points down, and it won’t seem so strange.

Select Your Study Material

We recommend:

- This review book, *First Aid for the Clinical Clerkship in Obstetrics & Gynecology*
- A full-text online journal database, such as www.mdconsult.com (subscription is $99/year for students)
- A small pocket reference book to look up lab values, clinical pathways, and the like, such as Maxwell Quick Medical Reference (ISBN 0964519119, $7)
- A small book to look up drugs, such as *Pocket Pharmacopoeia* (Tarascon Publishers, $8)

As You See Patients, Note Their Major Symptoms and Diagnosis for Review

Your reading on the symptom-based topics above should be done with a specific patient in mind. For example, if a postmenopausal patient comes to the office with increasing abdominal girth and is thought to have ovarian cancer, read about ovarian cancer in the review book that night.

Prepare a Talk on a Topic

You may be asked to give a small talk once or twice during your rotation. If not, you should volunteer! Feel free to choose a topic that is on your list; however, realize that this may be considered dull by the people who hear the lecture. The ideal topic is slightly uncommon but not rare. To prepare a talk on a topic, read about it in a major textbook and a review article not more than two years old, and then search online or in the library for recent developments or changes in treatment.
HOW TO PREPARE FOR THE CLINICAL CLERKSHIP EXAM

If you have read about your core illnesses and core symptoms, you will know a great deal about medicine. To study for the clerkship exam, we recommend:

2 to 3 weeks before exam: Read the entire review book, taking notes.
10 days before exam: Read the notes you took during the rotation on your core content list and the corresponding review book sections.
5 days before exam: Read the entire review book, concentrating on lists and mnemonics.
2 days before exam: Exercise, eat well, skim the book, and go to bed early.
1 day before exam: Exercise, eat well, review your notes and the mnemonics, and go to bed on time. Do not have any caffeine after 2 P.M.

Other helpful studying strategies include:

Study with Friends
Group studying can be very helpful. Other people may point out areas that you have not studied enough and may help you focus on the goal. If you tend to get distracted by other people in the room, limit this to less than half of your study time.

Study in a Bright Room
Find the room in your house or in your library that has the best, brightest light. This will help prevent you from falling asleep. If you don’t have a bright light, get a halogen desk lamp or a light that simulates sunlight (not a tanning lamp).

Eat Light, Balanced Meals
Make sure your meals are balanced, with lean protein, fruits and vegetables, and fiber. A high-sugar, high-carbohydrate meal will give you an initial burst of energy for 1 to 2 hours, but then you'll drop.

Take Practice Exams
The point of practice exams is not so much the content that is contained in the questions but the training of sitting still for 3 hours and trying to pick the best answer for each and every question.

Tips for Answering Questions
All questions are intended to have one best answer. When answering questions, follow these guidelines:

Read the answers first. For all questions longer than two sentences, reading the answers first can help you sift through the question for the key information.
Look for the words “EXCEPT,” “MOST,” “LEAST,” “NOT,” “BEST,” “WORST,” “TRUE,” “FALSE,” “CORRECT,” “INCOR-
RECT,” “ALWAYS,” and “NEVER.” If you find one of these words, circle or underline it for later comparison with the answer.

Evaluate each answer as being either true or false. Example:

Which of the following is least likely to be associated with pelvic pain?
A. endometriosis T
B. ectopic pregnancy T
C. ovarian cancer F
D. ovarian torsion T

By comparing the question, noting LEAST, to the answers, “C” is the best answer.

**SAMPLE PROGRESS NOTES AND ORDERS**

**Terminology**

G (gravidity) 3 = total number of pregnancies, including normal and abnormal intrauterine pregnancies, abortions, ectopic pregnancies, and hydatidiform moles (Remember, if patient was pregnant with twins, $G = 1$.)
P (parity) 3 = number of deliveries > 500 grams or ≥ 24 weeks’ gestation, stillborn (dead) or alive (Remember, if patient was pregnant with twins, $P = 1$.)
Ab (abortion) 0 = number of pregnancies that terminate < 24th gestational week or in which the fetus weighs < 500 grams
LC (living children) 3 = number of successful pregnancy outcomes (Remember, if patient was pregnant with twins, $LC = 2$.)

Or use the “TPAL” system if it is used at your medical school:

T = number of term deliveries (3)
P = number of preterm deliveries (0)
A = number of abortions (0)
L = number of living children (3)

**SAMPLE OBSTETRIC ADMISSION HISTORY AND PHYSICAL**

Date
Time
Identification: 25 yo G3P2
Estimated gestational age (EGA): 38 5/7 weeks
Last menstrual period (LMP): First day of LMP
Estimated date of confinement: Due date (specify how it was determined) by LMP or by ____ wk US (Sonograms are most accurate for dating EGA when done at < 20 weeks.)
Chief complaint (CC): Uterine contractions (UCs) q 7 min since 0100
History of present illness (HPI): 25 yo G3P2 with an intrauterine pregnancy (IUP) at 38 5/7 wks GA, well dated by LMP (10/13/99) and US at 10 weeks GA, who presented to L&D with CC of uterine contractions q 7 min. Prenatal care (PNC) at Highland Hospital (12 visits, first visit at 7 wks GA), uterine size = to dates, prenatal BP range 100–126/64–83. Problem list includes H/o + group B Streptococcus (GBS) and a +PPD with subsequent negative chest x-ray in 5/00. Pt admitted in early active labor with a vaginal exam (VE) 4/90/-2.
Past Obstetric History
'92 NSVD @ term, wt 3,700 g, no complications
'94 NSVD @ term, wt 3,900 g, postpartum hemorrhage
Allergies: NKDA
Medications: PNV, Fe
Medical Hx: H/o asthma (asymptomatic × 7 yrs), UTI × 1 @ 30 wks s/p
Macrobid 100 mg × 7 d, neg PPD with subsequent neg CXR (5/00)
Surgical Hx: Negative
Social Hx: Negative
Family Hx: Mother—DM II, father—HTN
ROS: Bilateral low back pain

PE
General appearance: Alert and oriented (A&O), no acute distress (NAD)
Vital signs: T, BP, P, R
HEENT: No scleral icterus, pale conjunctiva
Neck: Thyroid midline, no masses, no lymphadenopathy (LAD)
Lungs: CTA bilaterally
Back: No CVA tenderness
Heart: II/VI SEM
Breasts: No masses, symmetric
Abdomen: Gravid, nontender
Fundal height: 36 cm
Estimated fetal weight (EFW): 3,500 g by Leopold's
Presentation: Vertex
Extremities: Mild lower extremity edema, nonpitting
Pelvis: Adequate
VE: Dilatation (4 cm)/effacement (90%)/station (−2); sterile speculum exam (SSE)? (Nitrazine?, Ferning?, Pooling?); membranes intact
US (L&D): Vertex presentation confirmed, anterior placenta, AFI = 13.2
Fetal monitor: Baseline FHR = 150, reactive. Toco = UCs q 5 min

Labs
Blood type: A+
Antibody screen: Neg
Rubella: Immune
HbsAg
VDRL: Nonreactive
FTA
GC
Chlamydia
HIV: See prenatal records
1 hr GTT: 105
3 hr GTT
PPD: + s/p neg CXR
CXR: Neg 5/00
AFP: Neg x 3
Amnio
PAP: NL
Hgb/Hct
Urine: + blood, − protein, − glucose, − nitrite, 2 WBCs
GBS: +
Assessment
1. Intrauterine pregnancy @ 38 5/7 wks GA in early active labor
2. Group B strep +
3. H/o + PPD with subsequent – CXR 5/00
4. H/o UTI @ 30 wks GA, s/p Rx—resolved
5. H/o asthma—stable × 7 yrs, no meds

Plan
1. Admit to L&D
2. NPO except ice chips
3. H&H, VDRL, and hold tube
4. D5 LR TRA 125 cc/hr
5. Ampicillin 2 g IV load, then 1 g IV q 4 hrs (for GBS)
6. External fetal monitors (EFMs)
7. Prep and enema

SAMPLE DELIVERY NOTE

Always sign and date your notes.
NSVD of viable male infant over an intact perineum @ 12:35 P.M., Apgars 8&9, wt 3,654 g without difficulty. Position LOA, bulb suction, nuchal cord × 1 reducible. Spontaneous delivery of intact 3-vessel cord placenta @ 12:47 P.M., fundal massage and pitocin initiated, fundus firm. 2nd-degree perineal laceration repaired under local anesthesia with 3-0 vicryl. Estimated blood loss (EBL) = 450 cc. Mom and baby stable. Doctors: Johnson & Feig.

SAMPLE POSTPARTUM NOTE

S: Pt ambulating, voiding, tolerating a regular diet
O: Vitals
   Heart: RR without murmurs
   Lungs: CTA bilaterally
   Breasts: Nonengorged, colostrum expressed bilaterally
   Fundus: Firm, mildly tender to palpation, 1 fingerbreadth below umbilicus
   Lochia: Moderate amount, rubra
   Perineum: Intact, no edema
   Extremities: No edema, nontender
   Postpartum Hgb: 9.7
   VDRL: NR
A: S/p NSVD, PP day # 1—progressing well, afebrile, stable
P: Continue postpartum care
SAMPLE POST-NSVD DISCHARGE ORDERS

1. D/c pt home
2. Pelvic rest × 6 weeks
3. Postpartum check in 4 weeks
4. D/c meds: FeSO₄ 300 mg 1 tab PO tid, #90 (For Hgb < 10; opinions vary on when to give Fe postpartum)
   Colace 100 mg 1 tab PO bid PRN no bowel movement, #60

SAMPLE POST–CESAREAN SECTION NOTE

S: Pt c/o abdominal pain, no flatus, minimal ambulation
O: Vitals
   I&O (urinary intake and output): Last 8 hrs = 750/695
   Heart: RR without murmurs
   Lungs: CTA bilaterally
   Breasts: Nonengorged, no colostrum expressed
   Fundus: Firm, tender to palpation, 1 fingerbreadth above umbilicus; incision without erythema/edema; C/D/I (clean/dry/intact); normal abdominal bowel sounds (NABS)
   Lochia: Scant, rubra
   Perineum: Intact, Foley catheter in place
   Extremities: 1+ pitting edema bilateral LEs, nontender
   Postpartum Hgb: 11
   VDRL: NR
A: S/p primary low-transverse c/s secondary to arrest of descent, POD # 1–afebrile, + flatus, stable
P: 1. D/c Foley
   2. Strict I&O—Call HO if UO < 120 cc/4 hrs
   3. Clear liquid diet
   4. Heplock IV once patient tolerates clears
   5. Ambulate qid
   6. Incentive spirometry 10×/hr
   7. Tylenol #3 2 tabs PO q 4 hrs PRN pain

SAMPLE DISCHARGE ORDERS POST–CESAREAN SECTION

1. D/c patient home
2. Pelvic rest × 4 weeks
3. Incision check in 1 week
4. Discharge meds:
   Tylenol #3 1–2 tabs PO q 4 hrs PRN pain, #30
   Colace 100 mg 1 tab PO bid, #60
SECTION IIA

High-Yield Facts in Obstetrics

- Normal Anatomy
- Diagnosis of Pregnancy
- Physiology of Pregnancy
- Antepartum
- Intrapartum
- Postpartum
- Medical Conditions and Infections in Pregnancy
- Complications of Pregnancy
- Spontaneous Abortion, Ectopic Pregnancy, and Fetal Death
- Induced Abortion
The vulva consists of the labia majora, labia minora, mons pubis, clitoris, vestibule of the vagina, vestibular bulb, and the greater vestibular glands. Basically, it is the external female genitalia (see Figure 2-1).

**Blood Supply**

From branches of the external and internal pudendal arteries

**Figure 2-1.** External female genitalia.

Lymph
Medial group of superficial inguinal nodes

Nerve Supply
Anterior parts of vulva: Ilioinguinal nerves and the genital branch of the genitofemoral nerves
Posterior parts: Perineal nerves and posterior cutaneous nerves of the thigh

VAGINA

Blood Supply
- Vaginal branch of the uterine artery is the primary supply of the vagina.
- Middle rectal and inferior vaginal branches of the hypogastric artery (internal iliac artery) are secondary blood supplies.

Nerve Supply
- Hypogastric plexus—sympathetic innervation
- Pelvic nerve—parasympathetic innervation

UTERUS

Components of the Uterus
- Fundus: Uppermost region of uterus
- Corpus: Body of the uterus
- Cornu: Part of uterus that joins the fallopian tubes
- Cervix: Inferior part of cervix that connects to the vagina via the cervical canal
  - Internal os: Opening of cervix on the uterine side
  - External os: Opening of cervix on the vaginal side

Histology
Mesometrium: The visceral layer of the peritoneum reflects against the uterus and forms this outmost layer of the organ (the side that faces the viscera).
Myometrium: The smooth muscle layer of uterus. It has three parts:
1. Outer longitudinal
2. Middle oblique
3. Inner longitudinal
Endometrium: The mucosal layer of the uterus, made up of columnar epithelium
Blood Supply

Uterine arteries—arise from internal iliac artery
Ovarian arteries

Nerve Supply

- Superior hypogastric plexus
- Inferior hypogastric plexus
- Common iliac nerves

LIGAMENTS OF THE PELVIC VISCERA

Broad ligament: Extends from the lateral pelvic wall to the uterus and adnexa. Contains the fallopian (uterine) tube, round ligament, uterine and ovarian blood vessels, lymph, uterovaginal nerves, and ureter (see Figure 2-2).
Round ligament: The remains of the gubernaculum; extends from the corpus of the uterus down and laterally through the inguinal canal and terminates in the labia majora.
Cardinal ligament: Extends from the cervix and lateral vagina to the pelvic wall; functions to support the uterus.

FALLOPIAN (UTERINE) TUBES

The fallopian tubes extend from the superior lateral aspects of the uterus through the superior fold of the broad ligament laterally to the ovaries.

FIGURE 2-2. Supporting structures of the pelvic viscera.
Parts, from Lateral to Medial
- **Infundibulum**: The lateralmost part the uterine tube. The free edge is connected to the fimbræae.
- **Ampulla**: Widest section
- **Isthmus**: Narrowest part
- **Intramural part**: Pierces uterine wall

**Blood Supply**
From uterine and ovarian arteries

**Nerve Supply**
Pelvic plexus (autonomic) and ovarian plexus

**OVARIES**

The ovaries lie on the posterior aspect of the broad ligament, and are attached to the broad ligament by the mesovarium. They are not covered by peritoneum.

**Blood Supply**
Ovarian artery, which arises from the aorta at the level of L1. Veins drain into the vena cava on the right side and the left renal vein on the left.

**Nerve Supply**
Derived from the aortic plexus

**FIGURE 2-3.** Fascia of the pelvis.
**Histology**

Ovaries are covered by tunica albuginea, a fibrous capsule. The tunica albuginea is covered by germinal epithelium.
NOTES
History
The majority of women have amenorrhea from the last menstrual period (LMP) until after the birth of their baby.

Symptoms
Although not specific to pregnancy, these symptoms may alert the patient to the fact that she is pregnant:
- Breast enlargement and tenderness from about 6 weeks’ gestational age (GA)
- Areolar enlargement and increased pigmentation after 6 weeks’ GA
- Colostrum secretion may begin after 16 weeks’ GA
- Nausea with or without vomiting, from about the date of the missed period
- Urinary frequency, nocturia, and bladder irritability due to increased bladder circulation and pressure from the enlarging uterus

Signs
Some clinical signs can be noted, but may be difficult to quantify:
- Breast enlargement, tension, and venous distention—particularly obvious in the primigravida
- Bimanual examination reveals a soft, cystic, globular uterus with enlargement consistent with the duration of pregnancy (see Table 3-1)
- Chadwick’s sign: Bluish discoloration of vagina and cervix, due to congestion of pelvic vasculature

Pregnancy Testing
How?
The beta subunit of human chorionic gonadotropin (hCG) is detected in maternal serum or urine.
- hCG is a glycoprotein produced by the developing placenta shortly after implantation
A monoclonal antibody to the hCG antigen is utilized to measure the hCG–antibody complex qualitatively. Pregnancy tests not only detect hCG produced by the syncytiotrophoblast cells in the placenta, but also in:

- Hydatidiform mole
- Choriocarcinoma
- Other germ cell tumors
- Ectopically producing breast cancers and large cell carcinoma of the lung

When?
- Blood levels become detectably elevated 8 to 10 days after fertilization (3 to 3.5 weeks after the LMP)
- hCG rises in a geometric fashion during T1, producing different ranges for each week of gestation:

<table>
<thead>
<tr>
<th>Duration of Pregnancy (from Time of Ovulation)</th>
<th>Plasma hCG (mU/mL)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 week</td>
<td>5–50</td>
</tr>
<tr>
<td>2 weeks</td>
<td>50–500</td>
</tr>
<tr>
<td>3</td>
<td>100–1,000</td>
</tr>
<tr>
<td>4</td>
<td>1,000–30,000</td>
</tr>
<tr>
<td>5</td>
<td>3,500–115,000</td>
</tr>
<tr>
<td>6–8</td>
<td>12,000–270,000</td>
</tr>
<tr>
<td>8–12</td>
<td>15,000–220,000</td>
</tr>
<tr>
<td>20–40</td>
<td>3,000–15,000</td>
</tr>
</tbody>
</table>

Urine hCG
- Preferred method to recognize normal pregnancy
- Total urine hCG closely parallels plasma concentration
- First morning specimens have less variability in relative concentration and generally higher levels, improving accuracy
- Assays detecting 25 mU/mL recognize pregnancy with 95% sensitivity by 1 week after the first missed menstrual period

Due to engagement and descent of the fetal head, the fundal height at 40 weeks is typically less than the fundal height at 36 weeks.
- False negatives may occur if:
  - The test is performed too early
  - The urine is very dilute
- False positives may occur if:
  - Proteinuria (confirm with plasma hCG)
  - Urinary tract infection (UTI)

Plasma hCG

Used when quantitative information is needed:
- Diagnosing ectopic pregnancy
- Monitoring trophoblastic tumors
- Screening for fetal abnormalities

Do not provide additional information in diagnosing routine pregnancy since they are positive < 1 week before urine hCG.

**INDICATIONS**

Women of reproductive age with:
- Pain
- Amenorrhea

**FETAL HEART TONES (FHTs)**

The electronic Doppler device can detect fetal heart tones as early as 8 weeks’ GA, albeit with difficulty.

**ULTRASONIC SCANNING (US)**

Not generally used to diagnose pregnancy, but can do so once a gestation sac is present within the uterus.

**When?**
- To confirm an intrauterine pregnancy (if it is suspected to be ectopic)
- To confirm the presence of a fetal heartbeat in a patient with a history of miscarriage
- To diagnose multiple pregnancy
- To estimate gestational age
- To screen for fetal structural anomalies

**Limitations**

Scan dating becomes progressively less accurate and should be utilized only up to 20 weeks’ GA:
- US measures the size of the fetus, not the gestational age.
- Biologic variation in size increases as gestation advances.
Physiology of Pregnancy

**Aldosterone**: Enhances Na\(^+\) reabsorption at the collecting duct of the kidney

**Aneuploidies**: Abnormal numbers of chromosomes that may occur as a consequence of abnormal meiotic division of chromosomes in gamete formation

**Antidiuretic hormone (arginine vasopressin)**: Acts to conserve water by increasing the permeability of the collecting duct of the kidney

**Blastocyst**: At the 8- to 16-cell stage, the blastomere develops a central cavity and becomes a blastocyst. The cells on the outer layer differentiate to become trophoblasts.

**Blastogenic period**: The first 4 weeks of human development

**Blastomere/morula**: In 2 to 4 days after fertilization, a fertilized oocyte undergoes a series of cellular divisions and becomes a blastomere or morula

**BMI**: A calculation that relates patient’s height to weight:
- Weight(kg)/height(m\(^2\))
  - Obese \(\geq 30\)
  - Overweight = 25 to 29.9
  - Norm = 18.5 to 24.9
  - Does not consider lean body mass or percentage of body fat

**Conception**: The fertilization of an ovum by sperm

**Decidua**: The name given to the endometrium or lining of the uterus during pregnancy and the tissue around the ectopically located fertilized ovum

**Embryonic period**: Begins with the folding of the embryonic disk (which is formed from the inner cell mass) in week 2 of development

**Erythrocyte sedimentation rate (ESR)**: A nonspecific laboratory indicator of infectious disease and inflammatory states. An anticoagulant is added to a tube of blood, and the distance the red blood cells fall in 1 hour is the rate.

**Fetus**: The term given to the conceptus after 8 weeks of life; it has a crown–rump length of 30 mm and a gestational age of 10 weeks. The fetal period continues until birth.

**Gestational age**: The time calculated from the last menstrual period and by convention exceeds the developmental age by 2 weeks
Oocyte: The primitive ovum before it has completely developed
Primary: The oocyte at the end of the growth period of oogonium and before the first maturation division has occurred
Secondary: The larger of two oocytes resulting from the first maturation division

Oogenesis: Formation and development of the ovum
Oogonium: The primordial cell from which an oocyte originates
Organogenesis: Occurs between 4 and 8 weeks after conception
Polar body: The small cell produced in oogenesis resulting from the divisions of the primary and secondary oocytes
Preembryonic period: The first 2 weeks after fertilization
Pregenesis: The time period between the formation of germ cells and the union of sperm and egg
Puerperium: The period of up to 6 weeks after childbirth, during which the size of the uterus decreases to normal
Residual volume (RV): The volume of gas contained in the lungs after a maximal expiration
Tidal volume (TV): The volume of air that is inhaled and exhaled during normal quiet breathing
Total lung capacity (TLC): The volume of gas contained in the lungs after a maximal inspiration
Vital capacity (VC): The volume of gas that is exhaled from the lungs in going from TLC to RV
Zona pellucida: Inner, solid, thick membranous envelope of the ovum (vitelline membrane, zona radiata)

GENERAL EFFECTS OF PREGNANCY ON THE MOTHER

Table 4-1 summarizes maternal physiologic changes during pregnancy.

Total Body Water
Increases by an average of 8.5 L and is composed of:
- Fetal water
- Amniotic fluid
- Placental tissue
- Maternal tissue
- Edema
- Increased hydration of connective tissue ground substance → laxity and swelling of connective tissue → changes in joints that mainly occur in T3.
- Generalized swelling → corneal swelling, intraocular pressure changes, gingival edema, increased vascularity of cranial sinuses, tracheal edema

Energy Requirements
Energy requirements increase gradually from 10 weeks to 36 weeks by 50 to 100 kcal/day. In the final 4 weeks, requirements increase by 300 kcal/day.
### TABLE 4-1. Summary of Changes in the Body During Pregnancy

<table>
<thead>
<tr>
<th></th>
<th>T1 (1–14 wks)</th>
<th>T2 (14–28 wks)</th>
<th>T3 (28 wks–term) Term = 37–42 wks</th>
<th>During Labor</th>
<th>9-Month Period</th>
</tr>
</thead>
<tbody>
<tr>
<td>Body water</td>
<td></td>
<td></td>
<td></td>
<td>↑ by 8.5 L</td>
<td></td>
</tr>
<tr>
<td>Energy requirements</td>
<td>↑ by 50–100 kcal/d</td>
<td>↑ by 300 kcal/d</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Body weight</td>
<td>↑ (primarily reflects maternal growth)</td>
<td>↑ (primarily reflects maternal growth)</td>
<td>↑ (primarily reflects fetal growth)</td>
<td>↑ by 25–35 lb</td>
<td></td>
</tr>
<tr>
<td>Tidal volume</td>
<td>↑</td>
<td></td>
<td></td>
<td>↑ by 200 mL</td>
<td></td>
</tr>
<tr>
<td>Vital capacity</td>
<td>↑</td>
<td></td>
<td></td>
<td>↑ by 100–200 mL</td>
<td></td>
</tr>
<tr>
<td>Cardiac output</td>
<td>↑ by 60%</td>
<td></td>
<td></td>
<td>↑</td>
<td></td>
</tr>
<tr>
<td>Blood pressure (BP)</td>
<td>↓</td>
<td></td>
<td></td>
<td>↑ by 10–20 mm Hg during each contraction May ↑ further in second stage of labor</td>
<td></td>
</tr>
<tr>
<td>Systolic BP</td>
<td>↔</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diastolic BP</td>
<td>↓</td>
<td></td>
<td>↓ by 15 mm Hg at 16–20 wks</td>
<td>↑ to T1 level</td>
<td></td>
</tr>
<tr>
<td>Heart rate</td>
<td>↑ by 10–15%/min</td>
<td></td>
<td></td>
<td>↔</td>
<td></td>
</tr>
<tr>
<td>Stroke volume</td>
<td>↑ by 10%</td>
<td></td>
<td></td>
<td>↑</td>
<td></td>
</tr>
<tr>
<td>Central venous pressure</td>
<td>↔</td>
<td></td>
<td></td>
<td>↑ of 3–5 mm Hg during each contraction</td>
<td></td>
</tr>
<tr>
<td>Systemic vascular resistance</td>
<td>↓ from pregancy level</td>
<td>↓↓ from pregancy level</td>
<td>↑, but not to pregancy level</td>
<td>↑ with each contraction</td>
<td></td>
</tr>
<tr>
<td>Glomerular filtration rate (GFR)</td>
<td>↑</td>
<td>↑ to 60% above nonpregnant levels by 16 wks</td>
<td></td>
<td>↑</td>
<td></td>
</tr>
<tr>
<td>Renal plasma flow</td>
<td>↑</td>
<td></td>
<td>↑ to 30–50% above nonpregnant levels by 20 wks</td>
<td>Peaks at 30 wks</td>
<td>↑</td>
</tr>
<tr>
<td>Plasma aldosterone</td>
<td>↑ w/in 2 wks of conception</td>
<td>↑ 3–5 times the nonpregnant level</td>
<td>↑ 8–10 times the nonpregnant level</td>
<td>↑</td>
<td></td>
</tr>
</tbody>
</table>

(Continued)
### TABLE 4-1. Summary of Changes in the Body During Pregnancy (continued)

<table>
<thead>
<tr>
<th>Parameter</th>
<th>T1 (1–14 wks)</th>
<th>T2 (14–28 wks)</th>
<th>T3 (28 wks–term)</th>
<th>Term = 37–42 wks</th>
<th>During Labor</th>
<th>9-Month Period</th>
</tr>
</thead>
<tbody>
<tr>
<td>Serum alkaline phosphatase</td>
<td>↑</td>
<td></td>
<td></td>
<td></td>
<td>↑</td>
<td></td>
</tr>
<tr>
<td>Plasma prolactin</td>
<td>↑</td>
<td></td>
<td></td>
<td></td>
<td>↑ 10–20 times nonpregnant level</td>
<td></td>
</tr>
<tr>
<td>Cortisol and other corticosteroids</td>
<td>↑ from 12 wks</td>
<td>↑</td>
<td>↑</td>
<td></td>
<td>↑ to 3–5 times nonpregnant levels</td>
<td></td>
</tr>
<tr>
<td>Glucagon</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>↑</td>
<td></td>
</tr>
<tr>
<td>Insulin sensitivity</td>
<td>↑</td>
<td>↓ at 20 wks</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fasting insulin levels</td>
<td>↑ at 20 wks</td>
<td></td>
<td>Peak at 32 wks</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Plasma volume</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td></td>
<td>↑ by 50%</td>
<td></td>
</tr>
<tr>
<td>Red blood cell (RBC) mass</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td></td>
<td>↑ by 18–30%</td>
<td></td>
</tr>
<tr>
<td>Mean corpuscular volume (MCV)</td>
<td>↔ or ↑ from 82–84 fl</td>
<td>↑ from 86–100 fl or more</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Neutrophils</td>
<td>↑</td>
<td></td>
<td></td>
<td></td>
<td>↑ to 30 wks</td>
<td></td>
</tr>
<tr>
<td>Erythrocyte sedimentation rate (ESR)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>↑</td>
<td></td>
</tr>
<tr>
<td>Albumin blood levels</td>
<td>↓</td>
<td>↓ from 3.5–2.5 g/100 mL</td>
<td>↓ by 22%</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total globulin</td>
<td>↑ by 0.2 g/100 mL</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total proteins</td>
<td>↓ by 20 wks</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Thyroxine-binding globulin</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>↑ (Thyroxine-binding globulin levels double)</td>
<td></td>
</tr>
<tr>
<td>Total plasma cholesterol</td>
<td>↓ by 5%</td>
<td>↑</td>
<td>↑</td>
<td></td>
<td>↑ by 24–206%</td>
<td></td>
</tr>
<tr>
<td>Low-density lipoprotein (LDL)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>↑ by 50–90%</td>
<td></td>
</tr>
<tr>
<td>Very low-density lipoprotein (VLDL)</td>
<td></td>
<td></td>
<td></td>
<td>Peaks at 36 wks</td>
<td>↑ by 36%</td>
<td></td>
</tr>
<tr>
<td>High-density lipoprotein (HDL)</td>
<td>↑ by 30%</td>
<td></td>
<td></td>
<td>Decreases from T2</td>
<td>↑ by 10–23%</td>
<td></td>
</tr>
<tr>
<td>Triglycerides</td>
<td></td>
<td></td>
<td></td>
<td>Reach 2–4 times nonpregnant level at 36 wks</td>
<td>↑ by 90–570%</td>
<td></td>
</tr>
<tr>
<td>Lipoprotein (a)</td>
<td>↑</td>
<td>↑ until 22 wks</td>
<td>↓ to nonpregnant levels</td>
<td></td>
<td>↔</td>
<td></td>
</tr>
<tr>
<td>Uterine contractions</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Begin at 20 wks</td>
<td>↑</td>
</tr>
</tbody>
</table>
Metabolism

- Metabolic modifications begin soon after conception and are most marked in the second half of pregnancy when fetal growth requirements increase.
- The uterus and placenta require carbohydrate, fat, and amino acids.

Carbohydrate

The placenta is freely permeable to glucose, which increases availability to fetus.

First 20 Weeks

*Insulin sensitivity increases in first half of pregnancy.*
- Fasting glucose levels are lower.
- This favors glycogen synthesis and storage, fat deposition, and amino acid transport into cells.

After 20 weeks

*After 20 weeks, insulin resistance develops and plasma insulin levels rise.*
- A carbohydrate load produces a rise in plasma insulin 3 to 4 times greater than in the nonpregnant state, but glucose levels also are higher.
- This reduces maternal utilization of glucose and induces glycogenolysis, gluconeogenesis, and maternal utilization of lipids as energy source.
- Despite these high and prolonged rises in postprandial plasma glucose, the fasting level in late pregnancy remains less than nonpregnant levels.

Amino Acids

- Plasma concentration of amino acids falls during pregnancy due to hemodilution.
- Urea synthesis is reduced.

Lipids

- All lipid levels are raised, with the greatest increases being in the triglyceride-rich component.
- Lipids cross the placenta.
- Hyperlipidemia of pregnancy is not atherogenic, but may unmask a pathologic hyperlipidemia.

Fat

- Early in pregnancy, fat is deposited.
- By midpregnancy, fat is the primary source of maternal energy.
- Postpartum, lipid levels return to normal.
- May take 6 months

Cholesterol

- There is an increased turnover of cholesterol from lipoproteins, creating an increased supply to most tissues and increased supply for steroid production.
- Total cholesterol is raised postpartum in all mothers, but can be reduced by dieting after delivery.

Triglycerides, very low-density lipoprotein (VLDL), low-density lipoprotein (LDL), and high-density lipoprotein (HDL) increase during pregnancy.
**DRUGS/OTHER SUBSTANCES**
- Plasma levels of phenytoin fall during pregnancy.
- The half-life of caffeine is doubled.
- Antibiotics are cleared more rapidly by the kidney.

**Central Nervous System**

Syncope may occur from multiple etiologies:

1. Venous pooling in lower extremities → dizziness/light-headedness especially with abrupt positional changes
2. Dehydration
3. Hypoglycemia
4. Postprandial shunting of blood flow to the stomach
5. Overexertion during exercise

Emotional and psychiatric symptoms may result from:
- Hormonal changes of pregnancy
- Progesterone → tiredness, dyspnea, depression
- Euphoria secondary to endogenous corticosteroids

**Respiratory System**

Fetal PCO₂ must be greater than maternal PCO₂; thus, the maternal respiratory center must be reset. This is done in several ways:

- During pregnancy, progesterone reduces the carbon dioxide threshold at which the respiratory center is stimulated and increases the respiratory center sensitivity. This may lead to hyperventilation of pregnancy.
- Tidal volume (TV) increases by 200 mL.
- Vital capacity (VC) increases by 100 to 200 mL.

**Cardiovascular System**

**CARDIAC OUTPUT**

- Cardiac output (CO) increases by 40% by week 10, due to a 10% increase in stroke volume and increase in pulse rate by 10 to 15% per minute.
- Generalized enlargement of the heart and enlargement of left ventricle
- Heart is displaced anterolaterally secondary to rise in level of diaphragm → alters electrocardiogram (ECG) and may produce changes that mimic ischemia.

**Physical Exam**

- At end of T1—both components of S₁ become louder, with exaggerated splitting.
- After midpregnancy—90% of pregnant women demonstrate a third heart sound or S₃ gallop.
- Systolic ejection murmurs along the left sternal border occur in 96% of pregnant patients (due to increased flow across aortic and pulmonic valves).
- Diastolic murmurs are never normal, and their presence warrants evaluation by a cardiologist.
During Labor
- CO increases by 30% during each contraction with an increase in stroke volume, but no increase in heart rate.

Venous System
Venous dilation results from:
- Relaxation of vascular smooth muscle
- Pressure of enlarging uterus on inferior vena cava and iliac veins

Gastrointestinal System
Reflux esophagitis (heartburn):
- Enlarging uterus displaces the stomach above the esophageal sphincter and causes increased intragastric pressure.
- Progesterone causes a relative relaxation of the esophageal sphincter.
- There may also be reflux of bile into the stomach due to pyloric incompetence.
- Constipation may occur secondary to progesterone, which relaxes intestinal smooth muscle and slows peristalsis.

Gallbladder
- Increases in size
- Empties more slowly
- Cholestasis, probably due to a hormonal effect since it also occurs in some users of oral contraceptives (OCs) and hormone replacement therapy (HRT)

Liver
- Hepatic function increases.
- Plasma globulin and fibrinogen concentrations increase.
- Synthetic rate of albumin increases → total albumin mass increases by 19%, plateauing at 28 weeks.
- Velocity of blood flow in hepatic veins decreases.
- Serum alkaline phosphatase increases largely due to placental production

Genitourinary System
- Urinary stasis secondary to decreased ureteral peristalsis and mechanical uterine compression of the ureter at pelvic brim as pregnancy progresses
- Asymptomatic bacteruria occurs in 5 to 8% of pregnant women.
- Urinary frequency increases:
  - During first 3 months of pregnancy due to bladder compression by enlarging uterus
  - During last week of pregnancy as the fetal head descends into pelvis
- Nocturia:
  - Physiologic after T1
  - Passing urine four times per night is normal
  - Fetal movements and insomnia contribute to the nocturia
- Stress incontinence:
  - Occurs frequently during normal pregnancy

Patients with hypertensive heart disease or cardiac disease may develop progressive or sudden deterioration.

Increased distensibility and pressure of veins → predisposition to development of varicose veins of legs, vulva, rectum, and pelvis.

Decreased GI motility may be responsible for the increased absorption of water, Na+, and other substances.

The superior rectal vein is part of the portal system and has no valves, hence the high pressure within the system is communicated to the pelvic veins and produces hemorrhoids.

The increase in cholestasis plus increase in lipids and cholesterol lead to higher incidence of gallstones, cholecystitis, and biliary obstruction.
Due to relaxation of the bladder supports
- The urethra normally elongates during pregnancy, but not in those who develop stress incontinence.

**Bladder**
Bladder tone decreases, but bladder capacity increases progressively during pregnancy.

**Ureters**
Ureters undergo progressive dilatation and kinking in > 90% of pregnant women at ≥ 6 weeks
- Accompanied by a decreased urine flow rate
- Dilatation is greater on right secondary to dextrorotation of the uterus, and does not extend below the pelvic brim.
- Dilatation is secondary to the physical obstruction by the pregnant uterus and the effects of pregnancy hormones.
- Ureteric dilatation extends up to the calyces → increased glomerular size and increased interstitial fluid → enlarged kidneys (length increases by 1 cm and weight increases by 20%).

**Renal Function**
- Renal plasma flow increases from T1, reaching 30 to 50% above non-pregnant levels by 20 weeks. Flow remains elevated until 30 weeks and then slowly declines to nonpregnant levels postpartum.
- Glomerular filtration rate (GFR) increases soon after conception. It reaches 60% above nonpregnant level by 16 weeks and remains elevated for remainder of pregnancy.

**Renal Tubule Changes**
- Tubules lose some of their resorptive capacity—amino acids, uric acid, and glucose are not as completely absorbed in the pregnant female.
- Results in an increase in protein loss of up to 300 mg/24 hr

Renal retention of Na\(^+\) results in water retention. Mother and conceptus increase their Na\(^+\) content by 500 to 900 nmol (due to increased reabsorption by renal tubules).

**Hematologic**

**Plasma Volume**
Plasma volume increases by 50% during pregnancy due to increase in both red blood cells (RBCs) and plasma, but proportionately more plasma. This results in hemodilution.
- Greater in multigravidas than primigravidas
- Greater in multiple pregnancies than in single pregnancies
- Positively correlated with birth weight
- Increase in plasma volume is less in patients with recurrent abortions.
- Advantage of increased circulating volume:
  - Helps to compensate for increased blood flow to uterus and kidneys
  - Reduces viscosity of blood and increases capillary blood flow
**RED BLOOD CELLS**
- Circulating RBC mass increases progressively during pregnancy:
  - By 18% in women not given Fe supplements
  - By 30% in women on Fe supplementation
  - Reticulocyte count increases by ≥ 2%.
  - Mean corpuscular volume (MCV) usually increases.

**HEMOGLOBIN**
- Fetal Hgb (HbF) concentration increases 1 to 2% during pregnancy, secondary to an increase in the number of RBCs with HbF

**ERYTHROCYTE SEDIMENTATION RATE**
Erythrocyte sedimentation rate (ESR):
- Rises early in pregnancy due to the increase in fibrinogen and other physiologic changes
- An ESR = 100 mm/hr is not uncommon in normal pregnancy.

**WHITE BLOOD CELLS**

- **Neutrophils**
  - Neutrophil count increases in T1 and continues to rise until 30 weeks.
  - Neutrophilic metabolic activity and phagocytic function increases.

- **Lymphocytes**
  - Counts remain unchanged, but function is suppressed.

**PLATELETS**
- Platelet reactivity is increased in T2 and T3 and returns to normal at 12 weeks postpartum
- In 8 to 10% of normal pregnancies, the platelet count falls below 150 × 10^3 without negative effects on the fetus.

**Endocrine System**
In general, the endocrine system is modified in the pregnancy state by the addition of the fetoplacental unit. The fetoplacental unit produces human chorionic gonadotropin (hCG) and human placental lactogen (hPL) among other hormones.
- hPL (also called human chorionic somatomammotropin [hCS]): Anti-insulin and growth hormone-like effects → impaired maternal glucose and free fatty acid release.

**PITUITARY GLAND**
Pituitary gland increases in weight and sensitivity.

- **Prolactin**
  - Plasma levels rise within a few days postconception.
  - At term, levels are 10- to 20-fold higher than nonpregnant state.
Follicle-Stimulating Hormone
- Blunted response to gonadotropin-releasing hormone (GnRH)
- Shows a progressive decreased response → no response at 3 weeks after ovulation

Luteinizing Hormone
- Response to GnRH diminishes and finally disappears.

Adrenal Gland
- Plasma cortisol and other corticosteroids increase progressively from 12 weeks to term and reach 3 to 5 times nonpregnant levels.
- Half-life of plasma cortisol is increased, while its clearance is reduced.

Thyroid Gland
The following changes are thought to be due to the increase in estrogen during pregnancy:
- Increases in size during pregnancy
- Total thyroxine levels and thyroxine-binding globulin increase. The result is that free thyroxine remains normal and the mother remains euthyroid.

Parathyroid Glands
- Parathyroid hormone levels increase in pregnancy, which increases maternal calcium absorption, to offset maternal losses across the placenta to the fetus.
- At term, serum parathyroid hormone levels are higher in the mother, but calcitonin is higher in the fetus. This results in fetal bone deposition.

Plasma Proteins
Concentrations of proteins in maternal serum fall markedly by 20 weeks, mostly due to a fall in serum albumin. This fall reduces the colloid osmotic pressure in the plasma → edema in pregnancy.

Pancreas
- Size of islets of Langerhans increases during pregnancy.
- The number of beta cells increases during pregnancy.
- The number of insulin receptor sites increases during pregnancy.

Insulin
- Serum levels rise during second half of pregnancy, but insulin resistance increases as well.
- This insulin resistance may be due to presence of hPL, prolactin, or other pregnancy hormones that have anti-insulin activity.

Glucagon
- Levels are slightly raised in pregnancy, but not as much as insulin levels.

Integumentary System/Skin
Many physiologic changes in the skin can occur during gestation. Some are believed to result from changes in the hormonal milieu of pregnancy (see Table 4-2).
Melanocyte-stimulating hormone effects can result in the following:

- **Linea nigra**: Black line/discoloration of the abdomen that runs from above the umbilicus to the pubis; may be seen during the latter part of gestation.
- **Darkening of nipple and areola**.
- **Facial cholasma/melasma**: A light- or dark-brown hyperpigmentation in exposed areas such as the face. More common in persons with brown or black skin color, who live in sunny areas, and who are taking OCs.
- A suntan acquired in pregnancy lasts longer than usual.

### TABLE 4-2. Pruritic Dermatologic Disorders Unique to Pregnancy

<table>
<thead>
<tr>
<th>Disease</th>
<th>Onset</th>
<th>Pruritis</th>
<th>Lesions</th>
<th>Distribution</th>
<th>Incidence</th>
<th>Intervention</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pruritic urticarial papules and plaques of pregnancy (PUPPP)</td>
<td>T2–T3</td>
<td>Severe</td>
<td>Erythematous urticarial papules and plaques</td>
<td>Abdomen, thighs, buttocks, occasionally arms and legs</td>
<td>Common (0.25–1%)</td>
<td>No</td>
</tr>
<tr>
<td>Papular eruptions (prurigo gestationis and papular dermatitis)</td>
<td>T2–T3</td>
<td>Severe</td>
<td>Excoriated papules</td>
<td>No area of predilection</td>
<td>Uncommon (1:300–1:2,400)</td>
<td>Unlikely</td>
</tr>
<tr>
<td>Pruritis gravidarum</td>
<td>T3</td>
<td>Severe</td>
<td>Excoriations common</td>
<td>Generalized</td>
<td>Common (1–2%)</td>
<td>Yes</td>
</tr>
<tr>
<td>Impetigo herpetiformis</td>
<td>T3</td>
<td>Minimal</td>
<td>Pustules</td>
<td>Genitalia, medial thighs, umbilicus, breasts, axillae</td>
<td>Rare</td>
<td>Yes (maternal sepsis common)</td>
</tr>
<tr>
<td>Herpes gestationis</td>
<td>T2–post-partum</td>
<td>Severe</td>
<td>Erythematous papules, vesicles, bullae</td>
<td>Abdomen, extremities, generalized</td>
<td>Rare (1:10,000)</td>
<td>Yes</td>
</tr>
</tbody>
</table>
ESTROGEN EFFECTS
- Spider nevi are common (branched growths of dilated capillaries on the skin).
- Palmar erythema

CORTICOSTEROID EFFECTS
Striae on the abdomen, breasts, etc., develop in response to increased circulating corticosteroids.

FINGERNAILS
Grow more rapidly during pregnancy

HAIR
- The rate at which hair is shed is reduced.
- The excess retained hair is often lost in the puerperium, secondary to maternal emotional stress.

NORMAL ANATOMICAL ADAPTATIONS IN PREGNANCY

Vagina
- Vaginal epithelium hypertrophies and quantity of glycogen-containing cells shed into vagina increase.
- Connective tissue decreases in collagen content and there is an increase in water content (like the cervix—see below).
- Vagina becomes more acidic (pH = 4 to 5) → hinders growth of most pathogens and favors growth of yeasts.

Uterus
- Hypertrophy and hyperplasia of myometrial smooth muscle secondary to:
  - Action of steroid hormones
  - Uterine distention and wall thinning with the growing fetus, placenta, amniotic fluid
- Term uterus weighs 1,100 g with a 20-fold increase in mass (nonpregnant, parous uterus weighs 70 g).

ROUND LIGAMENT
Round ligament increases in length, muscular content, and diameter:
- During pregnancy, the ligaments may contract spontaneously or in response to uterine movement.
- In labor, contractions of the ligaments pulls the uterus forward → expulsive force is directed as much into the pelvis as possible.

VASCULAR SUPPLY OF THE UTERUS
- In the nonpregnant state, the uterine artery is most important blood source

HIGH-YIELD FACTS
- Parathyroid hormone and calcitonin do not cross the placenta.
- Thyroid-stimulating hormone, iodide, thyroid-releasing hormone, and T4 cross the placenta. TSH does not.
During pregnancy, the ovarian arteries contribute 20 to 30% of the blood supply in 70% of women.
- Uterine arteries dilate to 1.5 times their nonpregnant diameter.

**Uterine Cervix**
- Amount of collagen within cervix is reduced to one third of nonpregnant amount.
- The duration of spontaneous labor is inversely proportional to cervical collagen concentration at the beginning of dilation.

Accumulation of glycosaminoglycans and increase in water content and vascularity in the cervix results in softening and cyanosis = characteristic cervix of gravid female:
- Results in increased compliance to stretch
- This process is called “cervical ripening” and takes place gradually over the last few weeks of gestation.
- In early T1, squamous epithelium of ectocervix becomes hyperactive, endocervical glands become hyperplastic, and endocervical epithelium proliferates and grows out over the ectocervix.
- The resulting secretions within the endocervical canal create the antibacterial mucous plug of the cervix.

**Uterine Isthmus**
- The uterine isthmus is normally a small region of the uterus that lies between the uterine corpus and cervix.
- Beginning at 12 weeks of pregnancy, the isthmus enlarges and thins secondary to hormonal influences of pregnancy and uterine distention.
- During labor, the isthmus expands and is termed the lower uterine segment.

**Conception**

**Ovulation**
- Ovulation is necessary for normal fertilization to occur:
  - The ovum must leave the ovary and be carried into the fallopian tube.
  - The unfertilized ovum is surrounded by its zona pellucida.
  - This oocyte has completed its first meiotic division and carries its first polar body.

**Fertilization**
- Fertilization typically occurs within 24 hours after ovulation in the third of the fallopian tube adjacent to the ovary (ampulla):
  - The sperm penetrates the zona pellucida and fuses its plasma membranes with those of the ovum.
  - The sperm nucleus and other cellular contents enter the egg’s cytoplasm.
  - Fertilization signals the ovum to complete meiosis II and to discharge an additional polar body.
Preimplantation
- Fertilized ovum remains in the ampulla for 80 hours after follicular rupture and travels through isthmus of fallopian tube for 10 hours.
- The fertilized egg divides to form a multicellular blastomere.
- The blastomere passes from the fallopian tube into the uterine cavity.
- The embryo develops into a blastocyst as it freely floats in endometrial cavity 90 to 150 hours after conception (see Table 4-3).

Implantation
- On day 5 to 6 of development, the blastocyst adheres to the endometrium with the help of adhesion molecules on the secretory endometrial surface.
- After attachment, the endometrium proliferates around the blastocyst.

Placentation
- During week 2, cells in the outer cell mass differentiate into trophoblasts.

TABLE 4-3. Embryology

<table>
<thead>
<tr>
<th>Weeks</th>
<th>Embryo Development</th>
<th>Fetal Development</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Early morula; no organ differentiation.</td>
<td>Brain configuration roughly complete, internal sex organs now specific, uterus</td>
</tr>
<tr>
<td></td>
<td></td>
<td>now no longer bicornuate, and blood forming in marrow.External genitalia</td>
</tr>
<tr>
<td></td>
<td></td>
<td>forming (9–12 weeks).</td>
</tr>
<tr>
<td>3</td>
<td>Double heart recognized.</td>
<td>Fetus is active now, sex determination by visual inspection (ultrasound) is possible due to the formed external genitalia. Myelination of nerves, heart muscle well developed, vagina and anus open, and ischium ossified.</td>
</tr>
<tr>
<td>4</td>
<td>Initial organogenesis has begun.</td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>Genetic sex determined.</td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>Sensory organ development and nondifferentiated gonadal development.</td>
<td></td>
</tr>
<tr>
<td>12</td>
<td></td>
<td></td>
</tr>
<tr>
<td>16</td>
<td></td>
<td></td>
</tr>
<tr>
<td>20</td>
<td>Sternum ossifies.</td>
<td></td>
</tr>
<tr>
<td>24</td>
<td>Primitive respiratory movements.</td>
<td></td>
</tr>
<tr>
<td>28</td>
<td>Nails appear and testes at or below internal inguinal ring.</td>
<td></td>
</tr>
<tr>
<td>36</td>
<td>Earlobe soft with little cartilage, testes in inguinal canals, and scrotum small with few rugae.</td>
<td></td>
</tr>
<tr>
<td>40</td>
<td>Earlobes stiffen by thick cartilage, and scrotum well developed.</td>
<td></td>
</tr>
</tbody>
</table>

- A trophoblastic shell forms the initial boundary between the embryo and the endometrium.
- The trophoblasts nearest the myometrium form the placental disk; the other trophoblasts form the chorionic membranes.

**Postimplantation**
- The endometrium or lining of the uterus during pregnancy is termed decidua.
- Maternal RBCs may be seen in the trophoblastic lacunae in the second week postconception.

**The Placenta**

The placenta continues to adapt over T2 and T3. It is the primary producer of steroid hormones after 7 weeks’ gestational age.

**Blood Supply**

Flow in the arcuate and radial arteries during normal pregnancy is high with low resistance (resistance falls after 20 weeks).

**Developmental Ages**

<table>
<thead>
<tr>
<th>Postconception Day</th>
<th>Tissue/Organ Formation</th>
</tr>
</thead>
<tbody>
<tr>
<td>4</td>
<td>Blastula</td>
</tr>
<tr>
<td>7–12</td>
<td>Implantation</td>
</tr>
<tr>
<td>13</td>
<td>Primitive streak</td>
</tr>
<tr>
<td>16</td>
<td>Neural plate</td>
</tr>
<tr>
<td>19–21</td>
<td>First somite</td>
</tr>
<tr>
<td>23–25</td>
<td>Closure of anterior neuropore</td>
</tr>
<tr>
<td>25–27</td>
<td>Arms bud</td>
</tr>
<tr>
<td>28</td>
<td>Closure of posterior neuropore</td>
</tr>
<tr>
<td>44</td>
<td>Legs bud</td>
</tr>
<tr>
<td></td>
<td>Sexual differentiation</td>
</tr>
</tbody>
</table>

**Multiple Gestation (Figure 4-1)**

- Division of embryos before differentiation of trophoblast (between days 2 and 3) → 2 chorions, 2 amnions
- Division of embryos after trophoblast differentiation and before amnion formation (between days 3 and 8) → 1 placenta, 1 chorion, 2 amnions
- Division of embryos after amnion formation (between days 8 and 13) → 1 placenta, 1 chorion, 1 amnion

**Pregnancy Proteins**

**hCG (Human Chorionic Gonadotropin)**

*Source:* Placenta

*Function:*

- Maintains the corpus luteum
- Stimulates adrenal and placental steroidogenesis
Physiology of Pregnancy

ACTH (Adrenocorticotropic Hormone)
Source: Trophoblasts
Function: Stimulates an increase in circulating maternal free cortisol

hPL (Human Placental Lactogen)
Source: Trophoblasts
Function: Antagonizes insulin → maternal glucose intolerance, lipolysis, and proteolysis

CRH (Corticotropin-Releasing Hormone)
Source: Placental tissue and decidua
Function: Stimulates placental ACTH release and participates in the surge of fetal glucocorticoids associated with late T3 fetal maturation
Prolactin  
**Source:** Decidualized endometrium  
**Function:** Regulates fluid and electrolyte flux through the fetal membranes

**Alpha-Fetoprotein (AFP)**  
**Source:** Yolk sac, fetal gastrointestinal tract, and fetal liver  
**Function:** Regulates fetal intravascular volume (osmoregulator)  
- MSAFP peaks between 10 and 13 weeks’ gestational age, then declines thereafter.  
- Detectable as early as 7 weeks’ gestation

**PREGNANCY STEROIDS**

**Estrogens**  
**Function:** Estrogens affect uterine vasculature, placental steroidogenesis, and parturition.

**Estradiol**  
**Source:**  
- Maternal ovaries for weeks 1 through 6 of gestation  
- Subsequently, the placenta secretes increasing quantities of estradiol synthesized from the conversion of circulating maternal and fetal DHEA-S.  
- After T1, the placenta is the major source of circulating estradiol.

**Estrone**  
**Source:**  
- Maternal ovaries, adrenals, and peripheral conversion in the first 4 to 6 weeks of pregnancy  
- The placenta subsequently secretes increasing quantities.

**Estriol**  
**Source:**  
- Placenta  
- Continued production is dependent on the presence of a living fetus.

**Progesterone**  
**Source:**  
- Corpus luteum before 6 weeks’ gestational age  
- Thereafter, the placenta produces progesterone from circulating maternal low-density lipoprotein (LDL) cholesterol.  
**Function:**  
- Affects tubal motility, the endometrium, uterine vasculature, and parturition  
- Inhibits T lymphocyte-mediated tissue rejection

**Cortisol**  
**Source:** Decidual tissue  
**Function:** Suppresses the maternal immune rejection response of the implanted conceptus

---

Amniotic fluid AFP and maternal serum (MSAFP) are elevated in association with neural tube defects and low in trisomy 21.

MSAFP is decreased in pregnancies with Down’s syndrome.

In women with threatened T1 abortions, estradiol concentrations are abnormally low for gestational age.

During T3, low estradiol levels are associated with poor obstetrical outcomes.

Abortion will occur in 80% of women with progesterone levels under 10 ng/mL.
LDL Cholesterol
Source: Fetal adrenal gland
Function:
- Principal regulatory precursor of corpus luteum progesterone production
- Principal lipoprotein utilized in fetal adrenal steroidogenesis

Progestosterone concentrations of < 5 ng/mL are diagnostic of fetal death in T1. Prompt diagnostic studies should be performed to distinguish between ectopic pregnancy and intrauterine fetal demise.

Progestosterone concentrations are significantly elevated in women with hydatidiform mole complications of Rh isoimmunization.
Goal
To increase the probability of a healthy baby without maternal compromise

When and How Often
- < 28 weeks—every month
- 28 to 36 weeks—every 2 to 3 weeks
- 36 weeks to delivery—once per week until delivery

See Table 5-1.

Definitions
Gravidity: The number of times a woman has been pregnant
Parity: The number of times a woman has had a pregnancy that led to a birth after 20 weeks' gestation or an infant > 500 g

Terminology of Reproductive History
The mother's pregnancy history is described in terms of gravidity (G) and parity (P), in which parity includes term births, preterm births, abortions, and living children. The order expressed is as follows:
- Total number of times pregnant
  - (Gravidity); Term births; Preterm births;
  - Abortuses; Living Children
The terminology is written as in the following example: G3P1201.

The above indicates that a woman has been pregnant 3 times, has had 1 term birth, 2 preterm births, 0 abortions, and has 1 live child.
TABLE 5-1. Prenatal Visits

<table>
<thead>
<tr>
<th>First Visit</th>
<th>6–8 Weeks</th>
<th>16–18 Weeks</th>
<th>26–28 Weeks</th>
</tr>
</thead>
<tbody>
<tr>
<td>2. Labs:</td>
<td>2. Fetal exam:</td>
<td>2. Fetal exam:</td>
<td>2. Fetal exam:</td>
</tr>
<tr>
<td>■ Hct/Hgb</td>
<td>■ Fetal heart tones</td>
<td>■ Fetal heart</td>
<td>■ Fetal heart</td>
</tr>
<tr>
<td>■ Rh factor</td>
<td>■ Urine analysis and culture</td>
<td>■ Fundal height</td>
<td>■ Fundal height</td>
</tr>
<tr>
<td>■ Blood type</td>
<td>■ HIV testing (if repeat is warranted)</td>
<td>■ Fetal position</td>
<td>■ Fetal position</td>
</tr>
<tr>
<td>■ Antibody screen</td>
<td></td>
<td>3. Pelvic sonogram (optional)</td>
<td>3. Labs:</td>
</tr>
<tr>
<td>■ Pap smear</td>
<td></td>
<td>4. Amniocentesis (if indicated)</td>
<td>■ Complete blood count</td>
</tr>
<tr>
<td>■ Gonorrhea and Chlamydia cultures</td>
<td>5. Triple screen (serum alpha-fetoprotein, estriol, beta-hCG)</td>
<td></td>
<td>■ Ab screen</td>
</tr>
<tr>
<td>■ Urine analysis (glucose, proteins, ketones) and culture, microscopic exam for sediment</td>
<td>6. Urine analysis and culture</td>
<td></td>
<td>■ Gonorrhea and Chlamydia cultures (optional)</td>
</tr>
<tr>
<td>■ Infection screen: Rubella, syphilis, hepatitis B, human immunodeficiency virus (HIV), tuberculosis (TB)</td>
<td></td>
<td>4. Give Rhogam if nonsensitized Rh negative patient</td>
<td></td>
</tr>
<tr>
<td>3. Genetic screen</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4. Patient education</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Week 32</th>
<th>Week 36</th>
<th>Week 38</th>
<th>Week 39</th>
<th>Week 40</th>
</tr>
</thead>
<tbody>
<tr>
<td>2. Fetal exam:</td>
<td>2. Fetal exam:</td>
<td>2. Fetal exam:</td>
<td>2. Fetal exam:</td>
<td>2. Fetal exam:</td>
</tr>
<tr>
<td>■ Fetal heart</td>
<td>■ Fetal heart</td>
<td>■ Fetal heart</td>
<td>■ Fetal heart</td>
<td>■ Fetal heart</td>
</tr>
<tr>
<td>■ Fundal height</td>
<td>■ Fundal height</td>
<td>■ Fundal height</td>
<td>■ Fundal height</td>
<td>■ Fundal height</td>
</tr>
<tr>
<td>■ Fetal position</td>
<td>■ Fetal position</td>
<td>■ Fetal position</td>
<td>■ Fetal position</td>
<td>■ Fetal position</td>
</tr>
<tr>
<td>4. Group B strep culture</td>
<td>4. Cervical exam (frequency is controversial)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>4. Fetoplacental functional tests (if indicated)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Important Hallmarks in Prenatal Visits

- Pap smear—first visit
- Rh screen—first visit
- Gonorrhea and Chlamydia—first visit
- First sonogram—week 16 to 18
- Amniocentesis—week 16 to 18
- Triple screen—week 16 to 18
- Diabetes screen—week 26 to 28
- Group B strep culture—week 36
Definitions

Gestational age (GA): The time of pregnancy counting from the first day of the last menstrual period
Developmental age: The time of pregnancy counting from fertilization
First trimester: 0 to 14 weeks
Second trimester: 14 to 28 weeks
Third trimester: 28 weeks to birth
Embryo: Fertilization to 8 weeks
Fetus: 8 weeks until birth
Preivable: Before 24 weeks
Preterm: 24 to 37 weeks
Term: 37 to 42 weeks

Nägele’s Rule

- Nägele’s rule is used to calculate the estimated date of confinement (i.e., due date) +/- 2 weeks
- First day of patient’s last normal menstrual period – 3 months + 7 days + 1 year

Abdominal Exam and Fundal Height

As the fetus grows, the location of the uterus, or fundal height, grows superiorly in the abdomen, toward the maternal head. The location in the abdomen that the fetus and uterus are located is described in terms of weeks (see Figure 5-1).

- Fetus at the level of umbilicus: 20 weeks
- Fetus at level of pubic symphysis: 12 weeks
- Fetus between pubic symphysis and umbilicus: 16 weeks

The Triple Screen: Maternal Serum Screening

Maternal Serum Alpha-Fetoprotein (MSAFP)

- Normally, MSAFP begins to rise at 13 weeks and peaks at 32 weeks. It is produced in the placenta.
- MSAFP screening is most accurate between 16 and 18 weeks.
- An inaccurate gestational age is the most common reason for an abnormal screen.

High levels are associated with:
- Neural tube defects (NTDs)
- Abdominal wall defects (gastrochisis and omphalocele)
- Fetal death
- Placental abnormalities (i.e., abruption)
- Multiple gestations

Low levels are associated with:
- Down’s syndrome (Trisomy 21)
- One third to one fifth of Down’s syndrome fetuses exhibit low MSAFP

High-Yield Facts

Antepartum

Nägele’s rule assumes two things:
1. A normal gestation is 280 days.
2. Patients all have a 28-day menstrual cycle.

Example:
If LMP = July 20, 2001, then EDC = April 27, 2002

The first step in the workup of an abnormal triple screen should be an ultrasound for dating.

Most NTDs are thought to be polygenic or multifactorial.
Estradiol

Low levels are associated with:
- Trisomy 21 (Down's syndrome)
- Trisomy 18 (Edward's syndrome)
- Possibly low in trisomy 13 (Patau's syndrome)

Human Chorionic Gonadotropin (hCG)

High levels are associated with:
- Trisomy 21

Low levels are associated with:
- Trisomy 18
- Anencephaly

Rh INCOMPATIBILITY AND PREGNANCY

What Is Rh?

- The surface of the human red blood cell (RBC) may or may not contain a Rhesus (Rh) antigen. If so, that person is said to be Rhesus + (for example, if someone with blood type A has a Rhesus antigen, the blood type is A+). If that person has no Rhesus antigen, he is A–).
- Half of all antigens in a fetus come from the father, and half come from the mother.
The Problem with Rh Sensitization

The parental combination you must worry about: Mother Rh− and father Rh+.
- If the pregnant female is Rh− and her fetus is Rh+, then she may become sensitized to the Rh antigen and develop antibodies (Figure 5-2).
- These antibodies cross the placenta and attack the fetal RBCs → fetal RBC hemolysis.

Sensitization

Sensitization may occur during:
- Amniocentesis
- Miscarriage/threatened abortion
- Vaginal bleeding
- Placental abruption/previa
- Delivery
- Abdominal trauma
- Cesarean section
- External version

Scenario of Fetal Danger

Rh− mother becomes sensitized during an earlier pregnancy in which the child was Rh+. She is exposed to Rh+ blood during that pregnancy and/or delivery and develops antibodies. Then, in a later pregnancy, her immune system, already primed to recognize Rh+ blood, crosses the placenta and attacks Rh+ fetal blood.

Screening

In each pregnancy, a woman should have her Rh type determined and an antibody screen performed at the initial visit with an indirect Coombs’ test.

RhoGAM: Treatment for Exposure

If the Rh− mother is exposed to fetal blood, RhoGAM is given. RhoGAM is RhIgG (IgG that will attach to the Rh antigen) and prevent immune response by the mother.

Erythroblastosis fetalis

Hemolytic disease of the newborn/fetal hydrops occurs when the mother lacks an antigen present in the fetus → fetal RBCs trigger an immune response when they reach the mother’s circulation → maternal antibodies cause fetal RBC hemolysis and anemia → fetal hyperbilirubinemia → kernicterus → heart failure, edema, ascites, pericardial effusion.

After Rh sensitization, a Kleihauer–Bettke test is done to determine the amount of fetal RBCs in the maternal circulation. Adjustments in the amount of RhIgG are given to mother accordingly (see RhoGAM below).

FIGURE 5-2. Rh incompatibility.
(Reproduced, with permission, from DeCherney AH, Pernoll ML. Current Obstetric & Gynecologic Diagnosis & Treatment. Norwalk, CT: Appleton & Lange, 1994: 339.)
Managing the Unsensitized Rh− Patient (The Rh− Patient Who Has a Negative Antibody Screen)

1. Antibody screen should be done at 0, 24 to 28 weeks.
2. If negative, give 300 µg of RhIgG to prevent maternal development of antibodies.
3. At birth, determine if baby is Rh+; if so, give postpartum RhIgG.

Management of the Sensitized Rh− Patient (If on Initial Visit the Antibody Screen for Rh Is Positive)

1. Perform antibody screen at 0, 12 to 20 weeks.
2. Check the antibody titer.
   - If titer remains stable at < 1:16, the likelihood of hemolytic disease of the newborn is low.
   - If the titer is > 1:16 and/or rising, the likelihood of hemolytic disease of the newborn is high.
3. Amniocentesis begins at 16 to 20 weeks' GA.
   - Fetal cells are analyzed for Rh status.
   - Amniotic fluid is analyzed by spectrophotometer, which measures the light absorbance by bilirubin. Absorbance measurements are plotted on the Liley curve, which predicts the severity of disease.

FETAL IMAGING

Ultrasound
- Intrauterine pregnancy seen via vaginal ultrasound (US) when beta-hCG > 1,500
- Intrauterine pregnancy seen via abdominal US when beta-hCG > 6,000

Amniocentesis
Amniocentesis is the most extensively used fetal sampling technique and is typically performed at 15 weeks’ GA when the amniotic fluid is 200 mL.

Indications
- Fetal anomaly suspected on US
- Abnormal MSAFP
- Family history of congenital abnormalities
- Offered to all patients ≥ 35 years of age

Procedure
- Thirty milliliters of amniotic fluid is removed via a 20- to 22-gauge needle using a transabdominal approach with US guidance.
- Biochemical analysis is performed on the extracted fluid:
  - Amniotic fluid AFP levels
  - Fetal cells can be grown for karyotyping or DNA assays.

Risks
- Pain/cramping
- Vaginal spotting/amniotic fluid leakage in 1 to 2% of cases
Symptomatic amnionitis in < 1/1,000 patients
Rate of fetal loss ≤ 0.5%

Chorionic Villus Sampling (CVS)

Chorionic villus sampling is a diagnostic technique in which a small sample of chorionic villi is taken transcervically or transabdominally and analyzed.
- Typically done between 9 and 12 weeks’ GA
- Allows for chromosomal status, fetal karyotyping, and biochemical assays or DNA tests to be done earlier than amniocentesis

Risks
- 0.5% rate of complications
- Preterm delivery
- Premature rupture of membranes
- Fetal injury

Cordocentesis

Cordocentesis is a procedure in which a spinal needle is advanced transplacentally under US guidance into a cord vessel to sample fetal blood. Typically performed after 17 weeks.

Indications
- Fetal karyotyping because of fetal anomalies
- To determine the fetal hematocrit in Rh isoimmunization or severe fetal anemia
- To assay fetal platelet counts, acid–base status, antibody levels, blood chemistries, etc.
- Fetal abdominal measurements: Taken to determine their proportionality to the fetal head (head-to-abdominal circumference ratio) and assess fetal growth.
- Amniotic fluid index (AFI): Represents the total of linear measurements (in centimeters) of the largest amniotic fluid pockets in each of the four quadrants of the amniotic fluid sac.
  - Reduced amniotic fluid volume (AFI < 5) = oligohydramnios
  - Excessive fluid (AFI > 20) = polyhydramnios

Genetic Testing

Genetic testing, if indicated, is performed with the following techniques:
- FISH (fluorescent in situ hybridization): A specific DNA probe with a fluorescent label that binds homologous DNA → allows identification of specific sites along a chromosome
- Karyotyping: Allows visualization of chromosome size, banding pattern, and centromere position

Indications
- Advanced maternal age
- Previous child with abnormal karyotype
- Parental chromosome rearrangements
- Fetal structural abnormality on sonogram
- Unexplained intrauterine growth retardation (IUGR)
- Abnormally low MSAFP
**NUTRITIONAL NEEDS OF THE PREGNANT WOMAN**

**Weight Gain**
- Weight gain for normal BMI = 25 to 35 lb
- Optimal weight gain for an underweight teenager carrying a singleton pregnancy = 40 lb or 5 lb every 4 weeks in second half of pregnancy
- An obese woman may need to gain only 15 lb.

**Diet**
- The average woman must consume an additional 300 kcal/day beyond baseline needs.

**Vitamins**
- 400 µg/day folic acid is required.
- 30 mg elemental iron per day is recommended in T2 and T3.
- Total of 1 g Fe is needed for pregnancy (500 mg for increase RBC mass, 300 mg for fetus, 200 mg for GI losses).
- The recommended dietary allowance (RDA) for calcium is increased in pregnancy to 1,200 mg/day and may be met adequately with diet alone.
- The RDA for zinc is increased from 15 to 20 mg/day.

**Vegetarians**
- *Lactoovovegetarians* in general have no nutritional deficiencies, except possibly Fe and Zn.
- *Vegans* must consume sufficient quantities of vegetable proteins to provide all essential amino acids normally found in animal protein.
- Due to decreased protein density of most vegetables, patients may gain a greater than average amount of weight.
- Supplementation of Zn, vitamin B12, and Fe is necessary.

**Pica**
Occasionally seen in pregnancy, pica is the compulsive ingestion of nonfood substances with little or no nutritional value:
- Ice
- Clay (geophagia)
- Starch (amylophagia)

**ANSWERS TO COMMONLY ASKED QUESTIONS**

**Caffeine in Pregnancy**
- Contained in coffee, tea, chocolate, cola beverages
- Currently no studies have shown deleterious fetal effects with customary amounts
Adverse maternal effects include:
- Insomnia
- Acid indigestion
- Reflux
- Urinary frequency

**Exercise**
- No data exist to indicate that a pregnant woman must decrease the intensity of her exercise or lower her target heart rate.
- Women who exercised regularly before pregnancy should continue:
  - Exercise may relieve stress, decrease anxiety, increase self-esteem, and shorten labor.
- The form of exercise should be one with low risk of trauma, particularly abdominal.
- Exercise that requires prolonged time in the supine position should be avoided in T2 and T3.
- Exercise should be stopped if patient experiences oxygen deprivation → extreme fatigue, dizziness, or shortness of breath.
- Contraindications to exercise include:
  - Evidence of IUGR
  - Persistent vaginal bleeding
  - Incompetent cervix
  - Risk factors for preterm labor
  - Rupture of membranes
  - Pregnancy-induced hypertension

**Nausea and Vomiting (N&V)**
- Recurrent N&V in T1 occurs in 50% of pregnancies.
- If severe, can result in dehydration, electrolyte imbalance, and malnutrition.
- Management of mild cases includes:
  - Avoidance of fatty or spicy foods
  - Eating small, frequent meals
  - Inhaling peppermint oil vapors
  - Drinking ginger teas
- Management of severe cases includes:
  - Discontinuation of vitamin/mineral supplements until symptoms subside
  - Antihistamines
  - Promethazine
  - Metoclopramide
  - Intravenous droperidol

**Heartburn**
- Common in pregnancy
- Treatment consists of:
  - Elimination of spicy/acidic foods
  - Small, frequent meals
  - Decrease amount of liquid consumed with each meal
  - Limit food and liquid intake a few hours prior to bedtime

“Morning sickness” can occur day or night.
- Sleep with head elevated on pillows
- Utilize liquid forms of antacids and H$_2$-receptor inhibitors

**Constipation**
- Common in pregnancy
- Management includes:
  - Increase intake of high-fiber foods
  - Increase liquids
  - Psyllium-containing products

**Varicosities**
- Common in pregnancy, particularly in lower extremities and vulva
- Can lead to chronic pain and superficial thrombophlebitis
- Management includes:
  - Avoidance of garments that constrict at the knee and upper leg
  - Use of support stockings
  - Increased periods of rest with elevation of the lower extremities

**Hemorrhoids**
- Varicosities of the rectal veins are common in pregnancy
- Management includes:
  - Cool sitz baths
  - Stool softeners
  - Increase fluid and fiber intake to prevent constipation

**Leg Cramps**
- Occur in 50% of pregnant women, typically at night and in T3
- Most commonly occur in the calves
- Massage and stretching of the affected muscle groups is recommended.

**Backache**
- Typically progressive in pregnancy
- Management includes:
  - Minimize time standing.
  - Wear a support belt over the lower abdomen.
  - Acetaminophen
  - Exercises to increase back strength
  - Supportive shoes and avoidance of high heels

**Round Ligament Pain**
- Sharp, bilateral or unilateral groin pain
- Frequently occurs in T2
- May increase with sudden movement/change in position
- May be alleviated by patient getting on hands and knees with head on floor and buttocks in air
Sexual Relations

- There are no restrictions during the normal pregnancy.
- Nipple stimulation, vaginal penetration, and orgasm may release of oxytocin and prostaglandins → uterine contractions.
- Contraindications:
  - If membranes have ruptured
  - If + placenta previa

Employment

- Work activities that increase risk of falls/trauma should be avoided.
- Exposure to toxins/chemicals should be avoided.

Travel

- If prolonged sitting is involved, the patient should attempt to stretch her lower extremities and walk for 10 minutes every 2 hours.
- The patient should bring a copy of her medical record.
- Wear seat belt when riding in car.
- Airplane travel in pressurized cabin presents no additional risk to the pregnant woman.
- In underdeveloped areas or when traveling abroad, the usual precautions regarding ingestion of unpurified water and raw foods should be taken.

Immunizations

There is no evidence of fetal risk from inactivated virus vaccines, bacterial vaccines, toxoids, or tetanus immunoglobulin, and they should be administered as appropriate. Safe vaccines:

- Yellow fever
- Oral polio
- Hepatitis B
- Diphtheria
- Tetanus

Three immunizations should be avoided during pregnancy:

- Measles
- Mumps
- Rubella

Viral vaccinations may be safely given to the children of pregnant women.

Immune globulin is recommended for pregnant women exposed to measles, hepatitis A and B, tetanus, chickenpox, or rabies.

When to Call the Physician

- Vaginal bleeding
- Leakage of fluid from the vagina
- Rhythmic abdominal cramping of > 6/hr
- Progressive and prolonged abdominal pain
- Fever and chills
- Dysuria
- Prolonged vomiting with inability to hold down liquids or solids for > 24 hours
- Progressive, severe headache, visual changes, or generalized edema
- Pronounced decrease in frequency or intensity of fetal movements
THREE STAGES OF LABOR

The successive stages of labor are illustrated in Figure 6-1.

**First Stage**

The first stage of labor begins with onset of labor (uterine contractions of sufficient frequency, intensity, and duration to result in effacement and dilation of the cervix), and ends when the cervix is fully/completely dilated to 10 cm. The first stage of labor consists of two phases:

1. **Latent phase**: Begins with the onset of labor and ends at approximately 4 cm cervical dilatation.
   
   **Average Duration**
   - Nulliparous—20 hours
   - Multiparous—14 hours

2. **Active phase**: Rapid dilation. Begins at 4 cm dilation and ends at 10 cm.

   Active phase is further classified according to the rate of cervical dilation: 
   - *Acceleration phase*, phase of maximum slope, and *deceleration phase*.

Fetal descent begins at 7 to 8 cm of dilation in nulliparas and becomes most rapid after 8 cm.

**Second Stage**

The second stage of labor is the stage of fetal expulsion. It begins when the cervix is fully dilated and ends with the delivery of the fetus.

**Average Pattern of Fetal Descent**
- Nulliparous: 1 cm/hr
- Multiparous: 2 cm/hr

HIGH-YIELD FACTS IN INTRAPARTUM

Duration of labor is typically shorter in the multiparous woman than in nulliparous women.

There are three stages of labor, and two phases of stage 1.

Remember the three “Ps” that affect the duration of the Active Phase:
- **Power** (strength and frequency of contractions)
- **Passenger** (size of the baby)
- **Pelvis** (size and shape of mother’s pelvis)
Third Stage

The main event of the third stage is placental separation. It begins immediately after the delivery of the fetus and ends with the delivery of the fetal and placental membranes.

Duration

- Usually under 10 minutes; considered prolonged if more than 30 minutes

The three signs of placental separation are:

1. Gush of blood from vagina
2. Umbilical cord lengthening
3. Fundus of the uterus rises up and becomes firm

TRUE LABOR VERSUS FALSE LABOR

False Labor (Braxton Hicks Contractions)

- Occur at irregular intervals
- Intensity remains the same
- Discomfort in lower abdomen
- Cervix is not dilated
- Relieved by medications

True Labor

- Occur at regular intervals that shorten
- Increase in intensity
- Discomfort in back and lower abdomen
- Dilated cervix
- NOT relieved by medications
**Blood Facts About the Uterus**

- Blood supply to the uterus—uterine and ovarian arteries
- Normal blood flow to nonpregnant uterus—100 cc/min
- Normal blood flow to 17-week uterus—500 cc/min (intrauterine growth retardation occurs if flow is less)
- Normal blood loss for normal vaginal delivery—300 to 500 mL
- Normal blood loss for normal C-section—800 to 1,000 mL

**Clinical Signs of Labor**

**Bloody Show**
Discharge of small amount of blood-tinged mucus from vagina (mucous plug)

**Rupture of Membranes (ROM)**
ROM is characterized by sudden gush of nearly colorless fluid. ROM can be diagnosed with pool, nitrazine, and fern tests (described in PROM section).

**Assessment of the Laboring Patient**

**Initial Assessment**

**History and Physical**
- Patients without prenatal care require a complete H&P and those with prenatal care require an update and focused physical. Prenatal record should be obtained when possible.

**Labs**
- Patients without prenatal care require:
  - Complete blood count (CBC)
  - Blood typing
  - Rh determination
  - Urine testing
- Patients who have had antepartum care require:
  - Urine test for protein or glucose
  - CBC
  - A specimen of blood in the event that subsequent crossmatching is required

**Crucial Information for a Laboring Patient**

The following information should always be obtained from a laboring patient:
- Time of onset and frequency of contractions
- Status of fetal membranes
- Presence/absence of vaginal bleeding
- Notation of fetal activity
Vaginal Exam (VE)
A sterile speculum exam if:
- Suspect rupture of membranes
- Preterm labor
- Signs of placenta previa
Otherwise, a digital VE may be performed
The following must be assessed:

STATUS OF AMNIOTIC FLUID AND MEMBRANES
A sterile speculum is used to look for fluid in the posterior vaginal fornix (pool test), which determines if ROM has occurred.
Fluid may be collected on a swab for further study if the source of fluid is unclear:
- Ferning test (high estrogen content of amniotic fluid causes fern pattern on slide when allowed to air dry):
- Crystallization/arborization is due to interaction of amniotic fluid proteins and salts.
- Confirms ROM in 85 to 98% of cases
- Nitrazine test—nitrazine paper is pH sensitive and turns blue in presence of amniotic fluid:
- Amniotic fluid (pH = 7.15) is more alkaline than vaginal secretions.
- 90 to 98% accurate
Fluid should also be examined for vernix or meconium.
- The presence of meconium in the amniotic fluid may indicate fetal stress.
- Meconium staining is more common in term and postterm pregnancies than in preterm pregnancies.
- Meconium aspiration syndrome (MAS) can occur → infant tachypnea, costal retractions, cyanosis, coarse breath sounds, etc.
- Prevent MAS via amnioinfusion intrapartum and DeLee suction postpartum

CERVICAL EXAM
There are four parameters of the cervix that are examined: effacement, consistency, dilation, and position.

EFFACEMENT
Effacement describes the length of the cervix. With labor, the cervix thins out and softens, and the length is reduced. The normal length is 3 to 4 cm.
- Terminology: When the cervical length shrinks by 50% (to around 2 cm), it is said to be 50% effaced. When the cervix becomes as thin as the adjacent as the lower uterine segment it is 100% effaced.
Determination of effacement: Palpate with finger and estimate the length from the internal to external os.

Dilation

Dilation describes the size of the opening of the cervix at the external os.
- Ranges: Ranges from closed or zero to fully dilated (10 cm). The presenting part of a term-sized infant can usually pass through a cervix that is fully dilated.
- Determination of dilation: The examining finger is swept from the margin of the cervix on one side to the opposite side.

Cervical Position

Position describes the location of cervix with respect to the fetal presenting part. It is classified as one of the following:
- Posterior—difficult to palpate because it is behind the fetus, and usually high in the pelvis
- Midposition
- Anterior—easy to palpate, low down in pelvis

During labor, the cervical position usually progresses from posterior to anterior.

Cervical Consistency

Consistency ranges from firm to soft. Soft indicates onset of labor.

Bishop Score

- A scoring system that helps determine the status of the cervix—is it favorable or unfavorable for successful delivery?
- If induction of labor is indicated, the status of the cervix must be evaluated to help determine the method of labor induction that will be utilized.

See Table 6-1 and section on Labor Induction.

A score of $\geq 8$ indicates that the probability of vaginal delivery after labor induction is similar to that after spontaneous labor.

<table>
<thead>
<tr>
<th>TABLE 6-1. Bishop Scoring System</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Factor</strong></td>
</tr>
<tr>
<td>——</td>
</tr>
<tr>
<td>Dilation (cm)</td>
</tr>
<tr>
<td>Effacement (%)</td>
</tr>
<tr>
<td>Station$^a$</td>
</tr>
<tr>
<td>Consistency</td>
</tr>
<tr>
<td>Position</td>
</tr>
</tbody>
</table>

$^a$ Station reflects −3 to +3 scale.
Leopold Maneuvers

Leopold maneuvers are begun in midpregnancy through labor to assess the fetus and maternal abdomen (Figure 6-2). Consist of four parts:

First maneuver answers the question: “What fetal part occupies the fundus?”
Second maneuver answers the question: “On what side is the fetal back?”
Third maneuver answers the question: “What fetal part lies over the pelvic inlet?”
Fourth maneuver answers the question: “On which side is the cephalic prominence?”

Five aspects of the fetus are described from the Leopold maneuvers:

- Station
- Lie
- Presentation
- Position
- Attitude

**FIGURE 6-2.** Leopold maneuvers. Determining fetal presentation (A and B), position (C), and engagement (D).

**Station**

Station describes the degree of descent of the fetal head (or presenting part) in relation to ischial spines.

**Terminology (Two Systems)**

1. The ischial spine is zero station, and the areas above and below are divided into thirds. Above the ischial spines are stations $-3$, $-2$, and $-1$, with $-3$ being the furthest above the ischial spines and $-1$ being closest. Positive stations describe fetal descent below the ischial spines. $+3$ station is at the level of the introitus, and $+1$ is just past the ischial spines.

2. Very similar except that the areas above and below the ischial spines are divided by centimeters, up to 5 cm above and 5 cm below. Above are five stations or centimeters: $-5$, $-4$, $-3$, $-2$, and $-1$, with $-5$ being the 5 cm above the ischial spines and $-1$ being 1 cm above. Positive stations describe fetal descent below the ischial spines. $+5$ station is at the level of the introitus, and $+1$ is 1 cm past the ischial spines.

**Lie**

Lie describes the relation of the long axis of the fetus to that of the mother. Can be either:

- **Longitudinal** (99% of term or near term births). This can be vertex (head first) or breech (buttocks first).
- **Transverse** (0.4% of term or near term births)

**Presentation/Presenting Part**

Presentation describes the portion of the fetus that is foremost within the birth canal. It is normally determined by palpating through the cervix on vaginal examination.

- If the lie is longitudinal, the presentation is either the head (cephalic) or buttocks (breech). One type of cephalic presentation is the vertex presentation in which the posterior fontanel is the presenting part. This is considered normal.
- If the lie is transverse, the shoulder is the presenting part.

**The Fetal Skull**

The top of the fetal skull is composed of five bones: two frontal, two parietal, and one occipital. The anterior fontanel lies where the two frontal and two parietal meet, and the posterior fontanel lies where the two parietal meet the occipital bone.

**Fetal Positions**

Position refers to the relation of the presenting part to the right (R) or left (L) side of the birth canal and its direction anteriorly (A), transversely (T), or posteriorly (P).

For a cephalic occipital presentation, the position can be described in the following ways:

- Occipital anterior (OA)
- Occipital posterior (OP)
- Left occipital anterior (LOA)
- Left occipital posterior (LOP)
Fetal Attitude and Posture

In the later months of pregnancy, the fetus assumes a characteristic posture ("attitude/habitus"), which typically describes the position of the arms. Examples include arms folded over thorax or parallel to the sides.

Normal Presentation

Vertex Presentation (Occipital Presentation)

Vertex presentation is usual (96% of at or near term presentations). The head is flexed so that the chin is in contact with the chest. The posterior fontanel is the presenting part.
Malpresentations

Face Presentation
In face presentation (0.3% of presentations at or near term), the fetal neck is sharply extended so the occiput is in contact with the fetal back. The face is the presenting part. Diagnosis is made by palpation of the fetal face on vaginal exam.

Sinciput Presentation
The fetal head assumes a position between vertex presentation and face presentation so that the anterior fontanel presents first.

Brow Presentation
The fetal head assumes a position such that the eyebrows present first. This forces a large diameter through the pelvis; usually, vaginal delivery is possible only if the presentation is converted to a face or vertex presentation.

Breech Presentations
In breech presentations, the presenting fetal part is the buttocks. Normally, the delivery is C-section. Incidence: 3.5% at or near term but much greater in early pregnancy (14%). Those found in early pregnancy will often spontaneously convert to vertex as term approaches.

Risk Factors
- Low birth weight (20 to 30% of breeches)
- Congenital anomalies such as hydrocephalus or anencephaly
- Uterine anomalies
- Multiple gestation
- Placenta previa

Diagnosis can be made by:
- Leopold maneuvers
- Ultrasound

Types of Breech
- Frank breech (65%): The thighs are flexed (bent forward) and the legs are extended (straight) over the anterior surfaces of the body (feet are in front of the head or face).
- Complete breech (25%): The thighs are flexed (bent) on the abdomen and the legs are flexed (folded) as well.
- Incomplete (footling) breech (10%): One or both of the hips are not flexed so that a foot lies below.

Management
- Normally, C-section is the form of delivery.
- External cephalic version: This is maneuvering the infant to a vertex position. Can be done only if breech is diagnosed before onset of labor and the GA > 37 weeks. The success rate is 75%, and the risks are placental abruption or cord compression.
- Trial of breech vaginal delivery: This is the attempt at a vaginal delivery. It can be done only in a frank breech, GA > 36 weeks, fetal weight 2,500 to 3,800 g, fetal head flexed, and favorable pelvis. Risks are greater for birth trauma (especially brachial plexus injuries) and prolapsed cord that entraps the aftercoming head.
SHOULDER DYSTOCIA

Shoulder dystocia occurs when, after the fetal head has been delivered, the fetal shoulder is impacted behind the pubic symphysis.

Risk Factors
- Macrosomia
- Gestational diabetes
- Maternal obesity
- Post-term delivery
- Prolonged stage 2 of labor

Complications
- Fetal humeral/clavicular fracture
- Brachial plexus nerve injuries
- Hypoxia/death

Treatment
Several maneuvers can be done to displace the shoulder impaction:
- Suprapubic pressure on maternal abdomen
- McRoberts maneuver: Maternal thighs are sharply flexed against maternal abdomen. This decreases the angle between the sacrum and spine and may dislodge fetal shoulder.
- Woods corkscrew maneuver: Pressure is applied against scapula of posterior shoulder to rotate the posterior shoulder and "unscrew" the anterior shoulder.
- Posterior shoulder delivery: Hand is inserted into vagina and posterior arm is pulled across chest, delivering posterior shoulder and displacing anterior shoulder from behind pubic symphysis.
- Break clavicle or cut through symphysis
- Zavanelli maneuver: If the above measures do not work, the fetal head can be returned to the uterus. At this point, a C-section can be performed.

CARDINAL MOVEMENTS OF LABOR

The cardinal movements of labor are changes in the position of the fetal head during passage through the birth canal. The movements are as follows: engagement, flexion, descent, internal rotation, extension, and external rotation.

Engagement
Engagement is the descent of the biparietal diameter (the largest transverse diameter of the fetal head, 9.5 cm) to the plane of the pelvic inlet (Figure 6-4):
- Often occurs before the onset of true labor, especially in nulliparas

Descent
Descent is the fetal head passing down into the pelvis. It occurs in a discontinuous fashion. The greatest rate of descent occurs in the deceleration phase of the first stage of labor and during the second stage of labor (Figure 6-5).
Flexion refers to the chin-to-chest position that the fetus takes. This passive motion facilitates the presentation of the smallest possible diameter of the fetal head to the birth canal.

**Internal Rotation**

Internal rotation refers to the fetal occiput gradually rotating toward the pubic symphysis (Figure 6-6).

**Extension**

Extension moves the occiput to the fetal back (Figure 6-7):

- Occurs after the fetus has descended to the level of the maternal vulva
- This descent brings the base of the occiput into contact with the inferior margin of the symphysis pubis, where the birth canal curves upward.
- The fetal head is delivered by extension from the flexed to the extended position, thus curving under and past the pubic symphysis.
External Rotation (“Restitution”)

External rotation occurs after delivery of the head, when the fetus resumes its normal “face-forward” position with the occiput and spine lying in the same plane (Figure 6-8).

External rotation is completed by rotation of the fetal body to the transverse position (i.e., one shoulder is anterior behind the pubic symphysis and the other is posterior).

Expulsion

After external rotation, further descent brings the anterior shoulder to the level of the pubic symphysis. The shoulder is delivered under the pubic symphysis and then the rest of the body is quickly delivered (Figures 6-9 and 6-10).

The anterior shoulder is the one closest to the superior portions of the vagina, while the posterior shoulder is closest to the perineum and anus.
STANDARD METHOD OF DELIVERY

Delivery of the Head: Modified Ritgen Maneuver

The modified Ritgen maneuver is a technique that allows for delivery of the fetal head with its smallest diameter passing through the introitus and over the perineum (see Figure 6-6B).

- A towel-draped, gloved hand is placed over the perineum and rectum and exerts upward pressure on the fetal chin.
- Simultaneously, a gloved hand is placed superiorly and exerts downward pressure over the fetal occiput.

It is done during a contraction when the head distends the vulva and perineum enough to open the vaginal introitus to \( \geq 5 \) cm in diameter.

Checking for Nuchal Cord

A nuchal cord is when the umbilical cord wraps around the fetal neck. To check for this condition, following delivery of the head, a finger should be passed along the fetal neck to ascertain the presence of the cord.

- If so, a finger should be slipped under the cord and, if loose enough, it should be slipped over the infant’s head.
- If the cord is wrapped tightly around the infant’s neck, it should be cut between two clamps.
- The infant should then be delivered.

Typically, the rest of the body rapidly follows the delivery of the shoulders without effort.

Delivery of Shoulders

- Most frequently, the shoulders appear at the vulva just after external rotation and are born spontaneously (see Figures 6-9 and 6-10).
Occasionally, the shoulders must be extracted:
- The sides of the head are grasped with both hands and gentle downward traction is applied until the anterior shoulder descends from under the pubic arch.
- Next, gentle upward traction is applied to deliver the posterior shoulder.

**Vaginal Lacerations**

The perineum and anus become stretched and thin, which results in increased risk of spontaneous laceration and anterior tears involving the urethra and labia.
First Degree
Involve the fourchette, perineal skin, and vaginal mucosa, but not the underlying fascia and muscle.
Repair: Absorbable sutures (e.g., 3-0 vicryl)

Second Degree
First degree plus the fascia and muscle of the perineal body but not the rectal sphincter.
Repair: Done in layers, sometimes using a crown stitch to bring the perineal body together (e.g., with 3-0 vicryl)

Third Degree
Second degree plus involvement of the anal sphincter.
Repair: Repair anal sphincter with interrupted sutures (e.g., 2-0 vicryl) and repair vagina as in second-degree laceration.

Fourth Degree
Extend through the rectal mucosa to expose the lumen of the rectum.
Repair: Same as third-degree repair plus careful repair of anal mucosa (e.g., with 4-0 vicryl)

Episiotomy
An episiotomy is the incision of the perineum and/or labia to aid delivery. There are two types:

1. Midline: The incision is made in the midline from the posterior fourchette. Most common.
2. Mediolateral: The incision is oblique starting from 5 o’clock or 7 o’clock position of the vagina. Causes more infection and pain.

Indications
- Risk of perineal rupture
- Shoulder dystocia
- Breech delivery
- Forceps/vacuum delivery

Postdelivery Tasks
1. Clear the nasopharynx:
   - To minimize infant aspiration of amniotic fluid debris and blood that may occur once the thorax is delivered and the baby can inspire
   - Use a bulb syringe to aspirate the mouth and nares.
2. Clamping and cutting the cord:
   - The umbilical cord is clamped by two instruments and cut in between.
   - The infant is handed to the pediatrician/nurse/assistant for examination.
   - A sample of cord blood is taken from the umbilical cord that remains attached to the placenta.
Postdelivery Uterine Exam
- The height and consistency of the uterine fundus are ascertained.
- A moderate amount of bleeding is normal.

Placental Separation

**Signs**
1. Uterus becomes globular and more firm.
2. There is often a sudden gush of blood.
3. The uterus rises in the abdomen due to the bulk of the placenta, which has (separated) passed down into the lower uterine segment and vagina.
4. The umbilical cord protrudes farther out of the vagina, indicating descent of the placenta.

Delivery of the Placenta

- Pressure is applied to the body of the uterus as the umbilical cord is held slightly taut.
- The uterus is lifted cephalad with the abdominal hand.
- This maneuver is repeated until the placenta reaches the introitus.
- As the placenta passes to the introitus, pressure on the uterus is stopped.
- The placenta is gently lifted away from the introitus.
- The maternal surface of the placenta should be examined to ensure that no placental fragments are left in the uterus.

Postdelivery Hemostasis

After the uterus has been emptied and the placenta delivered, hemostasis must be achieved:
- The primary mechanism is myometrial contraction → vasoconstriction.
- Oxytocin (Pitocin) is administered in the third stage of labor → myometrial contractions → reduces maternal blood loss.

Dystocia

Dystocia literally means difficult labor and is characterized by abnormally slow progress of labor.

**Causes**
1. Abnormalities of the expulsive forces:
   - Uterine dysfunction → uterine forces insufficiently strong or inappropriately coordinated to efface and dilate cervix
   - Inadequate voluntary muscle effort during second stage of labor
2. Abnormalities of presentation, position, or fetal development
3. Abnormalities of the maternal bony pelvis
4. Abnormalities of the birth canal
Monitoring Uterine Activity

Uterine Contractions

Uterine activity is monitored by internal or external uterine pressure monitors. Pressure is calculated in Montevideo units, calculated by increases in uterine pressure above baseline (8 to 12 mm Hg) multiplied by contraction frequency per 10 minutes.

Uterine Pressure Increases and Stages of Labor

Uterine contractions in the first stage of labor increase progressively in intensity from 25 mm Hg to 50 mm Hg, and the frequency increases from three to five contractions per 10 minutes.

Contractions in the second stage increase further (aided by maternal bearing down) to 80 to 100 mm Hg, and the frequency increases to five to six per 10 minutes.

Vaginal Exams

Vaginal examinations should be kept to the minimum required for the evaluation of a normal labor pattern, for example, VE q 4 hours in latent phase and q 2 hours in active phase. Sterile glove and lubricant should be utilized.

Fetal Heart Rate Monitoring

The fetal heart rate (FHR) can be measured in two ways:

1. Intermittent auscultation with a fetal stethoscope or Doppler ultrasonic device
2. Continuous electronic monitoring of the FHR and uterine contractions

First Stage of Labor

Fetal heart rate should be recorded every 30 minutes (immediately after uterine contractions).

Second Stage of Labor

Fetal heart rate should be recorded every 15 minutes (immediately after uterine contractions).

Maternal Vital Signs

Maternal blood pressure and pulse should be evaluated and recorded every 10 minutes.

Other Considerations

In most U.S. hospitals, oral intake is limited to small sips of water, ice chips, or hard candies.
Same as above with addition of the following

**Continuous Electronic Fetal Monitoring**

Continuous electronic fetal monitoring should be done with evaluation of tracing every 15 minutes during first stage and every 5 minutes during second stage. It can be done in either of the following two ways:

1. *Internal electronic FHR monitoring:* Internal FHR monitoring is done with a bipolar spiral electrode attached to fetal scalp, which detects the peak R-wave voltage of the fetal electrocardiogram.
2. *External (indirect) electronic FHR monitoring:* FHR is detected through the maternal abdominal wall with a transducer that emits ultrasound. Uterine contractions are also detected.

**Nonstress Test**

If fetal compromise is suspected, the nonstress test (NST) is the first assessment of fetal well-being:

- The mother is placed in a left lateral, supine position.
- A continuous FHR tracing is obtained using external Doppler equipment.
- The heart rate changes that result from the fetal movements are determined:
  - A normal fetal response during each fetal movement is an acceleration in fetal heart rate of ≥ 15 bpm above the baseline for at least 15 seconds.
  - If at least two such accelerations occur in a 20-minute interval, the fetus is deemed healthy and the test is reactive.
  - If an NST is nonreactive, it should be followed by a biophysical profile (BPP).

**Biophysical Profile**

A BPP uses ultrasonography and cardiotocography to ascertain fetal well-being by assessing the following five parameters:

1. Fetal breathing movements (chest wall movements)
2. Fetal activity (gross trunk or limb movements)
3. Amniotic fluid index
4. Fetal tone (flexion and extension of an extremity)
5. Reactivity (nonstress test)

A score of 0 or 2 is given for each parameter and a normal profile equals 8 to 10.

**Amniotic Fluid Index**

Amniotic fluid plays an important role in fetal lung development protection against trauma and infection.
Amniotic fluid index (AFI) is examined in the BPP and reflects the volume of amniotic fluid. The calculation of AFI is as follows: The maternal abdomen is divided into quadrants, and with ultrasound, the maximum vertical pocket of each quadrant is measured in centimeters and added.

**Normal Amniotic Fluid Volumes**
- Maximum amniotic fluid is at 28 weeks—800 mL.
- After 28 weeks, amniotic fluid decreases.
- At 40 weeks, amniotic fluid is at 500 mL.

**Abnormal Amniotic Fluid Volumes**
- Oligohydramnios is < 5 amniotic fluid index.
  - Most common cause: Rupture of membranes.
  - Associated with intrauterine growth retardation (IUGR) in 60% of cases.
- Polyhydramnios is > 20 amniotic fluid index, or 2 L.

### Fetal Heart Rate Patterns

**Important definitions:**
- **Hypoxemia:** Decreased oxygen content in blood
- **Hypoxia:** Decreased level of oxygen in tissue
- **Acidemia:** Increased concentration of hydrogen ions in the blood
- **Acidosis:** Increased concentration of hydrogen ions in tissue
- **Asphyxia:** Hypoxia with metabolic acidosis

**Reactivity and the Normal FHR**
The normal fetal heart rate is 110 to 160 bpm. This baseline (a “baseline” rate refers to a heart rate lasting ≥ 10 minutes) normally has frequent periodic variations above and below termed accelerations (increases in HR) and decelerations (decreases in HR) (Figure 6-11).

<table>
<thead>
<tr>
<th><strong>TABLE 6-2. FHR Patterns</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Early Decel</strong></td>
</tr>
<tr>
<td><strong>Significance</strong></td>
</tr>
<tr>
<td><strong>Shape</strong></td>
</tr>
<tr>
<td><strong>Onset</strong></td>
</tr>
<tr>
<td><strong>Depth</strong></td>
</tr>
<tr>
<td><strong>When</strong></td>
</tr>
<tr>
<td><strong>Why</strong></td>
</tr>
<tr>
<td><strong>Initial treatment</strong></td>
</tr>
<tr>
<td></td>
</tr>
</tbody>
</table>
A normally reactive fetal tracing has two accelerations of at least 15 bpm greater than the baseline, lasting for at least 15 seconds, in 20 minutes. It represents intact neurohumoral cardiovascular control mechanisms and indicates that the fetus is unstressed.

Periodic FHR Changes

Periodic FHR changes refers to accelerations and decelerations related to uterine contractions.

Decelerations

Decelerations during labor have different meaning depending on when they occur in relation to contractions.

Early Decelerations

Early decelerations are normal and due to head compression during contractions. The timing of onset, peak, and end coincides with the timing of the contraction. The degree of deceleration is proportional to the contraction strength. The effect is regulated by vagal nerve activation.

NO intervention necessary!!

Late Decelerations

Late decelerations are abnormal and are due to uteroplacental insufficiency (not enough blood) during contractions. They begin at the peak of contraction and end slowly after the contraction has stopped.

Intervention

- Change maternal position to the lateral recumbent position.
- Give oxygen by face mask.
- Stop oxytocin (Pitocin) infusion.
- Provide an IV fluid bolus.
- Give an IV tocolytic drug (MgSO4).
- Monitor maternal blood pressure.
- If persist longer than 30 minutes, fetal scalp blood pH should be obtained and C-section considered.
Variable Decelerations

Variable decelerations are abnormal and can be mild or severe. They are due to cord compression and sometimes head compression. They can occur at any time. If they are repetitive, suspicion is high for the cord to be wrapped around the neck or under the arm of the fetus.

**Intervention**
- Amnioinfusion: Infuse normal saline into the uterus through the intrauterine pressure catheter to alleviate cord compression.
- Change maternal position to side/Trendelenburg position.
- Deliver fetus with forceps or C-section.

**Fetal Tachycardia**

Mild = 161 to 180 bpm  
Severe = ≥ 181

Fetal tachycardia may indicate intrauterine infection, severe fetal hypoxia, congenital heart disease, or maternal fever.

**Beat-to-Beat Variability (BTBV)**
- The single most important characteristic of the baseline FHR
- Variation of successive beats in the FHR BTBV is controlled primarily by the autonomic nervous system, thus an important index of fetal central nervous system (CNS) integrity
- At < 28 weeks’ GA, the fetus is neurologically immature; thus, decreased variability is expected.

**Short-Term Variability (STV)**
- Reflects instantaneous beat-to-beat (R wave to R wave) changes in FHR
- The roughness (STV present) or smoothness (STV absent) of the FHR tracing
- May be decreased/absent due to alterations in the CNS or inadequate fetal oxygenation

**Long-Term Variability (LTV)**
- Describes the oscillatory changes that occur in 1 minute
- Results in waviness of baseline
- Normal = 3 to 6 cycles/min

**Decreases in BTBV**
Beat-to-beat variability decreases with:
- Fetal acidemia
- Fetal asphyxia
- Maternal acidemia
- Drugs (narcotics, MgSO₄, barbiturates, etc.)

**Increases in BTBV**
Beat-to-beat variability increases with mild fetal hypoxemia.
Prolonged Decelerations

Isolated decelerations that last 2 to 10 minutes. Causes include:
- Cervical examinations
- Uterine hyperactivity
- Maternal hypotension → transient fetal hypoxia
- Umbilical cord compression

Management
- Stop Pitocin/prostaglandins.
- Change maternal position.
- Administer IV fluids.
- If mother is hypotensive, administer ephedrine/terbutaline.
- Administer maternal O₂.
- Rule out cord prolapse.

ABNORMAL LABOR PATTERNS

- Prolonged latent phase (see Table 6-3)
- Active phase abnormalities—may be due to cephalopelvic disproportion (CPD), excessive sedation, conduction analgesia, and fetal malposition (i.e., persistent OP).
- Protraction disorders—a slow rate of cervical dilation or descent
- Arrest disorders—complete cessation of dilation or descent (see Table 6-3)

INDUCTION OF LABOR

Indications
Generally any condition that makes normal labor dangerous to mother or fetus is an indication.

Maternal
- Premature ROM
- Diabetes mellitus
- Heart disease
- Prolonged labor
- Prolonged pregnancy

Fetal
- IUGR
- Abnormal fetal testing
- Infection
- Rh incompatibility

Contraindications
Maternal
- Contracted pelvis
- Prior uterine surgery (controversial)
TABLE 6-3. Abnormal Labor Patterns

<table>
<thead>
<tr>
<th>Labor Pattern</th>
<th>Diagnostic Criterion: Nulliparas</th>
<th>Diagnostic Criterion: Multiparas</th>
<th>Preferred Treatment</th>
<th>Exceptional Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prolongation disorder</td>
<td>&gt; 20 hrs</td>
<td>&gt; 14 hrs</td>
<td>Therapeutic rest (may be unrecognized false labor)</td>
<td>Oxytocin stimulation or cesarean delivery for urgent problems</td>
</tr>
</tbody>
</table>

Protraction disorder

1. Protracted active phase dilatation
   < 1.2 cm/hr  < 1.5 cm/hr

2. Protracted descent
   < 1 cm/hr  < 2 cm/hr Expectant and support

Arrest disorders

1. Prolonged deceleration phase
   > 3 hrs  > 1 hr Without CPD: Oxytocin Rest if exhausted

2. Secondary arrest of dilatation
   > 2 hrs  > 2 hrs

3. Arrest of descent
   > 1 hr  > 1 hr With CPD: Cesarean delivery Cesarean delivery

4. Failure of descent (no descent in deceleration phase or second stage of labor)
   > 1 hr  > 1 hr

- Classic cesarean section
- Myomectomy

Fetal
- Lung immaturity
- Acute distress
- Abnormal presentation

Induction Drugs

**OXYTOCIN**

A synthetic polypeptide hormone that stimulates uterine contraction:
- Acts promptly when given intravenously
- Should not be employed for more than a few hours

**Complications**
- Potent antidiuretic effects of oxytocin (oxytocin is related structurally and functionally to vasopressin or antidiuretic hormone) can cause water intoxication, which can lead to convulsions, coma, and death.
- Risk of uterine tetanic contractions (overstimulation)

**PROSTAGLANDINS**

Misoprostol, a synthetic PGE₁ analog:
- Can be administered intravaginally or orally
- Used for cervical ripening and induction

Scalp stimulation is done between decelerations to elicit a reactive acceleration and rule out metabolic acidosis.

The term CPD (cephalopelvic disproportion) has been used to describe a disparity between the size of the maternal pelvis and the fetal head that precludes vaginal delivery. This condition can rarely be diagnosed with certainty and is often due to malposition of the fetal head (i.e., asynclitism).
PGE\textsubscript{2} gel and vaginal insert:
- Both contain dinoprostone
- Used for cervical ripening in women at or near term

## CESAREAN DELIVERY

The birth of a fetus through incisions in the abdominal wall (laparotomy) and the uterine wall (hysterotomy).

### Basic Types

1. Low cervical (also called low-transverse cesarean section [LTCS]):
   - Incision made in lower uterine segment
   - Most common type performed
2. Classical:
   - Vertical incision made in uterine corpus
   - Done when:
     - Lower uterine segment not developed
     - Fetus is transverse lie with back down

### Indications

- Repeat cesarean (elective; patient does not desire a trial of labor)
- Dystocia or failure to progress in labor
- Breech presentation
- Transverse lie
- Concern for fetal well-being (i.e., fetal distress)

## VAGINAL BIRTH AFTER CESAREAN DELIVERY (VBAC)

- VBAC is associated with a small but significant risk of uterine rupture with poor outcome for mother and infant:
  - Classical uterine scar → 4 to 9% risk
  - Low-transverse incision → 0.2 to 1.5% risk
- Maternal and infant complications are also associated with an unsuccessful trial of labor.

### Candidates for VBAC

- One or two prior LTCSs
- Clinically adequate pelvis
- No other uterine scars or previous rupture
- Physician immediately available throughout active labor capable of monitoring labor and performing an emergency C-section
- Availability of anesthesia and personnel for emergency C-section
Contraindications for VBAC

- Prior classical or T-shaped incision or other transfundal uterine surgery
- Contracted pelvis
- Medical/obstetric complication that precludes vaginal delivery
- Inability to perform emergency C-section because of unavailable surgeon, anesthesia, sufficient staff, or facility

Forceps and Vacuum Delivery

**INDICATIONS**

Prolonged second stage, maternal heart disease, acute pulmonary edema, intrapartum infection, maternal aneurysm, prolapse of the cord, abnormal fetal heart rate, inadequate uterine contractions, abnormal positioning of fetal head, maternal exhaustion, or need to hasten delivery

**PREREQUISITES FOR FORCEPS DELIVERY**

A fully dilated cervix, ROM, engaged fetal head, > +2 station, no cephalo-pelvic disproportion, empty bladder, and vertex presentation

**PAIN CONTROL DURING LABOR AND DELIVERY**

Three essentials of obstetrical pain relief are simplicity, safety, and preservation of fetal homeostasis.

**Uterine Innervation**

Pain early in the first stage of labor is largely generated from uterine contractions. Visceral sensory fibers from the uterus, cervix, and upper vagina traverse through the Frankenhäuser ganglion (lies just lateral to the cervix) → pelvic plexus → middle and superior internal iliac plexus → lumbar and lower thoracic sympathetic chains → enter the spinal cord through the white rami communicantes associated with the 11th and 12th thoracic and first lumbar nerves.

**Lower Genital Tract Innervation**

During the second stage of labor, much of the pain arises from the lower genital tract:

- Painful stimuli from the lower genital tract are primarily transmitted by the pudendal nerve → passes beneath the posterior surface of the sacrospinous ligament (just as the ligament attaches to the ischial spine).
- The sensory nerve fibers of the pudendal nerve are derived from the ventral branches of the second, third, and fourth sacral nerves.

**Nonpharmacological Methods of Pain Control**

Women who are free from fear and who have confidence in their obstetrical staff require smaller amounts of pain medication:
An understanding of pregnancy and the birth process
- Appropriate antepartum training in breathing
- Appropriate psychological support (e.g., by a friend or family member)
- Considerate obstetricians and labor assistants who instill confidence

**Analgesia and Sedation**

Pain relief with a narcotic (e.g., Stadol/Butorphanol) plus an antiemetic (e.g., promethazine) is typically sufficient, with **no significant risk** to the mother or infant:
- Bearable discomfort is still felt at the acme of an effective uterine contraction.
- Slightly increase uterine activity
- Does not prolong labor

**INTRAMUSCULAR (IM)**

Meperidine + Promethazine:
- Small doses given more frequently are preferable to large boluses less often.
- Analgesia is maximal 45 minutes post injection.

**INTRAVENOUS (IV)**

Meperidine + Phenergan:
- A more rapid effect is produced by this route—the maternal analgesic and fetal depressant effects are immediate post injection.

**OTHER SAFE NARCOTICS**

- Butorphanol (Stadol)
- Fentanyl
- Nalbuphine

**NARCOTIC ANTAGONISTS**

Naloxone hydrochloride:
- Displaces the narcotic from receptors in the CNS
- 0.1 mg/kg of body weight of the newborn injected into the umbilical vein
- Acts within 2 minutes

**General Anesthesia**

General anesthesia should not be induced until all steps preparatory to actual delivery have been completed, so as to minimize transfer of the agent to the fetus → avoids newborn respiratory depression.

**Concerns of General Anesthesia**

- All anesthetic agents that depress the maternal CNS cross the placenta → depress the fetal CNS.
- General anesthetics can cause aspiration of gastric contents and particulate matter → airway obstruction → pneumonitis, pulmonary edema, and death.
**Inhalation Anesthesia**

Nitrous oxide (N\textsubscript{2}O) is the only anesthetic gas in current use in the intrapartum in the United States:
- Provides pain relief during labor and delivery
- Produces an altered consciousness
- Does not prolong labor or interfere with uterine contractions
- Self-administered N\textsubscript{2}O in a 50% mixture with 50% \textsubscript{O}2 (face mask) provides excellent pain relief in the second stage of labor.
- Also used for cesarean delivery and some forceps deliveries with IV administration of a short-acting barbituate (e.g., thiopental) and a muscle relaxant (e.g., succinylcholine)

**Regional Analgesia**

Nerve blocks that provide pain relief for women in labor and delivery without loss of consciousness (anesthesia)

**Pudendal Block**
- Local infiltration of the pudendal nerve with a local anesthetic agent (e.g., lidocaine)
- Allows pinching of the lower vagina and posterior vulva bilaterally without pain
- Effective, safe, and reliable method of providing analgesia for spontaneous delivery
- Can be used along with epidural analgesia

**Complications**
Inadvertent intravascular injection will cause systemic toxicity, hematoma, infection.

**Paracervical Block**
- Lidocaine or chloroprocaine is injected at the 3 o’clock and 9 o’clock positions around the cervix.
- Provides good relief of pain of uterine contractions during first stage of labor
- Requires additional analgesia for delivery because the pudendal nerves are not blocked

**Complications**
Fetal bradycardia (usually transient)

**Spinal (Subarachnoid) Block**
- Introduction of local anesthetic into the subarachnoid space
- Used for uncomplicated cesarean delivery and vaginal delivery of normal women of low parity
- Local anesthetics used include lidocaine and tetracaine.

**Vaginal Delivery**
- Low spinal block
- Level of analgesia extends to the tenth thoracic dermatome (corresponds to the level of the umbilicus)
- Popular for forceps or vacuum delivery

**High-Yield Facts**

Prophylactic measures against aspiration include fasting for at least 6 hours prior to anesthesia and antacid administration before induction.

Always pull back on the syringe prior to injection of anesthetic to look for blood flow into the syringe; if positive, you are in a vessel and must reposition your needle.
- Provides excellent relief of pain from uterine contractions
- Proceeded by infusion of 1 L of crystalloid solution → prevents hypotension

Cesarean Delivery
- A higher level of spinal blockade is necessary to at least the level of the eighth thoracic dermatome (just below the xiphoid process of the sternum).
- A larger dose of anesthetic agent is required to anesthetize the larger area → increased frequency and intensity of toxic reactions.

Complications with Spinal Analgesia
- Maternal hypotension
- Total spinal blockade
- Spinal (postpuncture) headache
- Convulsions
- Bladder dysfunction

Contraindications to Spinal Analgesia
- Severe preeclampsia
- Coagulation/hemostasis disorders
- Neurological disorders

Epidural Analgesia
Injection of local anesthetic into the epidural or peridural space:
- Lumbar epidural analgesia— injection into a lumbar intervertebral space
- Caudal epidural analgesia— injection through the sacral hiatus and sacral canal

Relieves pain of uterine contractions, abdominal delivery (block begins at the eighth thoracic level and extends to first sacral dermatome) or vaginal delivery (block begins from the tenth thoracic to the fifth sacral dermatome)

The spread of the anesthetic agent depends on:
1. Location of the catheter tip
2. Dose, concentration, and volume of anesthetic agent used
3. Maternal position (e.g., head up, head down, horizontal)
4. Individual anatomy of epidural space (i.e., presence of synechiae may preclude a satisfactory block)

Complications
- Inadvertent spinal blockade (puncture of dura with subarachnoid injection)
- Ineffective analgesia
- Hypotension
- Convulsions

Effects on Labor
- Increased duration of labor
- Increased incidence of:
  - Chorioamnionitis

When vaginal delivery is anticipated in 10 to 15 minutes, a rapidly acting agent is given through the epidural catheter to effect perineal analgesia.
Intrapartum Gynecoid Android Anthropoid Platypelloid

**Frequency**
- In 50% of all females
- One third of white women; one sixth of nonwhite women
- One fourth of white women; one half of nonwhite women
- Rarest, < 3% of women

**Inlet shape**
- Round
- Heart shaped
- Vertically oriented oval
- Horizontally oriented oval

**Sidewalls**
- Straight
- Convergent
- Convergent
- Divergent, then convergent

**Ischial spines**
- Not prominent (diameter ≥ 10 cm)
- Prominent (diameter < 10 cm)
- Prominent (diameter < 10 cm)
- Not prominent (diameter > 10 cm)

**Sacrum**
- Inclined neither anteriorly nor posteriorly
- Forward and straight with little curvature
- Straight = pelvis deeper than other three types
- Well curved and rotated backward; short = shallow pelvis

**Significance**
- Good prognosis for vaginal delivery
- Limited posterior space for fetal head → poor prognosis for vaginal delivery
- Good prognosis for vaginal delivery
- Poor prognosis for vaginal delivery

**Contraindications**
- Actual/anticipated serious maternal hemorrhage
- Infection at or near sites for puncture
- Suspicion of neurological disease

**Local Infiltration**
Employed for delivery:
- Before episiotomy and delivery
- After delivery in the site of lacerations to be repaired
- Around the episiotomy wound if there is inadequate analgesia

**PELVIC TYPES**

<table>
<thead>
<tr>
<th></th>
<th>Gynecoid</th>
<th>Android</th>
<th>Anthropoid</th>
<th>Platypelloid</th>
</tr>
</thead>
<tbody>
<tr>
<td>Frequency</td>
<td>In 50% of all females</td>
<td>One third of white women; one sixth of nonwhite women</td>
<td>One fourth of white women; one half of nonwhite women</td>
<td>Rarest, &lt; 3% of women</td>
</tr>
<tr>
<td>Inlet shape</td>
<td>Round</td>
<td>Heart shaped</td>
<td>Vertically oriented oval</td>
<td>Horizontally oriented oval</td>
</tr>
<tr>
<td>Sidewalls</td>
<td>Straight</td>
<td>Convergent</td>
<td>Convergent</td>
<td>Divergent, then convergent</td>
</tr>
<tr>
<td>Ischial spines</td>
<td>Not prominent (diameter ≥ 10 cm)</td>
<td>Prominent (diameter &lt; 10 cm)</td>
<td>Prominent (diameter &lt; 10 cm)</td>
<td>Not prominent (diameter &gt; 10 cm)</td>
</tr>
<tr>
<td>Sacrum</td>
<td>Inclined neither anteriorly nor posteriorly</td>
<td>Forward and straight with little curvature</td>
<td>Straight = pelvis deeper than other three types</td>
<td>Well curved and rotated backward; short = shallow pelvis</td>
</tr>
<tr>
<td>Significance</td>
<td>Good prognosis for vaginal delivery</td>
<td>Limited posterior space for fetal head → poor prognosis for vaginal delivery</td>
<td>Good prognosis for vaginal delivery</td>
<td>Poor prognosis for vaginal delivery</td>
</tr>
</tbody>
</table>
THE PUEPERIUM OF THE NORMAL LABOR AND DELIVERY

The period of confinement during birth and 6 weeks after. During this time, the reproductive tract returns anatomically to a normal nonpregnant state.

Uterine Changes

INVOLUTION OF THE UTERINE CORPUS

Immediately after delivery, the fundus of the contracted uterus is slightly below the umbilicus. After the first 2 days postpartum, the uterus begins to shrink in size. Within 2 weeks, the uterus has descended into the cavity of the true pelvis.

ENDOMETRIAL CHANGES: SLOUGHING AND REGENERATION

Within 2 to 3 days postpartum, the remaining decidua become differentiated into two layers:

1. Superficial layer → becomes necrotic → sloughs off as vaginal discharge = lochia
2. Basal layer (adjacent to the myometrium) → becomes new endometrium

Placental Site Involution

Within hours after delivery, the placental site consists of many thrombosed vessels. Immediately postpartum, the placental site is the size of the palm of the hand. The site rapidly decreases in size and by 2 weeks postpartum = 3 to 4 cm in diameter.

Changes in Uterine Vessels

Blood vessels are obliterated by hyaline changes and replaced by new, smaller vessels.
Changes in the Cervix and Lower Uterine Segment

The external os of the cervix contracts slowly and has narrowed by the end of the first week.

The thinned-out lower uterine segment (that contained most of the fetal head) contracts and retracts over a few weeks → uterine isthmus.

Changes in the Vagina and Vaginal Outlet

Gradually diminishes in size, but rarely returns to nulliparous dimensions:

- Rugae reappear by the third week.
- The rugae become obliterated after repeated childbirth and menopause.

Peritoneum and Abdominal Wall

The broad ligaments and round ligaments slowly relax to the nonpregnant state.

The abdominal wall is soft and flabby due to the prolonged distention and rupture of the skin’s elastic fibers → resumes prepregnancy appearance in several weeks, except for silver striae.

Urinary Tract Changes

The puerperal bladder:

- Has an increased capacity
- Is relatively insensitive to intravesical fluid pressure

Hence, overdistention, incomplete bladder emptying, and excessive residual urine are common.

FLUID RETENTION AND THE RISK OF URINARY TRACT INFECTIONS

Residual urine + bacteruria in a traumatized bladder + dilated ureters and pelves → increased risk of UTI. Between days 2 and 5 postpartum, “puerperal diuresis” typically occurs to reverse the increase in extracellular water associated with normal pregnancy.

Dilated ureters and renal pelves return to their prepregnant state from 2 to 8 weeks postpartum.

---

**TABLE 7-1. Lochia**

<table>
<thead>
<tr>
<th>Type</th>
<th>Description</th>
<th>When Observed</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lochia rubra</td>
<td>Red due to blood in the lochia</td>
<td>Days 1–3</td>
</tr>
<tr>
<td>Lochia serosa</td>
<td>More pale in color</td>
<td>Days 4–10</td>
</tr>
<tr>
<td>Lochia alba</td>
<td>White to yellow-white due to leukocytes and reduced fluid content</td>
<td>Day 11 →</td>
</tr>
</tbody>
</table>

**HIGH-YIELD FACTS**

When involution is defective, late puerperal hemorrhage may occur.

At the completion of involution, the cervix does not resume its pregravid appearance: Before childbirth, the os is a small, regular, oval opening. After childbirth, the orifice is a transverse slit.

The uterine isthmus is located between the uterine corpus above and the internal cervical os below.

All postpartum women who cannot void should be promptly catheterized.

What causes fluid retention postpartum?

- High estrogen levels in pregnancy → fluid retention
- Increased venous pressure in the lower half of the body during pregnancy → fluid retention

When involution is defective, late puerperal hemorrhage may occur.
Changes in the Breasts

DEVELOPMENT OF MILK-SECRETING MACHINERY

Progesterone, estrogen, placental lactogen, prolactin, cortisol, and insulin act together → growth and development of the milk-secreting machinery of the mammary gland:

- Midpregnancy—lobules of alveoli form lobes separated by stromal tissue, with secretion in some alveolar cells
- T3—alveolar lobules are almost fully developed, with cells full of proteinaceous secretory material
- Postpartum—rapid increase in cell size and in the number of secretory organelles. Alveoli distend with milk.

DEVELOPMENT OF THE MILK

At delivery, the abrupt, large decrease in progesterone and estrogen levels leads to increased production of alpha-lactalbumin → stimulates lactose synthase → increased milk lactose.

COLOSTRUM

Colostrum can be expressed from the nipple by the second postpartum day and is secreted by the breasts for 5 days postpartum.

MATURE MILK AND LACTATION

Colostrum is then gradually converted to mature milk by 4 weeks postpartum. Subsequent lactation is primarily controlled by the repetitive stimulus of nursing and the presence of prolactin.

Breast engorgement with milk is common on days 3 to 4 postpartum:

- Often painful
- Often accompanied by transient temperature elevation (puerperal fever)

Suckling stimulates the neurohypophysis to secrete oxytocin in a pulsatile fashion → contraction of myoepithelial cells and small milk ducts → milk expression

Changes in the Blood

- Leukocytosis occurs during and after labor up to 30,000/µL
- There is a relative lymphopenia.
- There is an absolute eosinopenia.
- During the first few postpartum days, the hemoglobin and hematocrit fluctuate moderately from levels just prior to labor.

By 1 week postpartum, the blood volume has returned to the patient’s non-pregnant range.

CARDIAC OUTPUT

- The cardiac output remains elevated for ≥ 48 hours postpartum.
- By 2 weeks postpartum, these changes have returned to nonpregnant levels.
Elevation of plasma fibrinogen and the erythrocyte sedimentation rate remain for ≥ 1 week postpartum.

Changes in Body Weight

Most women approach their prepregnancy weight 6 months after delivery, but still retain approximately 1.4 kg of excess weight. Five to six kilograms are lost due to uterine evacuation and normal blood loss. Two to three kilograms are lost due to diuresis.

FACTORS THAT INCREASE Puerperal Weight Loss

- Weight gain during pregnancy
- Primiparity
- Early return to work outside the home
- Smoking

Routine Postpartum Care

Immediately After Labor

FIRST HOUR

- Take BP and HR at least every 15 minutes.
- Monitor the amount of vaginal bleeding.
- Palpate the fundus to ensure adequate contraction:
  - If the uterus is relaxed, it should be massaged through the abdominal wall until it remains contracted.

First Several Hours

EARLY AMBULATION

Women are out of bed (OOB) within a few hours after delivery. Advantages include:

- Decreased bladder complications
- Less frequent constipation
- Reduced frequency of puerperal venous thrombosis and pulmonary embolism

CARE OF THE VULVA

The patient should be taught to cleanse and wipe the vulva from front to back toward the anus.

If Episiotomy/Laceration Repair

- An ice pack should be applied for the first several hours to reduce edema and pain.
- Periodic application of a local anesthetic spray can relieve pain as well.
- At 24 hours postpartum, moist heat (e.g., via warm sitz baths) can decrease local discomfort.
- The episiotomy incision is typically well healed and asymptomatic by week 3 of the puerperium.
**BLADDER FUNCTION**

Ensure that the postpartum woman has voided within 4 hours of delivery. If not:
- This typically indicates further trouble voiding to follow.
- An indwelling catheter may be necessary, with a prophylactic antibiotic after catheter removal.
- Consider a hematoma of the genital tract as a possible etiology.

**The First Few Days**

**BOWEL FUNCTION**

Lack of a bowel movement may be due to a cleansing enema administered prior to delivery. Encourage early ambulation and feeding to decrease the probability of constipation.

**If Fourth-Degree Laceration**

Fecal incontinence may result, even with correct surgical repair, due to injury to the innervation of the pelvic floor musculature.

**DISCOMFORT/PAIN MANAGEMENT**

During the first few days of the puerperium, pain may result due to:
- Afterpains
- Episiotomy/laceration repair
- Breast engorgement
- Postspinal puncture headache

Treat with any of the following:
- Codeine
- Aspirin
- Acetaminophen

**ABDOMINAL WALL RELAXATION**

Exercise may be initiated any time after vaginal delivery and after abdominal discomfort has diminished after cesarean delivery.

**DIET**

There are no dietary restrictions/requirements for women who have delivered vaginally. Two hours postpartum, the mother should be permitted to eat and drink.

Continue iron supplementation for a minimum of 3 months postpartum.

**IMMUNIZATIONS**

- The nonisoimmunized D-negative woman whose baby is D-positive is given 300 µg of anti-D immune globulin within 72 hours of delivery.
- Woman not previously immunized against/immune to rubella should be vaccinated prior to discharge.
- Unless contraindicated, woman may receive a diphtheria–tetanus toxoid booster prior to discharge.
POSTPARTUM PATIENT EDUCATION

1. Anticipated physiologic changes during the puerperium:
   - Lochia—the bloody discharge that follows delivery
   - Diuresis—the secretion and passage of large amounts of urine
   - Milk letdown—the influx of milk into the mammary ducts

2. She should go to hospital if she develops:
   - Fever
   - Excessive vaginal bleeding
   - Lower extremity pain and/or swelling
   - Shortness of breath
   - Chest pain

3. Family planning and contraception:
   - Do not wait until first menses to begin contraception; ovulation may come before first menses.
   - Contraception is essential after the first menses, unless a subsequent pregnancy is desired.

Lactational Amenorrhea Method of Contraception
The sole utilization of breast feeding to prevent ovulation and subsequent pregnancy:
- The lactational amenorrhea method is 98% effective for up to 6 months if:
  - The mother is not menstruating
  - The mother is nursing ≥ 2 to 3 times per night, and ≥ every 4 hours during the day without other supplementation.
  - The baby is < 6 months old.

Combined Oral Contraceptives Versus Progestin-Only Contraceptives in Postpartum
Combined oral contraceptive hormones reduce the amount of breast milk, although very small quantities of the hormones are excreted in the milk.

Progestin-only oral contraceptive pills are virtually 100% effective without substantially reducing the amount of breast milk.

Coitus in Postpartum
After 6 weeks, coitus may be resumed based on patient's desire and comfort. A vaginal lubricant prior to coitus may increase comfort.

Dangers of premature intercourse:
- Pain due to continued uterine involution and healing of lacerations/episiotomy scars
- Increased likelihood of hemorrhage and infection

Infant Care
Prior to discharge:
- Follow-up care arrangements should be made
All laboratory results should be normal, including:
- Coombs' test
- Bilirubin
- Hgb and Hct
- Blood glucose
- Maternal serologic tests for syphilis and HbsAg should be nonreactive.
- Initial HBV vaccine should be administered.
- All screening tests required by law should be done (e.g., testing for phenylketonuria [PKU] and hypothyroidism).
- Patient education regarding infant immunizations and well-baby care.

**Discharge**

**Vaginal Delivery**
One to two days post hospitalization, if no complications

**Cesarean Section**
Three to four days post hospitalization, if no complications

**MATERNAL FOLLOW-UP CARE**

**Breast Feeding**
Human milk is the ideal food for neonates for the first 6 months of life.

**Recommended Dietary Allowances**
Lactating women need an extra 500 nutritious calories per day. Food choices should be guided by the Food Guide Pyramid, as recommended by the U.S. Department of Health and Human Services/U.S. Department of Agriculture.

**Benefits**
*Uterine Involution*
Nursing accelerates uterine involution.

*Immunity*
Colostrum and breast milk contain secretory IgA antibodies against *Escherichia coli* and other potential infections.

Milk contains memory T cells, which allows the fetus to benefit from maternal immunologic experience.

Colostrum contains interleukin-6, which stimulates an increase in breast milk mononuclear cells.

*Nutrients*
All proteins are absorbed by babies, and all essential and nonessential amino acids available.
GI Maturation
Milk contains epidermal growth factor, which may promote growth and maturation of the intestinal mucosa.

Contraindications of Breast Feeding

Infection
Mothers with:
- Cytomegalovirus (CMV)
- Chronic hepatitis B (HBV)
- HIV infection
- Breast lesions from active herpes simplex virus

Medications
Mothers ingesting the following contraindicated medications:
- Bromocriptine
- Cyclophosphamide
- Cyclosporine
- Doxorubicin
- Ergotamine
- Lithium
- Methotrexate

Mothers ingesting the following medications with unknown effects on the infant:
- Psychotropic drugs
- Antianxiety drugs
- Antidepressants
- Chloramphenicol
- Metoclopramide
- Metronidazole
- Tinidazole

Drug Abuse
Mothers who abuse the following drugs:
- Amphetamines
- Cocaine
- Heroin
- Marijuana
- Nicotine
- Phencyclidine

Radiotherapy
Mothers undergoing radiotherapy with:
- Gallium
- Indium
- Iodine
- Radioactive sodium
- Technetium

Nursing mothers rarely ovulate within the first 10 weeks after delivery. Non-nursing mothers typically ovulate 6 to 8 weeks after delivery.

Breast-fed infants are less prone to enteric infections than are bottle-fed babies.

CMV, HBV, and HIV are excreted in breast milk.

A common misperception: Mothers who have a common cold should not breast feed (FALSE).

Most drugs given to the mother are secreted in breast milk. The amount of drug ingested by the infant is typically small.
Maternity/Postpartum Blues
A self-limited, mild mood disturbance due to biochemical factors and psychological stress:
- Affects 50% of childbearing women
- Begins within 3 to 6 days after parturition
- May persist for up to 10 days

**Symptoms**
Similar to depression, but milder (see below)

**Treatment**
- Supportive—acknowledgement of the mother’s feelings and reassurance
- Monitor for the development of more severe symptoms (i.e., of postpartum depression or psychosis).

Postpartum Depression
Similar to minor and major depression that can occur at any time:
- Classified as “postpartum depression” if it begins within 3 to 6 months after childbirth
- Eight to 15% of postpartum women develop postpartum depression within 2 to 3 months.

**Symptoms**
Symptoms are the same as major depression.

**Natural Course**
- Gradual improvement over the 6 months postpartum
- The mother may remain symptomatic for months → years.

**Treatment**
- Pharmacologic intervention is typically required:
  - Antidepressants
  - Anxiolytic agents
  - Electroconvulsive therapy
- Mother should be co-managed with a psychiatrist (i.e., for psychotherapy to focus on any maternal fears or concerns).

Postpartum Psychosis
- Mothers have an inability to discern reality from that which is unreal (can have periods of lucidity).
- Occurs in 1 to 4/1,000 births
- Peak onset—10 to 14 days postpartum, but may occur months later

**High-Yield Facts**
- Thirty percent of adolescent women develop postpartum depression.
- Criteria for major depression/postpartum depression:
  - Two-week period of depressed mood or anhedonia nearly every day plus one of the following:
    - Significant weight loss or weight gain without effort (or ↑ or ↓ in appetite)
    - Insomnia or hypersomnia
    - Psychomotor agitation/retardation
    - Fatigue or loss of energy
    - Feelings of worthlessness/excessive or inappropriate guilt
    - Decreased ability to concentrate/think
    - Recurrent thoughts of suicide/death
RISK FACTORS
- History of psychiatric illness
- Family history of psych disorders
- Younger age
- Primiparity

COURSE
Variable and depends on the type of underlying illness; often 6 months

TREATMENT
- Psychiatric care
- Pharmacologic therapy
- Hospitalization (in most cases)

HIGH-YIELD FACTS
If these drugs are prescribed to nursing mothers, infant blood concentrations of the drug should be monitored.

Postpartum

Usually remits after 2 to 3 days.
Medical Conditions and Infections in Pregnancy

**SOCIAL RISK FACTORS**

**Alcohol**
- Alcohol is teratogenic.
- An occasional drink during pregnancy carries no known risk.
- Fetal alcohol syndrome (FAS) may occur with chronic exposure to alcohol in the later stages of pregnancy. Features may include:
  - Growth retardation
  - Facial anomalies:
    - Small palpebral fissures
    - Indistinct/absent philtrum
    - Epicanthic folds
    - Flattened nasal bridge
    - Short length of nose
    - Thin upper lip
    - Low-set, unparallel ears
    - Retarded midfacial development
  - Central nervous system (CNS) dysfunction:
    - Microcephaly
    - Mental retardation
    - Abnormal neurobehavior (e.g., attention deficit hyperactivity disorder)

**Tobacco**
- The leading preventable cause of low birth weight in the United States
- Smoking is associated with decreased birth weight and increased prematurity.
- There is a positive association between sudden infant death syndrome (SIDS) and smoking.
- Use of nicotine patch is controversial

There is no consensus on the quantity of alcohol that leads to adverse fetal outcomes. Hence, the best maternal advice is to discontinue alcohol use when trying to become pregnant and during pregnancy.

Smoking by pregnant women and all household members should be stopped and not resumed postpartum.
Illicit Drugs

**Marijuana**

Derived from the plant *Cannabis sativa*; active ingredient, tetrahydrocannabinol:
- No evidence of significant teratogenesis in humans
- Metabolites detected in urine of users for days to weeks
- Commonly used by multiple substance abusers; thus, its presence in urine may identify patients at high risk for being current users of other substances as well

**Cocaine**

- Pregnancy does not increase one's susceptibility to cocaine's toxic effects
- **Complications of pregnancy:**
  - Spontaneous abortion and fetal death in utero
  - Preterm labor and delivery (25%)
  - Meconium-stained amniotic fluid (29%)

**Teratogenic Effects of Cocaine**
- Growth retardation
- Microcephaly
- Neurobehavioral abnormalities (e.g., impairment in orientation and motor function)
- SIDS

**Opiates**

**Heroin**
- Three- to sevenfold increase in incidence of stillbirth, fetal growth retardation, prematurity, and neonatal mortality
- Signs of infant withdrawal occur 24 to 72 hours after birth.
- Treatment with methadone improves pregnancy outcome.

Newborn infants born to narcotic addicts are at risk for severe, potentially fatal narcotic withdrawal syndrome, characterized by:
- High-pitched cry
- Poor feeding
- Hypertonicity/tremors
- Irritability
- Sneezing
- Sweating
- Vomiting/diarrhea
- Seizures

**Hallucinogens**
- No evidence that lysergic acid diethylamide (LSD) or other hallucinogens cause chromosomal damage or other deleterious effects on human pregnancy
- There have been no studies on the potential long-term effects on neonatal neurodevelopment.
AMPHETAMINES

Crystal methamphetamine ("ice," "blue ice"), a potent IV stimulant, has been associated with:
- Decreased fetal head circumference
- Placental abruption
- Intrauterine growth retardation (IUGR)
- Fetal death in utero

The anorectic properties of amphetamines may severely impair nutrition during pregnancy.

EXPOSURE TO VIOLENCE

- Twenty percent of all pregnant women are battered during pregnancy.
- For some women, the violence is initiated at the time of pregnancy.
- One half of women who are physically abused prior to pregnancy continue to be battered during pregnancy.
- Ask: "Are you in a relationship in which you are being hit, kicked, slapped, or threatened?"
- All abused patients should be given information regarding their immediate safety and referrals for counseling and support.

CONTRAINDICATIONS TO PREGNANCY

- Pulmonary hypertension:
  - Associated with a 50% maternal mortality rate and a > 40% fetal mortality rate
- Eisenmenger's syndrome:
  - Maternal mortality is 30 to 50%.

RISK INTERVENTIONS

Nutritional Recommendations
- Folic acid supplementation:
  - If previous pregnancies: 4 mg/day starting 4 weeks prior to conception, through T1
  - If nulligravida, 0.4 mg (400 µg) qd

Physical Activity Recommendations
- Women who exercise regularly before pregnancy are encouraged to continue.
- For the normal healthy woman, a low-impact exercise regimen may be continued throughout pregnancy.
The placenta permits the passage of many drugs and dietary substances:
- Lipid-soluble substances readily cross the placenta.
- Water-soluble substances cross less well because of their larger molecular weight.
- The greater degree to which a drug is bound to plasma protein, the less likely it is free to cross.
- The minimal effective dose should be employed.

Embryological Age and Teratogenic Susceptibility
- 0–3 weeks—predifferentiation phase of development: The conceptus either does not survive exposure to teratogen or survives without anomalies.
- 3–8 weeks—organogenesis phase: Maximum susceptibility to teratogen-induced malformation.
- > 8 weeks—organ growth phase: A teratogen can interfere with growth but not organogenesis.

FDA (Food and Drug Administration) Pregnancy Drug Categories

**CATEGORY A**
Safety has been established using human studies.

**CATEGORY B**
Presumed safety based on animal studies

**CATEGORY C**
Uncertain safety—animal studies show an adverse effect, no human studies.

**CATEGORY D**
Unsafe—evidence of risk that may in certain clinical circumstances be justifiable

**CATEGORY X**
Highly unsafe—risk outweighs any possible benefit.

**Vitamin A Derivatives**
- Isotretinoin (Accutane):
  - For treatment of cystic acne
  - 25% risk of anomalies
  - Malformed infants have characteristic craniofacial, cardiac, thymic, and CNS anomalies.
- Etretinate (Tegison):
  - For treatment of psoriasis
  - Similar teratogenic effects to that of isotretinoin

Drug exposure is responsible for 2 to 3% of birth defects.
Vitamin A:
- No evidence that normal doses are teratogenic
- Large doses ($\geq 25,000$ IU/day) should be avoided because birth defects have been reported at these dosages.

Antineoplastics
Methotrexate and aminopterin are folic acid derivatives. They cause IUGR, mental retardation, and craniofacial malformations.

Anticoagulants
- Warfarin (Coumadin) crosses the placenta and is associated with chondrodysplasia punctata, presumably due to microhemorrhages during development.
- Fetal and maternal hemorrhage has also been reported, but incidence can be reduced with careful control of the prothrombin time.
- Heparin, an alternative to Coumadin, has a large negative charge and does not cross the placenta.
- Does not have any adverse fetal effects
- Heparin-induced osteoporosis with fracture occurs in 1 to 2% of women in whom full anticoagulation has been achieved during pregnancy.
- Low-molecular-weight heparins (LMWH):
  - May have substantial benefit over standard unfractionated heparin
  - Molecules do not cross placenta

Hypoglycemic Agents
Insulin is safe in pregnancy:
- Does not cross the placenta per large molecular weight (6,000)
- Dosage is unimportant as long as it is sufficient to maintain normal maternal glucose levels.

Oral hypoglycemic agents are currently under investigation for safety and efficacy during pregnancy.

Psychotropics

ANTICONVULSANTS
- Phenytoin decreases absorption of folate and decreases serum folate and causes craniofacial, limb, and mental defects.
- Valproic acid and carbamazepine use is associated with a 1% risk of neural tube defects.

ANTIDEPRESSANTS
- Imipramine (Tofranil):
  - Tricyclic antidepressant
  - Associated with fetal cardiac anomalies
- Fluoxetine (Paxil):
  - No increased risk of major malformations or developmental abnormalities has been observed.
TRANQUILIZERS

- Chlordiazepoxide (Librium) is associated with congenital anomalies.
- Diazepam use perinatally has been associated with fetal hypothermia, hypotonia, and respiratory depression.

Analgesics

- Aspirin:
  - No teratogenic effects seen in T1
  - Significant perinatal effects seen, such as decreased uterine contractility, delayed onset of labor, prolonged duration of labor
  - Increases risk of antepartum bleeding and bleeding at delivery
- NSAIDs:
  - Ibuprofen (Motrin, Advil) and naproxen (Naprosyn) have not demonstrated any negative fetal effects with short-term use.
  - Chronic use may lead to oligohydramnios and constriction of the fetal ductus arteriosus.
- Acetaminophen (Tylenol, Datril) has shown no evidence of teratogenicity.

Antibiotics and Anti-infective Agents

- Penicillins, cephalosporins, and erythromycin are safe in pregnancy.
- Aminoglycosides (streptomycin)—risk of deafness
- Trimethoprim use in T1 is associated with increased risk of birth defects.
- Tetracyclines deposit in developing osseous sites and inhibit bone growth. They bind to developing enamel and discolor the teeth. Deciduous teeth are affected between 26 weeks’ GA and infant age of 6 months.
- Doxycycline has no teratogenic risk in T1.
- Quinolones (Ciprofloxacin, Norfloxacin) have a high affinity for cartilage and bone tissue → may cause arthropathies in children.

Antiasthmatics

- Epinephrine (sympathomimetic amine) exposure after T1 has been associated with minor malformations.
- Terbutaline (Brethine) is not associated with birth defects.
- Long-term use has been associated with increased risk of glucose intolerance.
- Isoproterenol (Isuprel) and Albuterol (Ventolin) are not teratogenic.
- Corticosteroids are inactivated by the placenta when maternally administered → < 10% of maternal dose is in the fetus.

Cardiovascular Drugs

- Angiotensin-converting enzyme inhibitors (Vasotec, Capoten) can cause fetal renal tubular dysplasia in T2 and T3 → oligohydramnios, fetal limb contractures, craniofacial deformities, hypoplastic lung development.
- Propranolol (Inderal) shows no evidence of teratogenicity:
  - Fetal bradycardia has been seen as a direct dose effect when given to mother 2 hours prior to delivery.
  - Increased risk of IUGR seen with maternal use.
Androgens/Progestins

- Androgens may masculinize a developing female fetus
- Progestational agents (e.g., Danazol) (often synthetic testosterone derivatives) may cause clitoromegaly and labial fusion if given prior to 13 weeks' GA.

**MEDICAL CONDITIONS AND PREGNANCY**

Endocrine Disorders in Pregnancy

**DIABETES MELLITUS**

See Table 8-1.

- Pregestational diabetes—patient had DM before pregnancy
- Gestational diabetes—patient develops diabetes only during pregnancy. Gestational diabetes is classified as type A according to White classification.
  - White classification A1—controlled with diet
  - White classification A2—requires insulin

**Screening**

Screening is controversial, but tests often used are:

1. **Glucose challenge test**—at 26 to 28 weeks:
   - Give 50-mg glucose load (nonfasting state).
   - Draw glucose blood level 1 hour later.

**TABLE 8-1. Diabetes Classifications**

<table>
<thead>
<tr>
<th>Class</th>
<th>Onset</th>
<th>Duration (yrs)</th>
<th>Vascular Disease</th>
<th>Therapy</th>
</tr>
</thead>
<tbody>
<tr>
<td>A1</td>
<td>Gestational</td>
<td>&lt; 95 mg/dL</td>
<td>&lt; 120 mg/dL</td>
<td>Diet and exercise</td>
</tr>
<tr>
<td>A2</td>
<td>Gestational</td>
<td>&lt; 95 mg/dL</td>
<td>&gt; 120 mg/dL</td>
<td>Insulin</td>
</tr>
<tr>
<td>B</td>
<td>&gt; 20 yrs old</td>
<td>&lt; 10</td>
<td>None</td>
<td>Insulin</td>
</tr>
<tr>
<td>C</td>
<td>10–19 yrs old</td>
<td>10–19</td>
<td>None</td>
<td>Insulin</td>
</tr>
<tr>
<td>D</td>
<td>Before age 10</td>
<td>&gt; 20</td>
<td>Benign retinopathy (pronounced “neFropathy”)</td>
<td>Insulin</td>
</tr>
<tr>
<td>F</td>
<td>Any</td>
<td>Any</td>
<td>Nephropathy (pronounced “neFropathy”)</td>
<td>Insulin</td>
</tr>
<tr>
<td>R</td>
<td>Any</td>
<td>Any</td>
<td>Proliferative Retinopathy</td>
<td>Insulin</td>
</tr>
<tr>
<td>H</td>
<td>Any</td>
<td>Any</td>
<td>Heart</td>
<td>Insulin</td>
</tr>
</tbody>
</table>
> 140 is high (a 3-hour glucose tolerance test is then required to diagnose GDM).
If ≥ 200, the patient is diagnosed with GDM type A1 and a diabetic diet is initiated.

2. **3-Hour glucose tolerance test**—if glucose challenge test is > 140 and < 200
   - Draw fasting glucose level; normal (n) < 95
   - Give 100-g glucose load.
   - Draw glucose levels at 1 hour (n < 180), at 2 hours (n < 155), and at 3 hours (n < 140).
   - Positive for gestational diabetes if 2/4 high values

**Risk Factors**
- Be extra careful to test:
  - Previous or family history of gestational diabetes
  - Obesity
  - History of large babies
  - History of full-term stillbirth or child with cardiac defects

**Effects of Gestational Diabetes**

**Maternal Effects**
- Four times increased risk of preeclampsia
- Increased risk of bacterial infections
- Higher rate of C-section
- Increased risk of polyhydramnios
- Increased risk of birth injury

**Fetal Effects**
- Increased risk of perinatal death
- Three times increased risk of fetal anomalies (renal, cardiac, and CNS)
- Two to three times increased risk of preterm delivery
- Fetal macrosomia increases risk of birth injury.
- Metabolic derangements (hypoglycemia, hypocalcemia)

**Management**
The key factors involved in successful management of these high-risk pregnancies include:
- Good glucose control:
  - Prepregnancy glucose levels should be maintained during pregnancy with insulin.
  - Glucose control should be checked at each prenatal visit.

**Starting at 32 to 34 weeks:**
- **Fetal monitoring:**
  - Ultrasonography to evaluate fetal growth, estimated weight, amniotic fluid volume, and fetal anatomy at 16 to 20 weeks’ GA
  - Nonstress test and amniotic fluid index testing weekly to biweekly depending on disease severity
  - Biophysical profile
  - Contraction stress test (oxytocin challenge test)
- **Early elective delivery:**
  - Fetal macrosomia must be ruled out with ultrasonography.
If fetal weight is > 4,500 g, elective cesarean section should be considered to avoid shoulder dystocia. Unless there is an obstetric complication, induction of labor and vaginal delivery are done.

**Hyperthyroidism/Graves' Disease**
- Thyrotoxicosis complicates 1 in 2,000 pregnancies.
- Graves’ disease is the most common cause of thyrotoxicosis in pregnancy.
- Treatment is propylthiouracil or methimazole or surgery. **Radioactive iodine is contraindicated in pregnancy.**

**Thyroid Storm**
Thyroid storm is a major risk. Precipitating factors are infection, labor, and C-section.

**Treatment**
- Beta blocker
- Sodium iodide
- Parathyroid hormone (PTH)
- Dexamethasone

25% mortality rate

**Complications**
- 1% risk of neonatal thyrotoxicosis
- Fetal goiter/hypothyroid, usually from PTU
- Preterm delivery
- Preeclampsia
- Preterm delivery

**Hypothyroidism**
Subclinical hypothyroidism is more common than overt hypothyroidism, and often goes unnoticed. Diagnosed by elevated TSH.

**Postpartum Thyroiditis**
Transient postpartum hypothyroidism or thyrotoxicosis associated with autoimmune thyroiditis is common:
- Between 1 and 4 months postpartum, 4% of all women develop transient thyrotoxicosis.
- Between 4 and 8 months postpartum, 2 to 5% of all women develop hypothyroidism.

**Sheehan Syndrome**
Pituitary ischemia and necrosis associated with obstetrical blood loss leading to hypopituitarism. Patients do not lactate postpartum due to low prolactin.

**Epilepsy and Pregnancy**
- Epileptic women taking anticonvulsants during pregnancy have double the general population risk of malformations and preeclampsia.
- Women with a convulsive disorder have an increased risk of birth defects even when they do not take anticonvulsant medications.
Pregnant epileptics are more prone to seizures due to the associated stress and fatigue of pregnancy.

- The fetus is at risk for megaloblastic anemia.
- The pregnant female and her fetus are at risk for hemorrhage due to a deficiency of vitamin K–dependent clotting factors induced by anticonvulsant drugs.
- Management of the epileptic female should begin with prepregnancy counseling.
- Anticonvulsant therapy should be reduced to the minimum dose of the minimum number of anticonvulsant medications.
- Folic acid supplementation (5 mg/day) should be taken by those women taking anticonvulsants.
- Once pregnant, the patient should be screened for NTDs and congenital malformations.
- Blood levels of anticonvulsant medications should be checked at the beginning of pregnancy to determine the drug level that controls epileptic episodes successfully.

**HIV and Pregnancy**

- HIV infection is now among the 10 leading causes of death among children aged 1 to 4 years.
- The vast majority of cases of pediatric AIDS are secondary to vertical transmission from mother to fetus.

At the preconception visit, encourage maternal HIV screening.

**The HIV+ Patient**

- Reduce maternal viral load.
  - Zidovudine (ZDV) should be given in the antepartum period beginning at 14 weeks.
  - CD4+ counts and viral loads should be monitored at regular intervals.
  - Blood counts and liver functions should be monitored monthly while on ZDV.
- Reduce intrapartum transmission.
  - Give maternal intravenous ZDV.
- Reduce peripartum exposure.
  - Reduce duration of ruptured membranes.
  - Offer elective cesarean section to mother.
  - Avoid breast feeding.
- Administer newborn prophylaxis.
  - Give ZDV syrup to newborn for 6 weeks.

**Cardiovascular Disease**

Pregnancy-induced hemodynamic changes have profound effects on underlying heart disease.

*Cardiovascular disease (CVD) complicates 1% of all pregnancies and significantly contributes to maternal mortality.*
MITRAL STENOSIS (MS)

Pathophysiology
- Increased preload due to normal increase in blood volume results in left atrial overload and backup into the lungs resulting in pulmonary hypertension.

Sequelae
- Tachycardia associated with labor and delivery is exacerbated the pulmonary HTN because of decreased filling time.
- Postpartum period is the most hazardous time.

Treatment
- Antibiotic prophylaxis

MITRAL VALVE PROLAPSE

These patients are normally asymptomatic and have a systolic click on physical exam. They will generally have a safe pregnancy. Antibiotics should be given for prophylaxis against endocarditis.

EISENMENGER SYNDROME AND OTHER CONDITIONS WITH PULMONARY HTN

These conditions are extremely dangerous to the mother and possibly justify the termination of pregnancies on medical grounds. Maternal mortality can be as high as 50%, with death usually occurring in the postpartum.

AORTIC STENOSIS
- Similar problems with mitral stenosis
- Avoid tachycardia and fluid overload.
- Give antibiotic prophylaxis.

Pulmonary Disease

The adaptations to the respiratory system during pregnancy must be able to satisfy the increased O₂ demands of the hyperdynamic circulation and the fetus. Advanced pregnancy may worsen the pathophysiological effects of many acute and chronic lung diseases.

ASTHMA

Epidemiology
One to four percent of pregnancies are complicated by asthma:
- 25% of asthmatics worsen in pregnancy.
- 25% improve.
- 50% have no change.

Management EXAM FACT
- Generally, asthma is exacerbated by respiratory tract infections, so killed influenza vaccine should be given.
- Pregnant asthmatics can be treated with theophylline, beta sympathomimetics, or steroids.

Cardiac output increases by 30 to 50% by midpregnancy.

Blood volume increases 50% by 30th week.

Twenty-five percent of women with mitral stenosis have cardiac failure for the first time during pregnancy.

Prolapse = okay to be pregnant
Stenosis = Sick in pregnancy

Asthmatics have no increase risk of fetal malformations.
Management of Status Asthmaticus
- Give oxygen.
- Give SQ terbutaline.
- Give IV corticosteroids.

PULMONARY EMBOLISM (PE)
The likelihood of venous thromboembolism in normal pregnancy and the puerperium is increased fivefold when compared to nonpregnant women of similar age:
- Occurs in 1/7,000 women
- Complications include maternal death.

Renal and Urinary Tract Disorders
Pregnancy causes hydronephrosis (dilatation of renal pelvis, calyces, and ureters) because the baby compresses the lower ureter and because the hormonal milieu decreases ureteral tone. This may lead to urinary stasis and increased vesicoureteral reflux.

Two to seven percent of pregnant women have UTIs; 25% are asymptomatic.

PYELONEPHRITIS
Acute pyelonephritis is the most common serious medical complication of pregnancy and occurs in 1 to 2% of pregnant women. Management includes:
- Hospitalization
- IV antibiotics (ampicillin or cefazolin)
- Monitor fluids

Acute Abdomen in Pregnancy
During advanced pregnancy, GI symptoms become difficult to assess and physical findings are often obscured by the enlarged uterus.

DIFFERENTIAL
- Pylonephritis
- Appendicitis
- Pancreatitis
- Cholecystitis
- Ovarian torsion

APPENDICITIS
- Appendicitis is the most common surgical condition in pregnancy (occurs 1 in 2,000 births).
- Has usual symptoms
- Uterus displaces the appendix superiorly and laterally. Pain and tenderness may not be found at McBurney’s point (RLQ).
- Incidence is same throughout pregnancy, but rupture is more frequent in T3 (40%) than T1 (10%).
- Management is appendectomy.
CHOLELITHIASIS AND CHOLECYSTITIS

- Incidence of cholecystitis is 1 in 4,000 pregnancies (more common than nonpregnant).
- Same clinical picture as nonpregnant
- Medical management unless common bile duct obstruction or pancreatitis develops, in which case a cholecystectomy should be performed.
- High risk of preterm labor

**Anemia**

- *Physiologic anemia* is normal anemia in pregnancy because of hemo- dilution due to volume expansion.
- Anemia for a pregnant woman is a drop in Hgb by 10 g/dL or Hct by 30%.
- **Incidence**: 20 to 60% of pregnant women, 80% is iron-deficiency type
- **Risks**: Preterm delivery, IUGR, low birth weight
- **Therapy** is 325 mg tid of FeSO₄ (prophylaxis is q d)

**INFECTION AND PREGNANCY**

See Tables 8-2 through 8-4

### TABLE 8-2. Perinatal Infections

<table>
<thead>
<tr>
<th>Intrauterine</th>
<th>Viral</th>
<th>Bacterial</th>
<th>Protozoan</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Varicella-zoster</td>
<td>Listeria</td>
<td>Toxoplasmosis</td>
</tr>
<tr>
<td></td>
<td>Coxsackie virus</td>
<td>Syphilis</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Parvovirus</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Rubella</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Cytomegalovirus</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Human immunodeficiency virus (HIV)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ascending</td>
<td>Herpes simplex (HSV)</td>
<td>Group B Streptococcus</td>
<td></td>
</tr>
<tr>
<td>infection</td>
<td></td>
<td>(GBS)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Coliforms</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Intrapartum</th>
<th>Viral</th>
<th>Bacterial</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Maternal</td>
<td>HSV</td>
<td></td>
<td>Gonorrhea</td>
</tr>
<tr>
<td>exposure</td>
<td>Papillomavirus</td>
<td></td>
<td>Chlamydia</td>
</tr>
<tr>
<td></td>
<td>HIV</td>
<td></td>
<td>GBS</td>
</tr>
<tr>
<td></td>
<td>HBV</td>
<td></td>
<td>TB</td>
</tr>
</tbody>
</table>

| External     | HSV                                        |                            | Staphylococcus           |
| contamination|                                            |                            | Coliforms                |
### TABLE 8-2. Perinatal Infections (continued)

<table>
<thead>
<tr>
<th>Neonatal</th>
<th>Viral Infections and Their Potential Fetal Effects</th>
</tr>
</thead>
<tbody>
<tr>
<td>Human</td>
<td>Varicella-zoster</td>
</tr>
<tr>
<td>transmission</td>
<td>Transmitted transplacentally</td>
</tr>
<tr>
<td></td>
<td>• Chorioretinitis</td>
</tr>
<tr>
<td></td>
<td>• Cerebral cortical atrophy</td>
</tr>
<tr>
<td></td>
<td>• Hydronephrosis</td>
</tr>
<tr>
<td></td>
<td>• Cutaneous and bony leg defects (scars)</td>
</tr>
<tr>
<td></td>
<td>• Microcephaly</td>
</tr>
<tr>
<td></td>
<td>Vaccination recommended for pregnant women</td>
</tr>
<tr>
<td></td>
<td>Vaccine not recommended for pregnant women</td>
</tr>
<tr>
<td></td>
<td>C-section should be performed if there are active lesions.</td>
</tr>
<tr>
<td></td>
<td>Hydronephrosis performed if there are active lesions.</td>
</tr>
<tr>
<td></td>
<td>Neisseria</td>
</tr>
<tr>
<td></td>
<td>Pneumonia</td>
</tr>
<tr>
<td></td>
<td>Vaccination is recommended for pregnant women</td>
</tr>
<tr>
<td></td>
<td>Amantadine within 48 hrs of onset of symptoms in non-immunized, high-risk patients</td>
</tr>
<tr>
<td></td>
<td>Parvovirus B19</td>
</tr>
<tr>
<td></td>
<td>• Abortion</td>
</tr>
<tr>
<td></td>
<td>• Death</td>
</tr>
<tr>
<td></td>
<td>• Congenital anomalies</td>
</tr>
<tr>
<td></td>
<td>• Hydrops</td>
</tr>
<tr>
<td></td>
<td>Viremia → slapped cheek appearance</td>
</tr>
<tr>
<td></td>
<td>If + serology → US; if + hydrops → consider fetal transfusion.</td>
</tr>
<tr>
<td></td>
<td>Rubella</td>
</tr>
<tr>
<td></td>
<td>Congenital rubella syndrome</td>
</tr>
<tr>
<td></td>
<td>• Cataracts/glaucoma</td>
</tr>
<tr>
<td></td>
<td>• Patent ductus arteriosus</td>
</tr>
<tr>
<td></td>
<td>• Deafness</td>
</tr>
<tr>
<td></td>
<td>• Mental retardation</td>
</tr>
<tr>
<td></td>
<td>Vaccination</td>
</tr>
<tr>
<td></td>
<td>Consider therapeutic abortion, depending on time of exposure during pregnancy.</td>
</tr>
<tr>
<td></td>
<td>Hepatitis B</td>
</tr>
<tr>
<td></td>
<td>Range from mild liver dysfunction to death</td>
</tr>
<tr>
<td></td>
<td>Maternal screening early in pregnancy. Maternal HbsAg positive is high risk of transmitting to fetus. If mother is positive, give neonate HepB IgG at birth, 3 months, and 6 months.</td>
</tr>
</tbody>
</table>

### TABLE 8-3. Viral Infections and Their Potential Fetal Effects

<table>
<thead>
<tr>
<th>Virus</th>
<th>Fetal Effects</th>
<th>Maternal Effects</th>
<th>Prophylaxis</th>
<th>Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Varicella-zoster</td>
<td>Transmitted transplacentally</td>
<td>Pneumonitis</td>
<td>Vaccine not recommended for pregnant women</td>
<td>Varicella-zoster immunoglobulin within 96 hrs of exposure C-section should be performed if there are active lesions.</td>
</tr>
<tr>
<td></td>
<td>Chorioretinitis</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Cerebral cortical atrophy</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Hydronephrosis</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Cutaneous and bony leg defects (scars)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Microcephaly</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Orthomyxoviridae</td>
<td>Infection</td>
<td>Pneumonia</td>
<td>Vaccination is recommended for pregnant women who have chronic underlying disease or who are routinely exposed.</td>
<td>Amantadine within 48 hrs of onset of symptoms in non-immunized, high-risk patients</td>
</tr>
<tr>
<td>Parvovirus B19</td>
<td>Abortion</td>
<td>Viremia → slapped cheek appearance</td>
<td>If + serology → US; if + hydrops → consider fetal transfusion.</td>
<td></td>
</tr>
<tr>
<td>Rubella</td>
<td>Congenital rubella syndrome</td>
<td></td>
<td>Vaccination (attenuated live virus) of the non-pregnant female</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Cataracts/glaucoma</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Patent ductus arteriosus</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Deafness</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Mental retardation</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hepatitis B</td>
<td>Range from mild liver dysfunction to death</td>
<td></td>
<td>Maternal screening early in pregnancy. Maternal HbsAg positive is high risk of transmitting to fetus. If mother is positive, give neonate HepB IgG at birth, 3 months, and 6 months.</td>
<td></td>
</tr>
</tbody>
</table>
### TABLE 8-3. Viral Infections and Their Potential Fetal Effects (continued)

<table>
<thead>
<tr>
<th>Virus</th>
<th>Fetal Effects</th>
<th>Maternal Effects</th>
<th>Prophylaxis</th>
<th>Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cytomegalovirus</td>
<td>Causes in utero infection in 1% of all newborns but only 10% of infected show disease.</td>
<td>Mononucleosis-like syndrome</td>
<td>None</td>
<td></td>
</tr>
<tr>
<td></td>
<td>- Cytomegalic inclusion disease</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>- Hepatosplenomegaly</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>- Thrombocytopenia</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>- Microcephaly</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>- Intracranial calcifications</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>- Chorioretinitis</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>- Mental retardation</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>- Jaundice</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* Infection may be especially severe in pregnant women.

### TABLE 8-4. Bacterial Infections and Their Potential Fetal Effects

<table>
<thead>
<tr>
<th>Bacteria</th>
<th>Fetal Effects</th>
<th>Maternal Effects</th>
<th>Prophylaxis</th>
<th>Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Group B Streptococcus (S. agalactiae)</td>
<td>- Preterm labor</td>
<td>- Chorioamnionitis</td>
<td>Intrapartum maternal penicillin G in women with + cultures at 35–37 wks’ GA</td>
<td>Neonatal penicillin G IM in the delivery room (there is no universal treatment)</td>
</tr>
<tr>
<td></td>
<td>- Premature rupture of membranes</td>
<td>- Puerperal sepsis</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>- Ophthalmia neonatorum</td>
<td>- Mastitis</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>- Sepsis</td>
<td>- Osteomyelitis</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>- Meningitis → neurologic sequelae in survivors</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Salmonella</td>
<td>- Death</td>
<td>- Enteritis</td>
<td>IV fluid rehydration*</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Bacteremia</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Borrelia burgdorferi (Lyme)</td>
<td>- Congenital infection</td>
<td>- Erythema migrans</td>
<td>Oral amoxicillin or penicillin</td>
<td></td>
</tr>
<tr>
<td></td>
<td>- Death</td>
<td>- Disseminated infection</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>- Preterm labor</td>
<td>- Meningitis</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>- Rash</td>
<td>- Carditis</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Arthritis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Primary and secondary syphilis</td>
<td>- Hepatosplenomegaly</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>- Lymphadenopathy</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>- Hemolysis</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chlamydia trachomatis</td>
<td>- Conjunctivitis</td>
<td></td>
<td>Screen in early pregnancy</td>
<td>Erythromycin or azithromycin</td>
</tr>
<tr>
<td></td>
<td>- Pneumonia</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Neisseria gonorrhoeae</td>
<td>- Conjunctivitis</td>
<td></td>
<td>Screen in early pregnancy</td>
<td>Penicillin or ceftriazone</td>
</tr>
<tr>
<td></td>
<td>- Otitis externa</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>- Pharyngitis</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### TABLE 8-4. Bacterial Infections and Their Potential Fetal Effects (continued)

<table>
<thead>
<tr>
<th>Bacteria</th>
<th>Fetal Effects</th>
<th>Maternal Effects</th>
<th>Prophylaxis</th>
<th>Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td><em>Toxoplasma gondii</em></td>
<td>Transplacental infection occurs.</td>
<td></td>
<td></td>
<td>Spiramycin (macrolide antibiotic)</td>
</tr>
<tr>
<td></td>
<td>- Congenital disease</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>- Hydrocephaly/microcephaly</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>- Hepatospleno-megaly</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>- Seizures</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>- Intracranial calcifications</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>- Chorioretinitis</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>- Mental retardation</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*a Antimicrobials prolong the carrier state and are not given in uncomplicated infections.*
HYPERTENSION IN PREGNANCY

Hypertension-related problems in pregnancy are classified in four ways:
- Chronic hypertension (HTN)
- Pregnancy-induced HTN
- Preeclampsia
- Eclampsia

The hypertension in each of these diagnoses is classified as:
- **Mild**: Systolic ≥ 140 mm Hg and/or diastolic ≥ 90 mm Hg
- **Severe**: Systolic > 160 mm Hg and/or diastolic > 110 mm Hg

See Figure 9-1 for management algorithm.

Pathophysiology of Hypertension in Pregnancy

**Normal**
Arachadonic acid triggers two pathways:

1. **Prostacycline**: Decreases blood pressure via:
   - Decreased vasoconstriction
   - Increased uteroplacental blood flow

2. **Thromboxane**: Increases blood pressure via:
   - Increased vasoconstriction
   - Decreased uteroplacental blood flow

**In Pregnancy-Hypertensive States**
The balance is thought to be tipped toward the thromboxane pathway.

CHRONIC HYPERTENSION (HTN) AND PREGNANCY

Defined as hypertension that antecedes pregnancy:
- **Mild**: Systolic ≥ 140 mm Hg and/or diastolic ≥ 90 mm Hg
- **Severe**: Systolic > 160 mm Hg and/or diastolic > 110 mm Hg

If during pregnancy a chronic hypertensive patient’s systolic blood pressure (BP) rises by 30 mm Hg or diastolic rises by 15 mm Hg, it is pregnancy-induced hypertension superimposed on chronic hypertension.
FIGURE 9-1. Management of hypertension in pregnancy.
Management

Mild: Early and serial ultrasounds, biophysicals

Severe:
- Serial ultrasounds and biophysicals
- Antihypertensives (methyldopa or nifedipine)

PREGNANCY-INDUCED HYPERTENSION (PIH)

Defined as hypertension during pregnancy in a previously normotensive woman (the patient had normal blood pressure prior to 20 weeks’ gestation):
Mild: Systolic $\geq 140$ mm Hg and/or diastolic $\geq 90$ mm Hg
Severe: Systolic $> 160$ mm Hg and/or diastolic $> 110$ mm Hg (same as chronic HTN)

Subsets of PIH

1. PIH (simple)
2. Preeclampsia: Renal involvement leads to proteinuria.
3. Eclampsia: Central nervous system involvement leads to seizures.
4. HELLP syndrome: The clinical picture is dominated by hematologic and hepatic manifestations.

Complications

- Heart failure
- Cerebral hemorrhage
- Placental abruption
- Fetal growth restriction
- Fetal death

Management

Mild: Observe, bed rest
Severe: Always hospitalize + antihypertensive pharmacotherapy (hydralazine or labetalol short term, nifedipine or methyldopa long term)

Generally, for all pregnancy-hypertensive states:
Plus the following:
- If $> 36$ weeks/fetal lung maturity: Induce labor.
- If $< 34$ weeks/fetal lung immaturity: Steroids plus expectant management
- If fetal or maternal deterioration at any gestational age, induce labor

PREECLAMPSIA

Preeclampsia is pregnancy-induced hypertension with proteinuria +/- pathological edema. It is classified as mild or severe.

Preeclampsia rarely develops before 20 weeks and usually occurs in a first pregnancy.

Criteria for Mild Preeclampsia

- BP: $\geq 140$ systolic or $\geq 90$ diastolic
- Proteinuria: 300 mg to 5 g/24 hrs (norm: $< 300$ mg/24 hrs in pregnancy, $< 150$ mg/24 hrs in nonpregnant state)

Manifestations of Severe Disease

- BP: $> 160$ systolic or $> 110$ diastolic
Proteinuria: > 5 g/24 hrs
Elevated serum creatinine
Oliguria (< 500 mL/24 hrs)
Symptoms suggesting end organ involvement:
  - Headache
  - Visual disturbances
  - Epigastric/right upper quadrant pain
  - Pulmonary edema
  - Hepatocellular dysfunction (elevated aspartate transaminase [AST], alanine transaminase [ALT])
  - Thrombocytopenia
  - IUGR or oligohydramnios
  - Microangiopathic hemolysis
  - Grand mal seizures (eclampsia)

Predisposing Factors
  - Nulliparity
  - Family history of preeclampsia–eclampsia
  - Multiple fetuses
  - Diabetes
  - Chronic vascular disease
  - Renal disease
  - Hydatidiform mole
  - Fetal hydrops

HELLP Syndrome
HELLP syndrome is a manifestation of preeclampsia with hemolysis, elevated liver enzymes, and low platelets. In contrast to typical presentations of preeclampsia, it is associated with:
  - High morbidity
  - Multiparous mothers
  - Mothers older than 25
  - Less than 36 weeks’ gestation

Diagnosis of Preeclampsia
Once preeclampsia is suspected, the following tests should be done:
  - Blood: Electrolytes, blood urea nitrogen (BUN), creatinine, liver function tests (LFTs) (ALT, AST), complete blood count (CBC), uric acid, and platelet count
  - Urine: Sediment, 24-hour protein, 24-hour creatinine
  - Fetal: Ultrasound, nonstress test, biophysical profile

Management
Varies depending on severity of disease and gestational age of fetus:

  - **Mild Preeclampsia**
    - Hospitalize, observe, bed rest, low-salt diet, monitor labs closely

  - **Severe Preeclampsia**
    - Hospitalize, bed rest, low salt, low calories
    - Antihypertensive pharmacotherapy: Hydralazine or labetalol short term, nifedipine or methyldopa long term
    - Anticonvulsive therapy: Magnesium sulfate
Plus the following:
- If > 36 weeks/fetal lung maturity: Induce labor.
- If < 34 weeks/fetal lung immaturity: Steroids plus expectant management
- If fetal or maternal deterioration at any gestational age: Induce labor.

The only cure is delivery.

**ECLAMPSIA**

**Criteria**
- Mild or severe preeclampsia
- Generalized seizures

**Management**
1. Control of the convulsions (magnesium sulfate IV and IM)
2. Correction of hypoxia and acidosis
3. BP control (hydralazine or labetalol)
4. Delivery after control of convulsions

**ANTIHYPERTENSIVE AGENTS USED IN PREGNANCY**

**Short-Term Control**
- *Hydralazine*: IV or PO, direct vasodilator
  Side effects: Systemic lupus erythematosus (SLE)-like syndrome, headache, palpitations
- *Labetalol*: IV or PO, nonselective beta-1 and alpha-1 blocker
  Side effects: Headache and tremor

**Long-Term Control**
- *Methyldopa*: PO, false neurotransmitter
  Side effects: Postural hypotension, drowsiness, fluid retention
- *Nifedipine*: PO, calcium channel blocker
  Side effects: Edema, dizziness
- *Atenolol*: PO, selective beta-1 blocker
  Side effect: Breathlessness

**PRETERM LABOR**

**Criteria**
Gestational age (GA) < 37 weeks with regular uterine contractions and:
- Progressive cervical change
  or
- A cervix that is 2 cm dilated
  or
- A cervix 80% effaced
  or
- Ruptured membranes
Epidemiology
Preterm labor has been associated with the following findings:

1. Infection:
   - Systemic
   - Pyelonephritis urinary tract infection (UTI)/sexually transmitted disease (STD)
   - Chorioamnionitis

2. Maternal factors:
   - Low socioeconomic status
   - Coitus
   - Long work hours
   - Youth
   - Grand multiparity
   - ETOH/smoking/narcotics
   - Previous preterm labor
   - Previous abortion
   - Preeclampsia/eclampsia/HTN

3. Anomalies:
   - Uterine (septated uterus, fibroids)
   - Cervical incompetence
   - Multifetal pregnancy
   - Polyhydramnios
   - Fetal anomalies
   - Placenta previa/abruptio

Assessment
- Frequency of uterine contractions
- Possible causes such as infection
- Confirm GA of fetus (i.e., by ultrasound).
- Assess fetal well-being with a biophysical profile.

Management of Preterm Labor
HYDRATION
Always hydrate first in preterm labor. It often stops contractions. Dehydration causes antidiuretic hormone (ADH) secretion, and ADH mimics oxytocin (both made in posterior pituitary).

TOCOLYTIC THERAPY
Tocolysis is used if < 34 weeks.

Tocolytic Agents
- IV magnesium sulfate—suppresses uterine contractions
- Oral calcium channel blocker (nifedipine)
- Beta mimetics (ritodrine, terbutaline)—stimulate beta-2 receptors on myometrial cells → increase cyclic adenosine monophosphate (cAMP) → decrease intracellular Ca → decrease contractions
Side effects: Pulmonary edema, tachycardia, headaches
Prostaglandin inhibitors (indomethacin)
Side effects: Premature constriction of ductus arteriosus, pulmonary HTN, and interventricular hemorrhage

Contraindications to Tocolysis
- Severe Bleeding from any cause
- Severe Abruptio placenta
- Fetal Death/life-incompatible anomaly
- Chorioamnionitis
- Severe pregnancy-induced Hypertension
- Unstable maternal hemodynamics

Action
- Acts as Ca\(^{2+}\) antagonist and reduces actin–myosin interaction (at 7 mg/100 mL)

Side Effects
- Decreases deep tendon reflexes (at 8 to 10 mg/100 mL)
- Respiratory/cardiac depression (at > 12 mg/100 mL)
- Flushing, warmth, headaches, nystagmus, dizziness, dry mouth, hypocalcemia

About Magnesium Sulfate
- Magnesium sulfate antagonizes Ca and decreases intracellular Ca, thus decreasing contractions. It is 70 to 90% effective in achieving 2 to 3 days of tocolysis.
- Side effects: Depressed reflexes, pulmonary edema, fatigue. Toxicity is treated with calcium gluconate.

<table>
<thead>
<tr>
<th>Mg Level</th>
<th>Side Effect</th>
</tr>
</thead>
<tbody>
<tr>
<td>4–7 mg</td>
<td>Uterine contractions decreased</td>
</tr>
<tr>
<td>8–12 mg</td>
<td>Depressed deep tendon reflexes</td>
</tr>
<tr>
<td>&gt; 12 mg</td>
<td>Respiratory/cardiac depression</td>
</tr>
</tbody>
</table>

Corticosteroids
- Given to patients in preterm labor from 24 to 35 weeks unless they have chorioamnionitis
- Reduce fetal mortality: Accelerate fetal lung maturity (decreases respiratory distress syndrome [RDS]), reduce intraventricular hemorrhage, and reduce necrotizing enterocolitis

Lecithin–Sphingomyelin Ratio
An amniocentesis may be performed to assess fetal lungs for risk of RDS. Fetal lungs are mature if:
- Phosphatidylglycerol is present in amniotic fluid
or
- Lecithin–sphingomyelin ratio is > 2
Premature rupture denotes spontaneous rupture of fetal membranes before the onset of labor. This can occur at term (PROM) or preterm (PPROM).

**Etiology**

Unknown but hypothesized: Vaginal and cervical infections, incompetent cervix, abnormal membranes, nutritional deficiencies

**Risks**

- **Prolonged rupture of membranes:** The rupture of membranes > 18 to 24 hours before labor. Patients who do not go into labor immediately will have prolonged rupture of membranes and are at increasing risk of infection as the duration of rupture increases:
  - Chorioamnionitis and other infections
  - Neonatal infection
  - Umbilical cord prolapse

Only if preterm PROM:

- **Prematurity:** If PROM occurs at < 37 weeks, the fetus is at risk of being born prematurely.
- **Oligohydramnios:** If PROM occurs at < 24 weeks, there is a risk of oligohydramnios (depleted amniotic fluid), which may cause pulmonary hypoplasia. Survival at this age is low.

**Diagnosis of Rupture of Membranes (ROM)**

A digital exam should not be performed, as it increases the risk of infection:

- **Sterile speculum examination:**
  - Visualize extent of cervical effacement and dilation, and exclude prolapsed cord or protruding fetal extremity.
  - **Pool test:** Identify fluid coming from the cervix or pooled in the posterior fornix of the vagina → supports diagnosis of PROM.
  - **Nitrazine test:** Put fluid on nitrazine paper, which turns blue if fluid is alkaline. Alkaline pH indicates fluid is amniotic.
  - **Ferning test:** A swab from the posterior fornix is smeared on a slide, allowed to dry, and examined under a microscope for “ferning” → + for amniotic fluid.

**Management of All PROM Patients**

- Evaluate patient for chorioamnionitis (common etiology of PROM):
  - Fever > 38°C, leukocytosis, maternal/fetal tachycardia, uterine tenderness, malodorous vaginal discharge
  - Gram stain and culture of amniotic fluid to assess for chorioamnionitis
  - If positive for chorioamnionitis, delivery is performed despite GA, and antibiotics are initiated (ampicillin, gentamicin).
Specific Management for PROM at Term

Ninety percent of term patients go into spontaneous labor within 24 hours after rupture:
- Patients in active labor should be allowed to progress.
- If labor is not spontaneous, it should be induced or cesarean delivery should be performed.

Specific Management of PPROM

Fifty percent of preterm patients go into labor within 24 hours after rupture.

Generally, one needs to balance the risks of premature birth against the risk of infection (which increases with the time that membranes are ruptured before birth). Management is aimed at assessing these risks and acting accordingly:
- Gram stain and culture of amniotic fluid to assess for chorioamnionitis
- If chorioamnionitis is suspected, begin ampicillin and/or erythromycin prophylaxis.
- Amniotic fluid assessment of lecithin–sphingomyelin ratio for lung maturity
- Perform ultrasound to assess gestational age, position of baby, and level of fluid.
- If < 34 weeks, give steroids to decrease incidence of RDS.
- Expectant management
- ROM: Rupture of membranes
- PROM: Premature rupture of membranes (ROM before the onset of labor)
- PPROM: Preterm (< 37 weeks) premature rupture of membranes
- Prolonged rupture of membranes: Rupture of membranes that lasts > 18 hours

THIRD-TRIMESTER BLEEDING

INCIDENCE

Occurs in 2 to 5% of pregnancies

WORKUP

- History and physical
- Vitals
- Labs: CBC, coagulation profile, type and cross, urine analysis

See Figure 9-2 for management algorithm.

Determine whether blood is maternal or fetal or both:
- **Apt test**: Put blood from vagina in tube with KOH:
  - Turns brown for maternal
  - Turns pink for fetus
- **Kleihauer–Betke test**: Take blood from mother’s arm and determine percentage of fetal RBCs in maternal circulation: > 1% = fetal bleeding.
- **Wright’s stain**: Vaginal blood; nucleated RBCs indicate fetal bleed.
Differential

Obstetric Causes
- Placental abruption
- Placenta previa
- Vasa previa/velamentous insertion
- Uterine rupture
- Circumvillate placenta
- Extrusion of cervical mucus (“bloody show”)

Nonobstetric Causes
- Cervicitis
- Polyp
- Neoplasm

Placental Abruption (Abruptio Placentae)
Premature separation of placenta from uterine wall before the delivery of baby (see Figure 9-3)

Incidence
0.5 to 4%

Mortality
- Maternal: 1 to 5%
- Fetal: 50 to 80%
RISK FACTORS

Trauma (usually shearing, such as a car accident), preeclampsia (and maternal HTN), smoking, cocaine abuse, high parity, previous history of abruption

CLINICAL PRESENTATION

- Vaginal bleeding (maternal and fetal blood present)
- Constant and severe back pain or uterine tenderness
- Irritable, tender, and typically hypertonic uterus
- Evidence of fetal distress
- Maternal shock

DIAGNOSIS

- Ultrasound will show retroplacental hematoma only part of the time.
- Clinical and pathological findings

MANAGEMENT

- Correct shock (packed RBCs, fresh frozen plasma, cryoprecipitate, platelets).
- Expectant management: Close observation of mother and fetus with ability to intervene immediately
- If there is fetal distress, perform C-section.

Placenta Previa

A condition in which the placenta is implanted in the immediate vicinity of the cervical canal. It can be classified into three types:

- **Complete placenta previa:** The placenta covers the entire internal cervical os.
- **Partial placenta previa:** The placenta partially covers the internal cervical os.
- **Marginal placenta previa:** One edge of the placenta extends to the edge of the internal cervical os.

See Figure 9-4.

**INCIDENCE**

0.5 to 1%

**ETIOLOGY**

Unknown, but associated with:

- Increased parity
- Older mothers
- Previous abortions
- Previous history of placenta previa
- Fetal anomalies

**CLINICAL PRESENTATION**

- Painless, profuse bleeding in T3
- Postcoital bleeding
- Spotting during T1 and T2
- Cramping (10% of cases)

**FIGURE 9-4.** A. Partial placenta previa. B. Complete placenta previa.

(Reproduced, with permission, from DeCherney AH, Pernoll ML. Current Obstetric & Gynecologic Diagnosis & Treatment. Norwalk, CT: Appleton & Lange, 1994: 404.)
DIAGNOSIS

- **Transabdominal ultrasound** (95% accurate)
- **Double set-up exam**: Take the patient to the operating room and prep for a C-section. Do speculum exam: If there is local bleeding, do a C-section; if not, palpate fornices to determine if placenta is covering the os. The double set-up exam is performed only on the rare occasion that the ultrasound is inconclusive.

MANAGEMENT

Cesarean section is always the delivery method of choice for placenta previa. The specific management is geared toward different situations.

- **For Preterm**
  - If there is no pressing need for delivery, monitor in hospital or send home after bleeding has ceased.
  - Transfusions to replace blood loss, and tocolytics to prolong labor to 36 weeks if necessary

Even after the bleeding has stopped, repeated small hemorrhages may cause IUGR.

- **For Mature Fetus**
  - C-section

- **For a Patient in Labor**
  - C-section

- **If Severe Hemorrhage**
  - C-section regardless of fetal maturity

**Fetal Vessel Rupture**

Two conditions cause third-trimester bleeding resulting from fetal vessel rupture: (1) Vasa previa and (2) velamentous cord insertion. These two conditions often occur together.

**Vasa Previa**

A condition in which the fetal cord vessels unprotectedly pass over the internal os, making them susceptible to rupture and bleeding

- **Incidence**
  - 0.03 to 0.05%

- **Presentation**
  - Rapid vaginal bleeding and fetal distress (sinusoidal variation of fetal heart rate)

- **Management**
  - Correction of shock and immediate C-section
**Velamentous Cord Insertion**

The velamentous insertion of the umbilical cord into the fetal membranes: In other words, the fetal vessels insert between amnion and chorion. This leaves them susceptible to ripping when the amniotic sac ruptures.

**Epidemiology**

- 1% of single pregnancies
- 10% of twins
- 50% of triplets

**Clinical Presentation**

Vaginal bleeding with fetal distress

**Management**

Correction of shock and immediate C-section

**Uterine Rupture**

The ripping of the uterine musculature through all of its layers, usually with part of the fetus protruding through the opening

**Incidence**

0.5%

**Risk Factors**

Prior uterine scar is associated with 40% of cases:
- Vertical scar: 5% risk
- Transverse scar: 0.5% risk

**Presentation and Diagnosis**

- Sudden cessation of uterine contractions with a “tearing” sensation
- Recession of the fetal presenting part
- Increased suprapubic pain and tenderness with labor (may not be readily apparent if analgesia/narcotics are administered)
- Vaginal bleeding (or bloody urine)
- Sudden, severe fetal heart rate decelerations
- Sudden disappearance of fetal heart tones
- Maternal hypovolemia from concealed hemorrhage

**Management**

- Total abdominal hysterectomy is treatment of choice (after delivery).
- If childbearing is important to the patient, rupture repair is possible but risky.

**Other Obstetric Causes of Third-Trimester Bleeding**

**Circumvillate Placenta:** The chorionic plate (on fetal side of the placenta) is smaller than the basal plate (located on the maternal side), causing amnion and chorion to fold back onto themselves. This forms a ridge around the placenta with a central depression on the fetal surface.
Extrusion of cervical mucus ("bloody show"): A consequence of effacement and dilation of the cervix, with tearing of the small veins → slight shedding of blood. Treatment is rarely necessary.

**ABNORMALITIES OF THE THIRD STAGE OF LABOR**

**Immediate Postpartum Hemorrhage**
- Postpartum hemorrhage denotes excessive bleeding (> 500 mL in vaginal delivery; > 1,000 for C-section) following delivery.
- Blood loss during first 24 hours: "Early" postpartum hemorrhage
- Blood loss between 24 hours and 6 weeks after delivery: "Late" postpartum hemorrhage

**CAUSES**
- Coagulation defects
- Uterine atony (myometrium cannot contract postpartum)
- Ruptured uterus
- Degrees of retained placental tissue
- Bleeding from the placental implantation site
- Trauma to the genital tract and adjacent structures

Most common cause is uterine atony. Normally the uterus contracts, compressing blood vessels and preventing bleeding.

**RISK FACTORS**
- Blood transfusion/hemorrhage during a previous pregnancy
- Coagulopathy
- Vaginal birth after cesarean (VBAC)
- High parity
- Large infant
- Midforceps delivery

**MANAGEMENT**
1. Manually compress and massage the uterus—controls virtually all cases of hemorrhage due to atony.
2. Obtain assistance.
3. Give oxytocin (20 units in 1 L of lactated Ringer’s) or mesterigonovine or prostaglandins if oxytocin is ineffective.
4. If not previously done, obtain blood for typing and crossmatching/begin fluid or blood replacement.
5. Carefully explore the uterine cavity to ensure that all placental parts have been delivered and that the uterus is intact.
6. Inspect the cervix and vagina.
7. Place Foley and monitor urine output.

If all this fails:
- Hysterectomy

or
- Radiographic embolization of pelvic vessels

or
- Uterine artery ligation or hypogastric artery ligation
Abnormal Placentation

The abnormal implantation of the placenta in the uterus: These conditions can cause retention of the placenta after birth.

Types of Abnormal Placentation

Placenta accreta: An abnormally adherent implantation of the placenta in which the placental villi attach directly to the myometrium rather than to the decidua basalis

Placenta increta: An abnormally adherent implantation in which the placental villi invade the myometrium

Placenta percreta: An abnormally adherent implantation in which the placental villi penetrate through the myometrium

ETIOLOGY

These conditions are associated with:

- Placenta previa
- Previous C-section
- Previous dilation and curettage (D&C)
- Grand multiparity

MANAGEMENT

All of these conditions often result in postpartum hemorrhage (third stage of labor hemorrhage) and require hysterectomy.

Uterine Inversion

This medical emergency results from an inexperienced person’s pulling too hard when delivering the placenta. It can be a result of abnormal placental implantation. Morbidity results from shock and sepsis.

INCIDENCE

1 in 2,200 deliveries

MANAGEMENT

- Call for assistance.
- An anesthesiologist should anesthetize.
- Separate placenta from uterus and replace inverted uterus by pushing on the fundus toward the vagina.
- Oxytocin is given after uterus is restored to normal configuration and anesthesia is stopped.

Macrosomia

Defined as birth weight > 4,500 g:

Risk factors for macrosomia: Diabetes, obesity, previous history, post-term pregnancy, multiparity, and advanced maternal age

Macrosomic infants are at risk for: Birth trauma, jaundice, hypoglycemia, low Apgar scores, childhood tumors
In the majority of instances, bacteria responsible for pelvic infections are those that normally reside in the bowel and colonize the perineum, vagina, and cervix.

**Causes**

Gram-positive cocci: Group A, B, and D streptococci  
Gram-positive bacilli: Clostridium species, Listeria monocytogenes  
Aerobic gram-negative bacilli: Escherichia coli, Klebsiella, Proteus species  
Anaerobic gram-negative bacilli: Bacteroides bivius, B. fragilis, B. disiens  
Other: Mycoplasma hominis, Chlamydia trachomatis

**Risk Factors**

- Prolonged rupture of membranes  
- C-section  
- Colonization of the lower genital tract with certain microorganisms (i.e., group B streptococci, C. trachomatis, M. hominis, and Gardnerella vaginalis)  
- Premature labor  
- Frequent vaginal exams

**Diagnosis**

- Fever > 100.4°F (38°C)  
- Soft, tender uterus  
- Lochia has a foul odor.  
- Leukocytosis (WBC > 10,000/µL)  
- Malaise

**Management**

- Identify source of infection (i.e., perform urinalysis).  
- Identify the cause of infection (i.e., culture the lochia).  
- Assess the severity of the infection.  
- Treat (i.e., with antibiotics).

**Types of Postpartum Infections**

**Endometritis**

- A postpartum uterine infection involving the decidua, myometrium, and parametrial tissue  
- Also called metritis with pelvic cellulitis, endomyometritis, and endoparametritis  
- Typically develops postpartum day 2 to 3  
- Treat with IV antibiotics (gentamicin and clindamycin) until patient is afebrile for 24 to 48 hours.
**Urinary Tract Infection**
- Caused by catheterization, birth trauma, conduction anesthesia, and frequent pelvic examinations
- Presents with dysuria, frequency, urgency, and low-grade fever
- Rule out pyelonephritis (costovertebral angle tenderness, pyuria, hematuria).
- Obtain a urinalysis and urinary culture (E. coli is isolated in 75% of postpartum women).
- Treat with appropriate antibiotics.

**Cesarean Section Wound Infection**
- Fever that persists to the fourth or fifth postoperative day suggests wound infection.
- Wound erythema and tenderness several days after surgery
- Obtain Gram stain and cultures from wound material.
- Wound should be drained, irrigated, and debrided.
- Antibiotics should be given if extensive infection is suspected.

**Episiotomy Infection**
- Look for pain at the episiotomy site, disruption of the wound, and a necrotic membrane over the wound.
- Rule out the presence of a rectovaginal fistula with a careful rectovaginal exam.
- Open, clean, and debride the wound to promote granulation tissue formation.
- Sitz baths are recommended.
- Reassess for possible closure after granulation tissue has appeared.

**Mastitis**
- Affects 1 to 2% of postpartum women
- Two types: Epidemic (nosocomial) and nonepidemic:
  - **Epidemic mastitis** is caused by infant acquiring Staphylococcus aureus in his nasopharynx from the hospital. Mother presents on day 2 to 4 with fever and breast tenderness. Treat with penicillin and isolate from other patients.
  - **Endemic (nonepidemic) mastitis** presents weeks or months after delivery, usually during period of weaning. Mother presents with fever, systemic illness, and breast tenderness. Treat with penicillin or dicloxacillin. Continue breast feeding.

**High-Yield Facts**
- **Wound infection occurs in 4 to 12% of patients following C-section.**
- **Antibiotic prophylaxis with IV cefazolin is commonly employed.**
- **The more extensive the laceration/incision, the greater the chance of infection and wound breakdown.**
- **Breast engorgement (painful, swollen, firm breasts) is not mastitis (due to infection) and is normal during the second to fourth postpartum day. Treat with supportive bra, 24-hour demand feedings, and ice packs if not breast feeding.**
Spontaneous Abortion, Ectopic Pregnancy, and Fetal Death

FIRST-TRIMESTER BLEEDING

DIFFERENTIAL DIAGNOSIS

- Spontaneous abortion
- Ectopic pregnancy
- Hydatidiform mole
- Benign and malignant lesions (i.e., choriocarcinoma, cervical cancer)

WORKUP

- Vital signs (rule out shock/sepsis/illness)
- Pelvic exam (look at cervix, source of bleed)
- Beta-human chorionic gonadotropin (hCG) level, complete blood count (CBC), antibody screen
- Ultrasound (US) (assess fetal viability; abdominal US detects fetal heart motion by ≥ 7 weeks’ gestational age [GA])

See Figure 10-1 for management algorithm.

SPONTANEOUS ABORTION

Spontaneous abortion is the termination of pregnancy resulting in expulsion of an immature, nonviable fetus:

- Occurs in 50 to 75% of all pregnancies
- Most are unrecognized because they occur before or at the time of the next expected menses.
- Fifteen to 20% of clinically diagnosed pregnancies are lost in T1 or early T2.
ETIOLOGIES

Chromosomal Abnormalities
- Majority of abnormal karyotypes are numeric abnormalities as a result of errors during gametogenesis, fertilization, or the first division of the fertilized ovum.
- Frequency:
  - Trisomy—50 to 60%
  - Monosomy (45,X)—7 to 15%
  - Triploidy—15%
  - Tetraploidy—10%

Infectious Agents
Infectious agents in cervix, uterine cavity, or seminal fluid can cause abortions. These infections may be asymptomatic:
- *Toxoplasma gondii*
- Herpes simplex
- *Ureaplasma urealyticum*
- *Mycoplasma hominis*

Uterine Abnormalities
- Septate/bicornuate uterus—25 to 30%
- Cervical incompetence
- Leiomyomas (especially submucosal)
- Intrauterine adhesions (i.e., from curettage)
Endocrine Abnormalities
- Progesterone deficiency
- Polycystic ovarian syndrome (POS)—hypersecretion of luteinizing hormone (LH)
- Diabetes—uncontrolled

Immunologic Factors
- Lupus anticoagulant
- Anticardiolipin antibody (antiphospholipid syndrome)

Environmental Factors
- Tobacco—≥ 14 cigarettes/day increases abortion rates
- Alcohol
- Irradiation
- Environmental toxin exposure

Threatened Abortion
Threatened abortion is vaginal bleeding that occurs in the first 20 weeks of pregnancy, without the passage of products of conception (POC) or rupture of membranes. Pregnancy continues, although up to 50% result in loss of pregnancy.

Diagnosis
Speculum exam reveals blood coming from a closed cervical os, without amniotic fluid or POC in the endocervical canal.

Management
Bed rest with sedation and without intercourse

Inevitable Abortion
Inevitable abortion is vaginal bleeding, cramps, and cervical dilation. Expulsion of the POC is imminent.

Diagnosis
Speculum exam reveals blood coming from an open cervical os. Menstrual-like cramps typically occur.

Management
- Surgical evacuation of the uterus
- Rh typing—D immunoglobulin (RhoGAM) is administered to Rh-negative, unsensitized patients to prevent isoimmunization.

Incomplete Abortion
Incomplete abortion is the passage of some, but not all, POC from the cervical os.
**DIAGNOSIS**
- Cramping and heavy bleeding
- Enlarged, boggy uterus
- Dilated internal os with POC present in the endocervical canal or vagina

**MANAGEMENT**
- Stabilization (i.e., IV fluids and oxytocin if heavy bleeding is present)
- Blood typing and crossmatching for possible transfusion if bleeding is brisk or low Hgb/patient symptomatic
- Rh typing
- POC are removed from the endocervical canal and uterus with ring forceps. Suction dilation and curettage (D&C) is performed after vital signs have stabilized.
- Karyotyping of POC if loss is recurrent

### COMPLETE ABORTION

Complete abortion is the complete passage of POC.

**DIAGNOSIS**
- Uterus is well contracted.
- Cervical os may be closed.
- Pain has ceased.

**MANAGEMENT**
- Examine all POC for completeness and characteristics.
- Between 8 and 14 weeks, curettage is necessary because of the large possibility that the abortion was incomplete.
- Observe patient for further bleeding and fever.

### MISSED ABORTION

Missed abortion is when the POC are retained after the fetus has expired.

**DIAGNOSIS**
- The pregnant uterus fails to grow, and symptoms of pregnancy have disappeared.
- Intermittent vaginal bleeding/spotting/brown discharge and a firm, closed cervix
- Decline in quantitative beta-hCG
- US confirms lack of fetal heartbeat.

**MANAGEMENT**

Although most women will spontaneously deliver a dead fetus within 2 weeks, the psychological stress imposed by carrying a dead fetus and the dangers of coagulation defects favor the practice of labor induction and early delivery:
- Check fibrinogen level, partial thromboplastin time (PTT), antibody screen, and ABO blood type.
- Evacuate the uterus (suction D&C in first trimester) or induce labor with IV oxytocin and cervical dilators or prostaglandin E2 suppositories.
- Administer RhoGAM to Rh-negative, unsensitized patients.
Septic abortion results from a maternal infection leading to sepsis, fetal infection, and fetal death. The infection is usually polymicrobial, often with *E. coli* and other gram-negative organisms.

**DIAGNOSIS**
- Generalized pelvic discomfort, pain, and tenderness
- Signs of peritonitis
- Fever of 37.8 to 40.6°C (100 to 105°F)
- Malodorous vaginal and cervical discharge
- Leukocytosis

**MANAGEMENT**
- Cultures of uterine discharge and blood
- Check CBC, urinalysis (UA), serum electrolytes, liver function tests (LFTs), blood urea nitrogen (BUN), creatinine, and coagulation panel.
- Abdominal and chest films to exclude free air in the peritoneal cavity helps determine the presence of gas-forming bacteria or foreign body
- Prompt uterine evacuation (D&C), IV antibiotics, IV fluids

### Recurrent Abortion

Three or more successive clinically recognized pregnancy losses prior to 20 weeks' GA constitutes recurrent abortion.

Women with two successive spontaneous abortions have a recurrence risk of 25 to 45%.

**Etiology**
- Parental chromosomal abnormalities (balanced translocation is the most common)
- Anatomic abnormalities (congenital and acquired)
- Endocrinologic abnormalities
- Infections (e.g., *Chlamydia, Ureaplasma*)
- Autoimmunity
- Unexplained (majority of cases)

**Management**
- Investigate possible etiologies.
- Potentially useful investigative measures include:
  1. Parental peripheral blood karyotypes
  2. Sonohysterogram (intrauterine structural study)
  3. Luteal-phase endometrial biopsy
  4. Anticardiolipin and antiphosphatidyl serine antibodies
  5. Lupus anticoagulant
  6. Cervical cultures for *Mycoplasma, Ureaplasma, Chlamydia*

See Table 10-1.
ECTOPIC PREGNANCY (EXTRAUTERINE PREGNANCY)

Ectopic pregnancy is the implantation of the blastocyst anywhere other than the endometrial lining of the uterine cavity: It is a medical emergency (see Figure 10-2).

Epidemiology

- > 1/50 pregnancies in the United States is ectopic.
- Carries a 7- to 13-fold increase in recurrence risk

<table>
<thead>
<tr>
<th>TABLE 10-1. Types of Abortions</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Complete abortion</strong></td>
</tr>
<tr>
<td><strong>Incomplete abortion</strong></td>
</tr>
<tr>
<td><strong>Threatened abortion</strong></td>
</tr>
<tr>
<td><strong>Inevitable abortion</strong></td>
</tr>
<tr>
<td><strong>Missed abortion</strong></td>
</tr>
<tr>
<td><strong>Recurrent spontaneous abortion</strong></td>
</tr>
<tr>
<td><strong>Septic abortion</strong></td>
</tr>
<tr>
<td><strong>Therapeutic abortion (induced)</strong></td>
</tr>
<tr>
<td><strong>Elective abortion (induced)</strong></td>
</tr>
</tbody>
</table>

Ectopic pregnancy is the leading cause of pregnancy-related death during T1. Diagnose and treat before tubal rupture occurs to decrease the risk of death!

Etiology/Risk Factors

- **Fallopian tube transport malfunction** due to:
  - Infection such as *Chlamydia* and gonorrhea (50%)
  - Previous ectopic pregnancy
  - Previous tubal surgery
  - Abdominal surgery resulting in adhesions
  - Endometriosis
  - Congenital abnormalities (often from diethylstilbestrol [DES] exposure)
  - Pregnancy with intrauterine device in place
- **Assisted reproduction:**
  - Ovulation-inducing drugs
  - In vitro fertilization

Symptoms and Diagnosis

- Amenorrhea followed by irregular vaginal bleeding
- Adnexal tenderness or mass
- US evidence of an adnexal mass without intrauterine gestation or an adnexal gestational sac with a fetal pole and cardiac activity
- Less-than-normal increase in hCG
- A serum progesterone level lower than normal for patients with an intrauterine pregnancy (i.e., < 25 ng/mL)
- Laparoscopy shows an adnexal mass or abdominal gestation.

Signs of Rupture

- Shock
- Bleeding
- Increased abdominal pain

Management

There are two options of treatment:

**Operative**

- Laparoscopy or laparotomy with salpingostomy or segmental resection if the tube is to be retained and salpingectomy if the tube requires removal

**Medical**

- Intramuscular methotrexate (prevents DNA synthesis via its antifolate actions)
- Patient is monitored as an outpatient.
- 67 to 100% effective

---

**HIGH-YIELD FACTS**

Spontaneous Abortion

The primary causes of ectopic pregnancy include conditions that either prevent or impede passage of a fertilized ovum through the fallopian tube.

Classic triad of ectopic pregnancy:

- Amenorrhea
- Vaginal bleeding
- Abdominal pain

These usually indicate rupture.

Always do a β-hCG level on a premenopausal woman with abdominal pain.
If ruptured, always stabilize with IV fluids, blood replacement, and pressors if necessary. Operative repair is used.

**Fetal Death**

- Fetal death is defined as death prior to complete expulsion or extraction from the mother, regardless of the duration of pregnancy.
- Fetal death can result in a spontaneous abortion and a missed abortion.

**Causes**

A carefully performed autopsy is the single most useful step in identifying the cause of fetal death.

**T1 (1 to 14 Weeks)**

- Chromosomal abnormalities
- Environmental factors (e.g., medications, smoking, toxins)
- Infection (e.g., herpes simplex virus, human papillomavirus, mumps, *Mycoplasma*)
- Antiphospholipid antibodies (after 10 weeks)
- Maternal anatomic defects (e.g., maternal müllerian defects)
- Endocrine factors (e.g., progesterone insufficiency, thyroid dysfunction)
- Maternal systemic disease (e.g., diabetes)
- Unknown

**T2 (14 to 28 Weeks)**

- Anticardiolipin antibodies
- Antiphospholipid antibodies
- Chromosomal abnormalities
- Anatomic defects of uterus and cervix
- Infection (e.g., BV, syphilis)
- Erythroblastosis
- Placental pathological conditions (e.g., circumvallate placentation, placenta previa)

**T3 (28 Weeks to Term)**

- Anticardiolipin antibodies
- Placental pathological conditions (e.g., circumvallate placentation, placenta previa, abruptio placentae)
- Infection

**Time Nonspecific**

- Trauma
- Cord entanglement
- Electric shock
- Maternal systemic disease
- Maternal infection
DISSEMINATED INTRAVASCULAR COAGULATION (DIC)

DIC or consumptive coagulopathy is a pathological condition associated with inappropriate activation of the coagulation and fibrinolytic system. Most commonly, it is associated with one of the following disease states:

- Fetal demise
- Amniotic fluid embolism
- Preeclampsia–eclampsia
- Placental abruption

Pathophysiology

In pathologic states (i.e., via thromboplastin production from dead POC), the coagulation cascade is activated, which results in consumption of platelets and coagulation factors. Fibrin deposition in small vessels results in bleeding and circulatory obstruction.

Diagnosis

- Physical exam may reveal multiple bleeding points associated with purpura and petechiae.
- Lab evaluation reveals thrombocytopenia, hypofibrinogenemia, an elevated prothrombin time, and increased fibrin split products.

Management

Supportive therapy to correct/prevent shock, acidosis, and tissue ischemia and, if applicable, prompt termination of pregnancy. Ultimately, the only care is to correct the underlying cause.

HIGH-YIELD FACTS

Spontaneous Abortion

Pregnancy normally induces:

- Increases in coagulation factors I (fibrinogen), VII, VIII, IX, and X
- Increased activation of platelet clotting

In any obstetric complication, obtain a coagulation panel and fibrin split-product levels to monitor for DIC.
DEFINITION

The termination of a pregnancy medically or operatively before fetal viability; definition of viability varies from state to state

ASSESSMENT OF THE PATIENT

Physical assessment is crucial before an elective abortion:
- Ultrasound should be performed if there is a discrepancy between dates and uterine size.
- Patient’s blood type and Rh type must be evaluated; if Rh negative, RhoGAM should be administered prophylactically.
- Careful patient counseling should be performed.

TYPES OF INDUCED ABORTION

Elective voluntary: Interruption of pregnancy at the request of the mother
Therapeutic: Interruption of pregnancy for the purpose of safeguarding the health of the mother

INDICATIONS FOR THERAPEUTIC ABORTION

Maternal Indications
- Cardiovascular disease
- Genetic syndrome (e.g., Marfan’s)
- Hematologic disease (e.g., TTP)
- Metabolic (e.g., proliferative diabetic retinopathy)
- Neoplastic (e.g., cervical cancer; mother needs prompt chemotherapy)
- Neurologic (e.g., Berry aneurysm; cerebrovascular malformation)
- Renal disease
- Intraterine infection
- Severe preeclampsia/eclampsia

Abortion may not be denied in first 3 months of pregnancy in any state.
Fetal Indications
- Major malformation (e.g., anencephaly)
- Genetic (e.g., Tay–Sachs disease)

METHODS OF ABORTION

First Trimester
**MEDICAL**
- Antiprogesterones such as mifepristone (RU 486) or epostane; used only before 9 weeks’ gestation. Without progesterone, the uterine lining sloughs off.
- Methotrexate IM + intrauterine misoprostol 1 week later; used only before 9 weeks’ gestation. Methotrexate is a folic acid antagonist that interferes with cell division.

**SURGICAL**
Cervical dilation followed by aspiration curettage (D&C): Risks include cervical/uterine injury and Asherman’s syndrome.

Second Trimester
**MEDICAL**
Intravaginal prostaglandin E$_2$ (PGE$_2$) or PGF$_{2\alpha}$ with urea

**SURGICAL**
Dilation and evacuation

Complications of Surgical Abortions
- Infection
- Incomplete removal of products of conception (POC)
- Disseminated intravascular coagulation (DIC)
- Bleeding
- Cervical laceration
- Uterine perforation/rupture
- Psychological sequelae
- Death

What abortion method has the lowest complication rate? Dilation and evacuation. Risks include: Hemorrhage/perforation.

Medical methods of abortions can only be used in first 9 weeks.
LESS COMMON METHODS OF ABORTION

Medical
- Intra-amnionic infusion of hyperosmolar fluid (saline + urea)
- High-dose IV oxytocin (induces uterine contractions)

Surgical
- Hysterotomy is used only if other methods have been unsuccessful. A hysterotomy is a C-section of a preterm fetus.
- Hysterectomy

HIGH-YIELD FACTS

Induced Abortion

- Infection is the most common complication of hysterectomy.

- Death is a risk of abortion, but it is 10 times less than the risk of death from giving birth.
SECTION II B

High-Yield Facts in Gynecology

- Contraception
- Sterilization
- Infertility
- Menstruation
- Abnormal Uterine Bleeding
- Pelvic Pain
- Endometriosis
- Pelvic Masses
- Cervical Dysplasia
- Cervical Cancer
- Endometrial Cancer
- Ovarian Cancer
- Vulvar Dysplasia and Cancer
- Gestational Trophoblastic Neoplasias (GTN)
- Sexually Transmitted Diseases (STDs) and Vaginitis
- Vulvar Disorders
- Menopause
- Pelvic Relaxation
- Women’s Health
GENERAL METHODS OF PREVENTING PREGNANCY

- Barrier
- Hormonal
- Intraruterine device (IUD)
- Sterilization

BARRIER METHODS

FEMALE CONDOM
Rarely used because of expense and inconvenience (it must not be removed for 6 to 8 hours after intercourse). It offers labial protection, unlike the male condom.

MALE CONDOM

Types
- Latex (cheapest and most common)
- Polyurethane (newest, sensitive, expensive)
- Animal skins (sensitive, least protection against sexually transmitted diseases [STDs])

Efficacy
- 88 to 98%, depending on if used properly

The only contraception effective in protecting against STDs

Drawbacks
- Interruption of coitus
- Decreased sensation

DIAPHRAGM
A flexible ring with a rubber dome that must be fitted by a gynecologist: It forms a barrier from the cervix to the anterior vaginal wall. It must be inserted with spermicide and left in place after intercourse for 6 to 8 hours.
Types
- Flat or coil spring type (for women with good vaginal tone)
- Arcing type (for poorer tone or vaginal/uterine irregularities such as cystocele or long cervixes)
- Wide seal rim

Efficacy
- 82 to 94%

Complications
- If left in for too long, may result in *Staphylococcus aureus* infection (which may lead to toxic shock syndrome)

**Cervical Cap**
A smaller version of a diaphragm that fits directly over the cervix; more likely to cause irritation or toxic shock syndrome. It is more popular in Europe.

Efficacy
- 82 to 94%

**Spermicide**
Foams, gels, creams placed in vagina up to 30 minutes before intercourse

Types
- Nonoxynol-9 and octoxynol-3; effective for only about 1 hour

Efficacy
- 80 to 97%

**Sponge**
A polyurethane sponge containing nonoxynol-9 that is placed over the cervix: It can be inserted up to 24 hours before intercourse.

Efficacy
- 84%

Risk
- Toxic shock syndrome

**Hormonal Agents**

**Oral Contraceptives**

Efficacy
- 97 to 99.9%

The following are the various types of oral contraceptives.

**Combination Pills**
Contain estrogen and progestin; come as fixed dosing and phasic dosing:
- Fixed dosing—requires the same dose every day of cycle
- Phasic dosing—gradual increase in amount of progestin as well as some changes in the level of estrogen
Mechanism (there are several)
- **Estrogen** suppresses follicle-stimulating hormone (FSH) and therefore prevents follicular emergence.
- **Progestosterone** suppresses the midcycle gonadotropin-releasing hormone (GnRH) surge, which suppresses luteinizing hormone (LH) and therefore prevents ovulation.
- Causes thicker cervical mucus
- Causes decreased motility of fallopian tube
- Causes endometrial atrophy

**Progestin-Only Pills**
Contain only progestin: There is LH suppression and therefore no ovulation. 
*The main differences from combination pills are:*
- A mature follicle is formed (but not released).
- No “sugar-pill” is used.

**Progestin-only pills are used in the following circumstances:**
- Lactating women (progestin, unlike estrogen, does not suppress breast milk)
- Women > 40 years old
- Women who cannot take estrogens for other medical reasons (e.g., estrogen-sensitive tumors)

**Benefits of Oral Contraceptives**
- Decreases risk of ovarian cancer by 75%
- Decreases risk of endometrial cancer by 50%
- Decreases bleeding and dysmenorrhea
- Regulates menses
- Protects against pelvic inflammatory disease (PID) (thicker mucus)
- Protects against fibrocystic change, ovarian cysts, ectopic pregnancy, osteoporosis, acne, and hirsutism

**Risks of Oral Contraceptives**
- Increases risk of venous thromboembolism/stroke (3/10,000)
- Increases risk of myocardial infarction (in smokers over 35 years old)
- Depression

**Contraindications of Oral Contraceptives**
- Thromboembolism
- Cerebrovascular accident (CVA) or coronary artery disease (CAD)
- Breast/endometrial cancer
- Cholestatic jaundice
- Undiagnosed vaginal bleeding
- Hepatic disease
- Known/suspected pregnancy
- Concomitant anticonvulsant therapy
- Some antibiotics
- Relative contraindications: Migraines, hypertension (HTN), lactation

In combination oral contraceptives, at the time of desired/expected menstruation, a placebo, or “sugar-pill,” is given to simulate the natural progesterone withdrawal.

**Mechanism in a nutshell:**
Estrogen inhibits FSH. Progestin inhibits LH.

Estrogen suppresses breast milk, so combination pills are not used for nursing mothers. Progestin-only pills are preferred.

Oral contraceptives’ link to an increase in breast cancer is not proven.

Why is estrogen a procoagulant? Estrogen increases factors VII and X and decreases antithrombin III.
Side Effects of Oral Contraceptives
- Breakthrough bleeding
- Breast tenderness
- Nausea (10 to 30% of women)

Injectable Hormonal Agent
Medroxyprogesterone acetate (Depo-Provera) IM injection given every 3 months

Efficacy
- 99.7%

Mechanism of Action
Sustained high progesterone level to block LH surge (and hence ovulation). Thicker mucus and endometrial atrophy also contribute. There is no FSH suppression.

Indications
- Systemic lupus erythematosus (SLE)
- Migraines
- Headaches
- Heavy bleeding

Side Effects of Injectable Hormonal Agents
- Bleeding irregularity/spotting
- 5 lb/yr weight gain
- Unknown when period will resume after treatment cessation
- Alopecia
- Mood changes
- Decreased high-density lipoprotein (HDL)
- Decreased libido

Contraindications
- Known/suspected pregnancy
- Undiagnosed vaginal bleeding
- Breast cancer
- Liver disease

Implantable Hormonal Agent
Subcutaneous implantation of six rods containing levonorgestrel (a progestin), which lasts about 5 years

Efficacy
- 99.8%

Mechanism of Action
- Suppression of LH surge
- Thickened mucus
- Endometrial atrophy

Women with SLE who want birth control should use injectable progesterone. Also good for people with poor compliance (e.g., retarded or drug addicts)
**Contraception**

**Side Effects**
- Irregular bleeding
- Acne
- Decreased libido
- Adnexal enlargement
- Possible difficult removal

**Indications**
- Oral contraceptives contraindicated/intolerated
- Smokers over 35 years old
- Women with diabetes mellitus, HTN, CAD

**Contraindications**
- Thrombophlebitis/embolism
- Known/suspected pregnancy
- Liver disease/cancer
- Breast cancer
- Concomitant anticonvulsant therapy

---

**INTRAUTERINE DEVICE**

Insertion of a T-shaped device (Paragard or Progestasert) into the endometrial cavity with a nylon filament extending through the cervix to facilitate removal

**Efficacy**
- 97%

**Types**
- **Paragard**—made with copper and lasts 10 years
- **Progestasert**—releases progesterone and lasts 1 year

**Mechanism of Action**
- Prevents fertilization by creating a hostile environment (a sterile inflammatory reaction) for sperm and for a fertilized ovum
- Prevents ovulation and causes endometrial atrophy (Progestasert only)

**Indications**
- Oral contraceptives contraindicated/intolerated
- Smokers over 35 years old

**Contraindications**
- Multiple sexual partners
- History of PID
- Immunocompromised (e.g., HIV, sickle cell disease)
- Known/suspected pregnancy

**Complications**
- PID
- Uterine perforation

---

The IUD filament provides an access for bacteria, so it is a high risk for infection.
- Ectopic pregnancy
- Menorrhagia and metrorrhagia
- IUD expulsion

**POSTCOITAL/EMERGENCY CONTRACEPTION**

Indicated after rape, barrier contraception failure, or any other unprotected intercourse

**Efficacy**
- > 95%

**Most Common Regimen**
- Two tablets of a combination estradiol (50 µg) and norgestrel (0.5 µg) at time of examination
- Two more tablets 12 hours later

Nausea occurs in about one half of cases following regimen.
With about 1 million procedures/yr in the United States, sterilization is the most popular form of birth control. There are 1 to 4 pregnancies per 1,000 sterilizations.

**Male type:** Vasectomy

**Female type:** Tubal ligation

---

**VASECTOMY**

Excision of a small section of both vas deferens, followed by sealing of the proximal and distal cut ends: Ejaculation still occurs.

Sperm can still be found proximal to the surgical site, so to ensure sterility one must:

- Have two consecutive negative sperm counts
- Use contraception for 6 weeks or 15 ejaculations

---

**TUBAL LIGATION**

Procedures can be performed either postpartum (immediately after delivery) or during an interval (between pregnancies).

**Laparoscopic Tubal Ligation**

Eighty to 90% of tubal ligations are done laparoscopically. All methods occlude the fallopian tubes bilaterally.

**ELECTROCAUTERY**

This involves the cauterization of a 3-cm zone of the isthmus. It is the most popular method (very effective but most difficult to reverse).
CLIPPING
The Hulka clip, similar to a staple, is applied at a 90° angle on the isthmus. It is the most easily reversed method but also has the highest failure rate.

BANDING
A length of isthmus is drawn up into the end of the trocar, and a silicone band, or Falope ring, is placed around the base of the drawn-up portion of fallopian tube.

Laparotomy Methods of Tubal Ligation
POMEROY METHOD
A segment of isthmus is lifted and a suture is tied around the approximated base. The resulting loop is excised, leaving a gap between the proximal and distal ends. This is the most popular laparoscopic method.

PARKLAND METHOD
Similar to the Pomeroy but without the lifting, a segment of isthmus is tied proximally and distally and then excised.

MADLENER METHOD
Similar to the Pomeroy but without the excision, a segment of isthmus is lifted and crushed and tied at the base.

IRVING METHOD
The isthmus is cut, with the proximal end buried in the myometrium and the distal end buried in the mesosalpinx.

KROENER METHOD
Resection of the distal ampulla and fimbrae following ligation around the proximal ampulla.

UCHIDA METHOD
Epinephrine is injected beneath the serosa of the isthmus. The mesosalpinx is pulled back off the tube, and the proximal end of the tube is ligated and excised. The distal end is not excised. The mesosalpinx is reattached to the excised proximal stump, while the long distal end is left to “dangle” outside of the mesosalpinx.

PARTIAL OR TOTAL SALPINGECTOMY
Removal of part or all of the fallopian tube

LUTEAL-PHASE PREGNANCY
A luteal-phase pregnancy is a pregnancy diagnosed after tubal sterilization but conceived before. Occurs around 2 to 3/1,000 sterilizations. It is prevented by either performing sensitive pregnancy tests prior to the procedure or performing the procedure during the follicular phase.
REVERSIBILITY OF TUBAL LIGATION

Around one third of tubal ligations can be reversed such that pregnancy can result. Some types of sterilization (i.e., banding, clipping) are more reversible.

Even pregnancies after reversal are ectopic until proven otherwise, and therefore reversal does not preclude a full ectopic workup.

COMPLICATIONS OF TUBAL LIGATION

- **Poststerility syndrome:** Pelvic pain/dysmenorrhea, menorrhagia, ovarian cyst
- **Fistula formation:** Uteroperitoneal fistulas can occur, especially if the procedure is performed on the fallopian tubes < 2 to 3 cm from the uterus.

OTHER METHODS OF STERILIZATION

**Colpotomy**
Utilizes entry through the vaginal wall near the posterior cul-de-sac and occludes the fallopian tubes by employing methods similar to those performed in laparoscopy and laparotomy

**Hysterectomy**
Removal of the uterus, either vaginally or abdominally; rarely performed for sterilization purposes

Failure rate is below 1%. Pregnancy after hysterectomy = ectopic pregnancy = emergency.
DEFINITION

- The inability to conceive after 12 months of unprotected sexual intercourse
- Affects 15% of couples

There are two types:
- **Primary infertility**: Infertility in the absence of previous pregnancy
- **Secondary infertility**: Infertility after previous pregnancy

FEMALE FACTORS AFFECTING INFERTILITY

- Tubal disease—20%
- Anovulation—15%
- Unexplained—10%
- Multifactorial—40%

INFERTILITY WORKUP

**Semen Analysis**

Performed after at least 48 hours of abstinence, with examination maximum 2 hours from time of ejaculation (for those who prefer to donate at home)

**CHARACTERISTICS OF SEMEN ANALYSIS**

- **Volume**—normal, > 2 mL
- **Semen count**—normal, ≥ 20 million/mL
- **Motility**—normal, > 50% with forward movement
- **Morphology**—normal, > 40% normal

**TREATMENT FOR ABNORMAL SPERM FINDINGS**

- Urology referral
- Quitting smoking, ETOH
- Avoidance of lubricants

HIGH-YIELD FACTS IN Infertility

- Female factors account for 40 to 50% of infertile couples.
- 40% of infertile couples have multiple causes.

Calcium channel blockers and furantoin can impair sperm function and quantity.
Intrauterine insemination (sperm injected through cervix)
Intracytoplasmic sperm injection
Artificial insemination

If semen analysis is normal, continue workup with analysis of ovulation.

Methods of Analyzing Ovulation

- History of monthly menses is a strong indicator of normal ovulation.
- Basal body temperature (BBT)—body temperature rises about 0.5 to 1°F during the luteal phase due to the increased level of progesterone. Presence of BBT increase is a good indicator that ovulation is occurring.
- Measurement of luteal-phase progesterone level (normal, 4 ng/mL)
- Sonogram—determines normal or abnormal endometrial anatomy
- Endometrial biopsy—determines histologically the presence/absence of ovulation

Possible Causes and Treatments of Anovulation

- Pituitary insufficiency: Treat with intramuscular luteinizing hormone/follicle-stimulating hormone (LH/FSH).
- Hypothalamic dysfunction: Treat with bromocriptine (a dopamine agonist)
- Polycystic ovary syndrome: Treat with clomiphene or human menopausal gonadotropin (hMG).
- Other causes: Hyper/hypothyroid, androgen excess, obesity/starvation, galactorrhea

If ovulation analysis and semen analysis are normal, analysis of the internal architecture is performed to determine if there is an anatomical impediment to pregnancy.

Internal Architecture Study

Hysterosalpingogram
- Performed during follicular phase
- Radio-opaque dye is injected into cervix and uterus and should fill both fallopian tubes and spill into peritoneal cavity
- Allows visualization of uterus and fallopian tubes
- There is risk of salpingitis.

Treatment for Structural Abnormalities

- Microsurgical tuboplasty
- Neosalpingostomy
- Tubal reimplantation for intramural obstruction

If findings of the semen analysis, ovulation analysis, and hysterosalpingogram are normal, an exploratory laparoscopy can be done.

Exploratory Laparoscopy

A laparoscope is inserted transabdominally to visualize the pelvis:
- Check for adhesions.
- Check for endometriosis.

If semen analysis is normal, continue workup with analysis of ovulation.

Methods of Analyzing Ovulation

- History of monthly menses is a strong indicator of normal ovulation.
- Basal body temperature (BBT)—body temperature rises about 0.5 to 1°F during the luteal phase due to the increased level of progesterone. Presence of BBT increase is a good indicator that ovulation is occurring.
- Measurement of luteal-phase progesterone level (normal, 4 ng/mL)
- Sonogram—determines normal or abnormal endometrial anatomy
- Endometrial biopsy—determines histologically the presence/absence of ovulation

Possible Causes and Treatments of Anovulation

- Pituitary insufficiency: Treat with intramuscular luteinizing hormone/follicle-stimulating hormone (LH/FSH).
- Hypothalamic dysfunction: Treat with bromocriptine (a dopamine agonist)
- Polycystic ovary syndrome: Treat with clomiphene or human menopausal gonadotropin (hMG).
- Other causes: Hyper/hypothyroid, androgen excess, obesity/starvation, galactorrhea

If ovulation analysis and semen analysis are normal, analysis of the internal architecture is performed to determine if there is an anatomical impediment to pregnancy.

Internal Architecture Study

Hysterosalpingogram
- Performed during follicular phase
- Radio-opaque dye is injected into cervix and uterus and should fill both fallopian tubes and spill into peritoneal cavity
- Allows visualization of uterus and fallopian tubes
- There is risk of salpingitis.

Treatment for Structural Abnormalities

- Microsurgical tuboplasty
- Neosalpingostomy
- Tubal reimplantation for intramural obstruction

If findings of the semen analysis, ovulation analysis, and hysterosalpingogram are normal, an exploratory laparoscopy can be done.

Exploratory Laparoscopy

A laparoscope is inserted transabdominally to visualize the pelvis:
- Check for adhesions.
- Check for endometriosis.
TREATMENT

- Laparoscopic lysis of adhesions
- Laparoscopic endometriosis ablation
- Medical treatment of endometriosis

ASSISTED REPRODUCTIVE TECHNOLOGIES

Definition

Directly retrieving eggs from ovary followed by manipulation and replacement: Generally employed for inadequate spermatogenesis. The following are examples.

In Vitro Fertilization (IVF) and Embryo Transfer

Fertilization of eggs in a lab followed by uterine placement: Intracytoplasmic sperm injection is a subtype of IVF to aid severe male factors. Success rate of IVF is about 20%.

Gamete Intrafallopian Transfer (GIFT)

Egg and sperm placement in an intact fallopian tube for fertilization: Success rate of GIFT is about 25%.

Zygote Intrafallopian Transfer (ZIFT)

Zygote (fertilized in vitro) is created and placed in fallopian tube, where it proceeds to uterus for natural implantation: Success rate of ZIFT is about 30%.
Menstruation

DEVELOPMENT

Puberty

Puberty is the transition from childhood to reproductive potential. More commonly, it refers to the final stage of maturation known as adolescence.

Puberty is believed to begin with disinhibition of the pulsatile gonadotropin-releasing hormone (GnRH) secretion from the hypothalamus (mechanism is unknown).

SECONDARY SEX CHARACTERISTICS

Development of the secondary sexual characteristics proceeds in the following order:

1. Breast budding (thelarche)
2. Axillary and pubic hair growth (pubarche)
3. First menses (menarche)

TANNER STAGES

The Tanner stages of development refer to the sequence of events of breast and pubic hair development.

Precocious Puberty

Appearance of the secondary sexual characteristics before 8 years of age is referred to as precocious puberty.

<table>
<thead>
<tr>
<th>Causes</th>
<th>Manifestation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Idiopathic (most common)</td>
<td>Thelarche/pubarche/menarche</td>
</tr>
<tr>
<td>Tumors (of the hypothalamic–pituitary stalk; prevent negative feedback)</td>
<td>Thelarche/pubarche/menarche</td>
</tr>
<tr>
<td>Inflammation of the hypothalamus (leads to ↑ GnRH)</td>
<td>Thelarche/pubarche/menarche</td>
</tr>
<tr>
<td>21-Hydroxylase deficiency (cortisol pathway is blocked, leading to excess androgens)</td>
<td>Pubarche</td>
</tr>
</tbody>
</table>

Average thelarche—10 years old due to ↑ estradiol
Average pubarche—11 years old due to ↑ adrenal hormones
Average menarche—12 years old due to ↑ estradiol

Tanner stages:
Stage 1: Prepubertal child
Stages 2–4: Developmental stages
Stage 5: Adult
Causes Manifestation

Excess estrogens from:
- Exogenous sources (e.g., oral contraceptives)
- Estrogen-secreting tumors

The Menstrual Cycle

The menstrual cycle is the cyclical changes that occur in the female reproductive system (see Figure 15-1): The hypothalamus, pituitary, ovaries, and uterus interact to cause ovulation approximately once per month (average 28 days [± 7 days]).

Menstruation—Days 1 Through 4 (First Part of the Follicular Phase)

- In the absence of fertilization, progesterone withdrawal results in endometrial sloughing (menses).
- Prostaglandins contained in those endometrial cells are released, often resulting in cramps from uterine contractions.

Many follicles are stimulated by FSH, but the follicle that secretes more estrogen than androgen will be released. This dominant follicle releases more and more estradiol so that its positive feedback causes an LH surge.

Average menses = 3 to 6 days

Blood loss in menstruation averages 30 to 50 mL, should not form clots. > 80 mL is an abnormal amount of blood loss.

FIGURE 15-1. The menstrual cycle.
Follicular Phase (Proliferative Phase)—Days 1 Through 14

The follicular phase begins on the first day of menses. Now that progesterone levels have fallen with the death of the corpus luteum, all hormone levels are low. Without any negative feedback, GnRH from the hypothalamus causes follicle-stimulating hormone (FSH) levels to rise.

FSH released from the pituitary stimulates maturation of granulosa cells in the ovary. The granulosa cells secrete estradiol in response.

Estradiol causes luteinizing hormone (LH) to be released from the pituitary while at the same time inhibiting FSH release. In the meantime, the estradiol secretion also causes the endometrium to proliferate.

LH acts on the theca cells to increase secretion of androgens (which are converted to estradiol), prepare the cells for progesterone secretion, and cause further granulosa maturation.

Ovulation—Day 14

The LH surge causes the oocyte to be released from the follicle. What remains is the corpus luteum, which secretes progesterone.

Luteal Phase—Days 14 Through 28

The effect of LH on the follicle was to change its secretion from estradiol to progesterone. This happens before ovulation.

The corpus luteum survives only about 11 days in the absence of hCG, during which time it continues progesterone secretion.

Progesterone causes the endometrium to mature in preparation for possible implantation. It becomes highly vascularized with increased gland secretion.

Progesterone also causes inhibition of FSH and LH release.

If fertilization does not occur, the corpus luteum dies, progesterone levels fall, and the cycle begins again.

AMENORRHEA

Primary amenorrhea: Absence of menses by age 16
Secondary amenorrhea: Absence of menses for ≥ 6 months in a woman who previously had normal menses

Etiologies

Etiologies of amenorrhea are categorized by where in the hormone cascade the lesion is.
HYPOTHALAMIC CAUSES OF AMENORRHEA

All hypothalamic causes result in ↓ FSH/LH levels:
- **Kallman’s syndrome**: Congenital lack of GnRH
- **Pituitary stalk compression**: Tumors, granulomas, irradiation
- **↓ GnRH release**: Stress, anorexia, hyperprolactinemia, severe weight loss, extreme exercise

PITUITARY CAUSES OF AMENORRHEA

All pituitary causes result in ↓ FSH/LH levels:
- **Sheehan’s syndrome**: Pituitary infarction resulting from hypotension during delivery, usually resulting from hemorrhage
- **Tumors**: Either compress stalk (as above) or are prolactin-secreting tumors
- **Hemosiderosis**: Iron deposition in pituitary that impairs its function

OVARIAN CAUSES OF AMENORRHEA

All ovarian causes result in ↑ FSH/LH levels:
- **Premature ovarian failure**: Menopause before age 35
- **Savage’s syndrome**: Ovarian resistance to FSH/LH
- **Enzyme defects**: Most commonly 17α-hydroxylase deficiency
- **Turner’s syndrome (XO karyotype)**: Ovarian dysgenesis
- **Polycystic ovary disease (PCOD)**: ↑ Estrogen levels cause ↑ LH levels, which cause abnormal follicular growth and androgen secretion

UTERINE CAUSES OF AMENORRHEA

- Imperforate hymen
- Uterine causes have normal levels of FSH/LH
- Congenital absence of uterus
- **Asherman’s syndrome**: Uterine scarring and adhesions following dilation and curettage (D&C)

Evaluation of Amenorrhea

I. Is it primary or secondary?
First step to evaluating amenorrhea is to determine if it is primary or secondary (see Figure 15-2).

<table>
<thead>
<tr>
<th>Workup</th>
<th>Positive Findings Indicate</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Examine hymen</td>
<td>Imperforate hymen</td>
</tr>
<tr>
<td>2. Determine presence of uterus</td>
<td>No uterus: Do karyotyping and consider testicular feminization, müllerian agenesis, 46,XY steroid enzyme defects</td>
</tr>
<tr>
<td>3. Determine if there is breast development</td>
<td>Yes: Work up as secondary amenorrhea. No: Work up as progestin-negative secondary amenorrhea (below).</td>
</tr>
</tbody>
</table>

II. Secondary amenorrhea workup
Once you have determined that the amenorrhea is not primary, do a secondary amenorrhea workup (see Figure 15-3). The secondary amenorrhea workup is divided into two groups: Without galactorrhea and with galactorrhea:
1. Without galactorrhea, administer **Progestin Challenge**: Give progestin and if menses results, ovaries are secreting estrogen.
   - If the progestin challenge results in menses, then the diagnosis is one of the following
     - PCOD
     - Ovarian or adrenal tumor
     - Hypothalamic dysfunction
   - If progestin challenge is negative:
     a) **Hysteroscopy** to determine if Asherman’s syndrome is the cause
     b) **Check FSH level**:
        - If ↑, suspect **ovarian** causes.
        - If ↓, suspect **hypothalamic–pituitary** failure.

2. Amenorrhea + galactorrhea:
   - Check TSH levels. If low, hypothyroidism is the cause.
   - If TSH is normal, check prolactin levels. Prolactin levels are high, perform a CT/MRI of the brain to confirm a prolactinoma.

See Figure 15-4.
(Redrawn, with permission, from DeCherney AH, Pernoll ML. Current Obstetric & Gynecologic Diagnosis & Treatment. Norwalk, CT: Appleton & Lange, 1994: 1012.)

(Redrawn, with permission, from DeCherney AH, Pernoll ML. Current Obstetric & Gynecologic Diagnosis & Treatment. Norwalk, CT: Appleton & Lange, 1994: 1011.)
Treatment of Amenorrhea

Hypothalamic Causes
- Tumor removal
- Weight gain
- Stress relief
- Exogenous pulsatile GnRH

Pituitary Causes
- Tumor removal
- Bromocriptine (dopamine agonist inhibits prolactin release)
- Exogenous FSH/LH

Ovarian Causes
- Ovarian failure—in vitro fertilization, oral contraceptives
- PCOD—clomiphene (an antiestrogen)

Uterine Causes
- Obstruction—surgery

HYPERPROLACTINEMIA

Elevated prolactin levels could be due to:
- Hypothyroidism—check TSH level (hypothyroidism causes a rise in prolactin).
- Central nervous system (CNS) tumors—perform head CT/MRI.
- Drugs:
  - Dopamine antagonists
  - Methylldopa
  - Serotonin agonists
  - Spinal cord lesions—perform spinal CT/MRI.

PREMENSTRUAL SYNDROME (PMS)

PMS refers to a group of symptoms experienced during the luteal phase of the menstrual cycle. Symptoms are cyclic in nature with resolutions and exacerbations.

Symptoms may manifest as:
- Somatic complaints: Headaches, bloating, breast tenderness
- Emotional changes: Anxiety, depression, irritability
- Behavior symptoms: Problems concentrating, food cravings, sleep changes

Management of PMS
- Diet—luteal-phase reductions in alcohol, caffeine, fats, tobacco, refined sugars: Decreases irritability by decreasing fluctuation in blood sugar levels
- Sodium restriction—decreases edema
- Oral contraceptive pills—cause anovulation, and this improves symptoms
Nonsteroidal anti-inflammatory drugs (NSAIDs) — decrease inflammation found in PMS
- Selective serotonin reuptake inhibitors (SSRIs)
- GnRH agonists

SOME MOST COMMONS
- Most common method of family planning: Tubal sterilization
- Most common reason for neonatal sepsis: Chorioamnionitis (GBS, E. coli)
- Most common reason for hospitalization in women of reproductive age: Endometriosis
- Most common postoperative complication: Pulmonary atelectasis
- Most common cause of primary amenorrhea: Gonadal dysgenesis
- Most common cause of fetal morbidity and mortality: Preterm labor

ANDROGEN EXCESS, HIRSUTISM, AND VIRILISM

Androgens

Androgens are steroid hormones produced in the gonads (ovaries in women, the testes in males) and in the adrenal glands.

EFFECTS OF ANDROGEN EXCESS: HIRSUTISM AND VIRILIZATION

Androgens promote hair growth at puberty, although to different extents in each sex. Females, with low levels of androgens, develop visible pubic and axillary hair. Males, with greater concentrations of androgen, get additional hair growth on the face and chest, as well as masculinization (i.e., increased muscle mass, broadening of shoulders, and deepening of the voice).

Excess androgen in women will also result in these changes as well. In this context, these effects are termed hirsutism and virilism.

Hirsutism — the development of increased terminal hairs on the chest, abdomen, and face in a woman.

Virilization — the development of masculine characteristics in a woman, such as deepening of the voice, clitoromegaly, loss of female body contour, decreased breast tissue, and male pattern balding.

Hair Types

Vellus hairs are fine hairs found on most parts of the body. They are barely visible. Terminal hairs are the coarse, darker hairs found, for example, in the axilla and pubic region. Androgens facilitate the conversion of vellus to terminal hairs.

Production of Androgens

In women, androgens are produced in two locations: The adrenals and the ovaries (in males, they are produced in the adrenals and testes).
**Adrenal Production of Androgens**

The *zona fasciculata* and the *zona reticularis* of the adrenal cortex produce androgens, as well as cortisol. ACTH regulates production.

A third layer of the adrenal cortex, the *zona glomerulosa*, produces aldosterone and is regulated by the renin–angiotensin system.

All three hormones—cortisol, androgens, and aldosterone—are derived from cholesterol. Androgen products from the andrenal are found mostly in the form of dehydroepiandrosterone (DHEA) and dehydroepiandrosterone-sulfate (DHEAS). Elevation in these products represents increased adrenal androgen production.

**Ovarian Production of Androgens**

In the ovaries, first, LH stimulates the theca cells to produce androgens (androstenedione and testosterone). Then, FSH stimulates granulosa cells to convert these androgens to estrone and estradiol. When LH levels become disproportionately greater than FSH levels, androgens become elevated.

**Pathologies**

Excess androgen can be either ovarian etiology or adrenal, neoplastic, or benign.

**Adrenal Etiologies**

*Cushing’s Syndrome and Cushing’s Disease*

*Cushing’s syndrome* is a general term meaning hypercortisolism along with the clinical picture that goes with it—moon face, buffalo hump, weakness, etc. Exogenous or endogenous cortisol can be the cause.

*Cushing’s disease* is a subset of Cushing’s syndrome, in which the increased cortisol level is due to ACTH hypersecretion by the pituitary, usually secondary to a benign pituitary adenoma. It accounts for 70% of Cushing’s syndromes. Virilism and hirsutism are associated with this condition because the ACTH stimulates androgen production as well.

*Paraneoplastic syndromes* in which tumors (usually small cell lung cancer) produce ectopic ACTH are another cause of increased cortisol. These account for 15% of Cushing’s syndromes.

*Adrenal tumors* (adenoma or carcinoma) account for the remaining 15% of Cushing’s syndromes. In general, adenomas produce only cortisol, so no hirsutism or virilization is present. Carcinomas, by contrast, often produce androgens as well as cortisol, so they may present with signs of hirsutism and virilization.

*Congenital Adrenal Hyperplasias*

Congenital adrenal hyperplasia is a general term for disease entities involving defects in steroid, androgen, and mineral corticoid synthesis. Two such common entities that result in virilism and hirsutism due to increased androgens are 21-hydroxylase deficiency and 11β-hydroxylase deficiency.
21-Hydroxylase deficiency — this is the most common congenital adrenal hyperplasia. The condition has various levels of severity. Affected individuals lack an enzyme crucial to cortisol and mineral corticoid production. Therefore, hormone synthesis is shunted to excessive production of androgens. Elevated serum 17-hydroxyprogesterone levels are found as well. In the severe form, affected females have ambiguous genitalia at birth, along with severe salt wasting and cortisol insufficiency. A milder form presents simply with virilization and hirsutism of females after puberty.

11β-Hydroxylase deficiency — this condition is associated with decreased cortisol, but increased mineral corticoids and androgens. The resultant picture is a severe hypertension with virilization/hirsutism (which results in pseudohermaphroditism of female babies). 11-Deoxycortisol levels are high.

Ovarian Etiologies

Polycystic Ovarian Syndrome (PCOS)

PCOS is a common condition (affecting 5% of reproductive age women) and is characterized by hirsutism, virilization, amenorrhea, obesity, and diabetes (sometimes). Ovaries are found to have multiple inactive cysts with hyperplastic ovarian stroma. The LH:FSH ratio is often greater than 3:1. The cause is unknown, and the treatment is oral contraceptives.

Hyperthecosis

Hyperthecosis is when an area of luteinization occurs in the ovary, along with stromal hyperplasia. The luteinized cells produce androgens and virilization may result.

Theca Lutein Cysts

As described above, theca cells produce androgens and granulose cells transform the androgens to estrogens. Theca lutein cysts produce abnormally high levels of androgens, in excess of the amount that can be converted to estrogens. Diagnosis is made by ovarian biopsy.

Luteoma of Pregnancy

Luteoma of pregnancy is a benign tumor that grows in response to human chorionic gonadotropin. Virilization may occur in both the mother and the female fetus, although it may occur in the fetus alone. The tumor usually disappears postpartum, as do the clinical features.

Androgen-Secreting Ovarian Neoplasms

Sertoli–Leydig cell tumors and hilar (Leydig) cell tumors are rare conditions in which the neoplasms secrete androgens. They can often be distinguished from each other in that Sertoli–Leydig tumors usually present in young women with palpable masses and hilar cell tumors are found in postmenopausal women with nonpalpable masses.

Granulosa–theca cell tumors and gonadoblastomas are other examples of androgen-secreting ovarian tumors.
DEFINITIONS

Menstrual abnormalities include:
- **Polymenorrhea**—menses with regular intervals that are too short (under 21 days)
- **Menorrhagia**—menses that are too long in duration (over 7 days) and/or menses associated with excessive blood loss (> 80 mL) occurring at normal intervals
- **Hypermenorrhagia**—menses that are too long in duration (over 7 days) and/or menses associated with excessive blood loss (> 80 mL) occurring at regular but not necessarily normal intervals
- **Oligomenorrhea**—menses with intervals that are too long (cycle lasts more than 35 days)
- **Menorrhagia**—bleeding occurring at irregular intervals; intermenstrual bleeding
- **Menometrorrhagia**—combination of both menorrhagia and metrorrhagia; menses too long in duration or excessive blood loss + irregular bleeding intervals
- **Kleine regnung**—bleeding for 1 to 2 days during ovulation (scant)

For an overview of bleeding, see Figure 16-1.

DIFFERENTIAL DIAGNOSES FOR MENORRHAGIA

Leiomyoma
Adenomyosis
Cervical cancer
Coagulopathy
Endometrial
Hyperplasia
Polyps
Cancer

Use mnemonic LACCE for differential diagnoses of menorrhagia:
Leiomyoma
Adenomyosis
Cervical cancer
Coagulopathy
Endometrial
Hyperplasia
Polyps
Cancer
**DIFFERENTIAL DIAGNOSES FOR PREMENOPAUSAL METRORRHAGIA**

- Polyps
- Increased estrogens
- Neoplasia
- Contraceptive complications

**HIGH-YIELD FACTS**

**Abnormal Uterine Bleeding**

**FIGURE 16-1.** A quick approach to bleeding.

- **PREMENOPAUSAL**
  - **β-hCG level**
    - (+) **Do ultrasound**
      - (Intrauterine pregnancy shows at > 7 weeks; alternatively, you might see ectopic or nothing.)
    - (-) **With pain**
      - Ruptured ectopic pregnancy
        - Surgery
      - +/- Pain
        - Consider
          - Threatened/inevitable/incomplete abortion or ectopic pregnancy
            - Look for POC in vagina/cervical canal
            - Serial β-hCGs
            - Normal pregnancy β-hCG levels increase 66%/48 hours, whereas ectopics are lower.
            - POC in vagina/cervical canal = abortion
          - Very high β-hCG + no fetal heartbeat = gestational trophoblastic neoplasia
          - Check PT/PTT for coagulopathy.
          - Physical exam or CT/ultrasound might show pelvic mass or neoplasia.
          - Consider laparoscopy to diagnose endometriosis.
          - Check estrogen levels to show PCOD.

- **POSTMENOPAUSAL**
  - Endometrial biopsy
    - Consider cervical or endometrial cancer.
DYSFUNCTIONAL UTERINE BLEEDING

Dysfunctional uterine bleeding (DUB) is abnormal uterine bleeding unrelated to anatomic lesions; usually caused by hormonal dysfunction.

DUB is a diagnosis made by exclusion after workup for other causes of abnormal uterine bleeding (caused by anatomical lesions) is negative.

CLASSIFICATION OF DUB

DUB is classified as either anovulatory or ovulatory, though it is most often caused by anovulation:

Anovulatory DUB: Anovulation results in constant endometrial proliferation without progesterone-mediated maturation and shedding. The “overgrown” endometrium continually and irregularly sheds. Causes of anovulatory DUB include:

- Polycystic ovaries (polycystic ovarian disease [PCOD])
- Obesity
- Unopposed exogenous estrogen

Ovulatory DUB: Inadequate progesterone secretion by corpus luteum causes a luteal-phase defect and results in DUB; it often presents with polymenorrhea or metrorrhagia.

EVALUATION OF DUB

History

- Thorough menstrual and reproductive history
- Signs of systemic disease (thyroid, liver, kidney)
- Social (extreme exercise, weight changes)
- Presence or absence of ovulation (regularity, premenstrual body changes)

TREATMENT OF DUB

- High-dose oral contraceptive pills
  or
- Medroxyprogesterone acetate ≥ 10 days

Because DUB is usually caused by anovulation (PCOD, exogenous estrogens, obesity), oral contraceptives prevent DUB by mimicking the normal menstrual cycle changes to allow for endometrial maturation and sloughing. If DUB is ovulatory, nonsteroidal anti-inflammatory drugs are useful.

Only if medical treatment fails should endometrial ablation or hysterectomy be performed.

TREATMENT OF ACUTE BLEEDING EPISODES

- High-dose oral or IV estrogen
- High-dose oral contraceptives
- D&C

HIGH-YIELD FACTS

Abnormal Uterine Bleeding

Tumors (benign and malignant) often present with menorrhagia or metrorrhagia.

Postcoital bleeds suggest trauma, infections, or cervical cancer.
POSTMENOPAUSAL BLEEDING

Postmenopausal bleeding is vaginal bleeding more than 1 year after menopause.

Differential Diagnoses for Postmenopausal Bleeding

- Endometrial Hyperplasia
- Cancer
- Cervical cancer
- Vulvar cancer
- Estrogen-secreting tumor
- Vaginal atrophy (most common)

Studies to Get

- Endometrial biopsy and endocervical curettage (because of the prevalence and danger of endometrial lesions)
- Pap smear for cervical dysplasia, neoplasia
- Ultrasound
- Hysteroscopy
- +/- Computed tomography (CT)

OTHER BLEEDING TIPS

- Postcoital bleeding in pregnant woman: Consider placenta previa.
- Postcoital bleeding in nonpregnant woman: Consider cervical cancer.
- Postmenopausal bleeding: Consider endometrial cancer.
- Premenopausal bleeding: Consider PCOD.
CHRONIC PELVIC PAIN

Definition and Criteria

- ≥ 6 months of pain
- Incomplete relief by medical measures
- Altered activities due to pain (e.g., missed work, homebound, depression, sexual dysfunction)

Etiologies

- Leiomyoma
- Endometriosis
- Adhesions, adenomyosis
- Pelvic inflammatory disease (PID)
- Infections other than PID
- Neoplasia

Workup

1. Detailed history (focusing on above etiologies):
   - Temporal pattern
   - Radiation
   - Associated symptoms
   - Past surgeries
   - Last menstrual period (LMP)
2. Physical exam:
   Look for:
   - Masses
   - Cervical motion tenderness
   - Gastrointestinal (GI) complaints
   - Neurological testing
3. Relation of pain to basal body temperature elevation (to rule out mittelschmerz pain associated with ovulation)
4. Blood work:
   - Complete blood count (CBC)
   - Pregnancy test
STCS (serotest for syphilis)
Urineysis (UA)
Occult blood
Blood culture

5. Radiographic studies:
- Abdominal and vaginal sonogram
- Computed tomography (CT)
- Magnetic resonance imaging (MRI)
- Barium enema
- Bone scan
- Renal sonogram/intravenous pyelogram (IVP)

6. Colonoscopy and/or cystoscopy (should be performed if all above are inconclusive)

7. Rule out psychosomatic pain.

8. Diagnostic laparoscopy

**ACUTE PELVIC PAIN**

**Differential of Acute Pelvic Pain**

- Appendicitis
- Ruptured ovarian cyst (most common)
- Ovarian torsion/abscess
- PID
- Ectopic pregnancy

(spells “A ROPE”)

See Table 17-1.

**Etiologies**

Same etiologies as above plus the following:

- GYN—all require surgery:
  - Ruptured ovarian cyst (life threatening)
  - Adnexal torsion
  - Tubo-ovarian abscess (life threatening)
- OB:
  - Ectopic pregnancy (life threatening)—requires surgery
  - Abortion (spontaneous, threatened, incomplete)
- GI/GU:
  - Diverticulitis
  - Appendicitis (life threatening)—requires surgery
  - Urinary tract infection (UTI)
  - Inflammatory bowel disease (IBD), irritable bowel syndrome (IBS)

**Workup**

1. History
2. Physical exam (cervical motion tenderness, adnexal tenderness, and abdominal tenderness are all signs of PID)
3. Labs:
   - Pregnancy test (positive might indicate ectopic pregnancy or abortion)
- CBC (PID or appendicitis might give elevated WBCs)
- UA (leukocytes indicate possible UTI)

4. Pelvic sonogram (will show cysts and possibly torsion)
5. Diagnostic laparoscopy

---

**TABLE 17-1. Differential Diagnosis of Acute GYN Pelvic Pain**

<table>
<thead>
<tr>
<th>Disease</th>
<th>CBC</th>
<th>UA</th>
<th>Pregnancy Test</th>
<th>Culdocentesis</th>
<th>Fever</th>
<th>Nausea and Vomiting</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ruptured ectopic pregnancy</td>
<td>Hematocrit low after</td>
<td>Red blood cells rare</td>
<td>Positive Beta-hCG low for gestational age</td>
<td>High hematocrit, Defibrinated, nonclotting sample with no platelets</td>
<td>No</td>
<td>Unusual</td>
</tr>
<tr>
<td></td>
<td>treatment of hypovolemia</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Salpingitis/PID</td>
<td>Rising white blood cell</td>
<td>White blood cells</td>
<td>Generally negative</td>
<td>Yellow, turbid fluid with many white blood cells and some bacteria</td>
<td>Progressively worsening; spiking</td>
<td>Gradual onset with ileus</td>
</tr>
<tr>
<td></td>
<td>count</td>
<td>occasionally present</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hemorrhagic ovarian cyst</td>
<td>Hematocrit may be low</td>
<td>Normal</td>
<td>Usually negative</td>
<td>Hematocrit generally &lt; 10%</td>
<td>No</td>
<td>Rare</td>
</tr>
<tr>
<td></td>
<td>after treatment of</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>hypovolemia</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Torsion of adnexa</td>
<td>Normal</td>
<td>Normal</td>
<td>Generally negative</td>
<td>Minimal clear fluid if obtained early</td>
<td>No</td>
<td>Rare</td>
</tr>
<tr>
<td>Degenerating leiomyoma</td>
<td>Normal or elevated</td>
<td>Normal</td>
<td>Generally negative</td>
<td>Normal clear fluid</td>
<td>Possibly</td>
<td>Rare</td>
</tr>
<tr>
<td></td>
<td>white blood cell count</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Endometriosis

**DEFINITION**

Endometriosis is the condition in which endometrial tissue is found outside of the uterus, often causing pain and/or infertility.

**PREVALENCE**

Five to 10% of women in reproductive age

**PATHOPHYSIOLOGY**

The ectopic endometrial tissue is *functional*. It responds to hormones and goes through *cyclic changes*, such as menstrual bleeding.

The result of this ectopic tissue is “ectopic menses,” which causes peritoneal inflammation, pain, fibrosis, and, eventually, adhesions.

**SITES OF ENDOMETRIOSIS**

**Common**
- Ovary (bilaterally)
- Cul-de-sac
- Fallopian tubes
- Uterosacral ligaments
- Bowel

**Less Common**
- Cervix
- Vagina
- Bladder

**Rare**
- Nasopharynx
- Lungs

Exam scenario: 37-year-old female complains of hemoptysis with each period. Diagnosis: Endometriosis of nasopharynx or lung.
ADHESIONS

Adhesions from prolonged endometriosis can cause:
- Infertility from fallopian tube or outer uterine adhesions
- Small bowel obstruction from intestinal adhesions

THEORIES OF ETIOLOGY

Though the etiology is unknown, there are three theories:

1. Retrograde menstruation: Endometrial tissue fragments are transported through the fallopian tubes and implant there or intra-abdominally.
2. Mesothelial (peritoneal) metaplasia: Peritoneal tissue becomes endometrial-like and responds to hormones.
3. Vascular/lymphatic transport: Endometrial tissue is transported via blood vessels and lymphatics.

CLINICAL PRESENTATION

Most commonly in women in their late 20s and early 30s:
- Pelvic pain:
  - Dysmenorrhea
  - Dyspareunia—implants on pouch of Douglas
  - Dyschezia (pain with defecation)—implants on rectosigmoid
- Infertility
- Vaginal staining (from vaginal implants)

SIGNS

- Retroflexed, tender uterus
- Nodular uterosacral ligaments
- Ovarian mass (endometrioma)
- Blue/brown vaginal implants (rare):
  - “Chocolate cyst”—an implant that occurs within the ovarian capsule and bleeds, creating a small blood-filled cavity in the ovary

DIAGNOSIS

1. Laparoscopy or laparotomy: Ectopic tissue must be seen for diagnosis:
   - Blue implants—new
   - Brown implants—older
   - White implants—oldest
2. Biopsy: Positive findings contain glands, stroma, hemosiderin.
**Clinical Course**

- 30% asymptomatic
- If left untreated, most lead to increasing pain and possible bowel complications.
- Often, there is improvement with pregnancy secondary to temporary cessation of menses.

**Treatment**

**Medical**

All of these treatments suppress estrogen:
- Gonadotropin-releasing hormone (GnRH) agonists—suppress follicle-stimulating hormone (FSH); creates a pseudomenopause
- Progesterone (with or without estrogen)—creates a pseudopregnancy
- Danazol—an androgen derivative that suppresses FSH/LH, thus also causing pseudomenopause

**Surgical**

- Conservative (if reproductivity is to be preserved): Laparoscopic lysis of adhesions and implants
  or
- Definitive: Total abdominal hysterectomy and bilateral salpingo-oophorectomy (TAH/BSO)

**Adenomyosis**

**Definition**

Adenomyosis is endometrial tissue found within the myometrium. Adenomyosis and endometriosis rarely coexist.

**Signs and Symptoms**

- **Common**
  - Uterine enlargement
  - Dysmenorrhea
  - Menorrhagia

**Treatment**

- GnRH agonist
- Mifepristone (RU 486)—a progesterone antagonist
- TAH/BSO if severe
**ADENOMYOSIS VS. ENDOMETRIOSIS**

**Adenomyosis**
- Found in older women
- Doesn’t respond to hormonal stimulation
- Noncyclical

**Endometriosis**
- Found in young women
- Tissue is responsive to estrogen.
- Cyclical
Pelvic Masses

**DIFFERENTIAL DIAGNOSES**

- Leiomyoma
- Pregnancy
- Endometriosis/adenomyosis
- Ovarian neoplasm
- Tubo-ovarian abscess (TOA)
- Ovarian cyst
- Adhesions (to uterus)
- Also, congenital anomalies, other carcinomas/sarcomas

**HISTORIES SUGGESTIVE OF DIAGNOSES**

In different contexts, pelvic masses are more likely to carry different diagnoses. The following are contexts and the likely diagnosis:

<table>
<thead>
<tr>
<th>Context in Which Pelvic Mass Is Found</th>
<th>Likely Diagnosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Painless abnormal uterine bleeding</td>
<td>Leiomyoma</td>
</tr>
<tr>
<td>Amenorrhea</td>
<td>Pregnancy, ovarian cysts</td>
</tr>
<tr>
<td>Dysmenorrhea</td>
<td>Endometriosis</td>
</tr>
<tr>
<td>Reproductive age</td>
<td>Pregnancy, ovarian cysts, leiomyoma, TOA, ovarian neoplasm</td>
</tr>
<tr>
<td>Postmenopausal</td>
<td>Neoplasm</td>
</tr>
<tr>
<td>History of pelvic inflammatory disease (PID)</td>
<td>Signs/symptoms of systemic illness—TOA, adhesions</td>
</tr>
<tr>
<td>History of surgery/endometriosis</td>
<td>Adhesions</td>
</tr>
</tbody>
</table>
DIAGNOSTIC TESTS FOR VARIOUS CAUSES OF PELVIC MASSES

- **Pregnancy**: Pregnancy test
- **Ovarian cysts**: Physical exam (+ ultrasound (US) if needed for confirmation)
- **Leiomyoma**: Physical exam (+ US, hysteroscopy if needed for confirmation)
- **Ovarian neoplasm**: US, computed tomography (CT) scan, CA-125 level, surgical exploration, high level of suspicion due to age, family history
- **Endometrial neoplasm**: ECC, D&C
- **Endometriosis/adenomyosis**: Laparotomy/scopy
- **Tubo-ovation abscess**: History of PID, tender mass, KUB x-ray (showing ileus)

BENIGN OVARIAN MASSES

FUNCTIONAL OVARIAN CYSTS

**Follicular Cysts**

Follicular cysts are the most common functional ovarian cysts.

**Physiology**

Failure of rupture or incomplete resorption of the ovarian follicle results in a cyst. Just like the original follicle, the ovarian cyst is granulosa cell lined and contains a clear to yellow estrogen-rich fluid.

**Signs and Symptoms**

- Asymptomatic
- Oligomenorrhea
- Polymenorrhea
- Unilateral abdominal pain
- Acute pelvic pain (usually signifies rupture)

**Diagnosis**

- Physical exam—pelvic and abdominal exam
- Sonography if necessary to confirm diagnosis

**Treatment**

- No treatment may be necessary, since most cysts resolve spontaneously within 2 months.
- Oral contraceptives may aid in the symptomatic patient.
- If the cyst is unresolved after 2 months, laparotomy/scopy is indicated to evaluate/rule out neoplasia.

**Lutein Cysts**

There are two types of lutein cysts: *Corpus luteum cysts* and *theca lutein cysts*. 

---

**HIGH-YIELD FACTS**

- Pregnancy tests should be given to all women of reproductive age.
- ECC is endocervical curettage—scraping of the endocervical canal with subsequent cytological examination.
- KUB x-ray is x-ray of the kidneys, ureters, and bladder (portions of the intestines are also visualized).
- Follicular cysts are usually asymptomatic.
**Corpus Luteum Cyst**

The corpus luteum cyst is an enlarged and longer living, but otherwise normal, corpus luteum. It can produce progesterone for weeks longer than normal.

- **Signs/symptoms**: Unilateral tenderness + amenorrhea
- **Diagnosis**: History and physical/pelvic exam (once ectopic pregnancy has been ruled out), sonogram
- **Treatment** (only if symptomatic): Analgesics, oral contraceptives, laparotomy/scopy if ruptured

**Corpus hemorrhagicum** is formed when there is hemorrhage into a corpus luteum cyst. If this ruptures, the patient will present with acute pain +/- bleeding symptoms (i.e., syncope, orthostatic changes).

**Theca Lutein Cyst**

*Increased levels of human chorionic gonadotropin (hCG) can cause follicular over-stimulation* and lead to theca lutein cysts, which are often multiple and bilateral.

Conditions that cause elevated hCG levels:
- Gestational trophoblastic disease (molar pregnancy)
- Polycystic ovarian disease
- Ovulation-inducing agents (clomiphene or hCG)
- Multiple gestation:
  - **Signs/symptoms**: Signs and symptoms are usually due to the accompanying condition that causes the elevated hCG.
  - **Diagnostic finding**: Elevated hCG levels
  - **Treatment**: One must treat the underlying condition; theca lutein cyst will resolve once hCG levels come down.

**Leiomyomas (Fibroids)**

Leiomyomas are localized, benign, *smooth muscle tumors* of the uterus. They are *hormonally responsive* and therefore become bigger and smaller corresponding to the menstrual cycle.

**Epidemiology**

Leiomyomas are found in 25 to 33% of reproductive-age women and in up to 50% of black women.

They are almost always multiple.

They are the most common indication for hysterectomy.

**Sequelea**

Changes in uterine fibroids over time (i.e., postmenopausal) include:
- Hyaline degeneration
- Calcification
- Red degeneration (painful interstitial hemorrhage, often with pregnancy)
- Cystic degeneration—may rupture into adjacent cavities

**Uterine Locations of Leiomyomas**

- **Submucous**—just below endometrium; tend to bleed
- **Intramural**—within the uterine wall
- **Subserous**—just below the serosa/peritoneum
SYMPTOMS
- Asymptomatic in > 50% of cases
- Bleeding +/- anemia—one third of cases present with bleeding. Bleeding is usually menorrhagia, caused by:
  - Abnormal blood supply
  - Pressure ulceration
  - Abnormal endometrial covering
  - Pain—secondary dysmenorrhea
  - Pelvic pressure
  - Infertility

DIAGNOSIS
- Physical exam (bimanual pelvic and abdominal exams): Fibroids are smooth, firm, and usually midline.
- Sonography (may also be visualized by x-ray, magnetic resonance imaging (MRI), CT, hysterosalpingogram (HSG), hysteroscopy, or intravenous urogram)
- Pap, ECC, and D&C can be done to rule out malignancy.

TREATMENT
No treatment is indicated for most women, as this hormonally sensitive tumor will likely shrink with menopause.

Pregnancy is usually uncomplicated. Bed rest and narcotics are indicated for pain with red degeneration. Tocolytics can be given to control/prevent premature contractions.

Treatment is usually initiated when:
- Tumor is > 12 to 14 weeks’ gestation size.
- Hematocrit falls.
- Tumor is compressed (ureter, vessel).

Gonadotropin-releasing hormone (GnRH) agonists can be given for up to 6 months to shrink tumors (i.e., before surgery) and control bleeding:
- Myomectomy—surgical removal of the fibroid in infertile patients with no other reason for infertility
- Hysterectomy—indicated for women without future reproductive plans and with unremitting disability

HIGH-YIELD FACTS
Pelvic Masses
- Submucosal and intramural types of fibroids usually present as menorrhagia. Subserous type often presents with torsion.
- Pregnancy with fibroids does carry increased risk for preterm labor and fetal malpresentation.
- About one third of fibroids recur following myomectomy.
OVERRIDE

Cervical dysplasia and cervical cancer lie on a continuum of conditions. Cervical dysplasia can take one of three paths:

1. Progress to cancer
2. Remain the same and not progress
3. Regress to normal

RISK FACTORS FOR CERVICAL DYSPLASIA AND CERVICAL CANCER

- Human papillomavirus (HPV) infection
  - 80% of cases
  - Risk highest if infected > 6 months
  - Types 16, 18, 31, 33, high oncogenic potential
- High sexual activity (increase risk of viral/bacterial infections)
  - Multiple sexual partners
  - Intercourse at early age (±17 years)
- Low socioeconomic status
- Genetic predisposition
- Cigarette smoking (smokers are deficient in folic acid and deficiency plays role in dysplasia)
- Alcohol, 2 to 4 drinks/wk, can increase risk of HPV infection.
- Oral contraceptives, particularly with use > 5 years (condoms decrease risk in these women)
- Young women whose mothers took DES during pregnancy

LOCATION OF CERVICAL DYSPLASIA: TRANSFORMATION ZONE

The transformation zone is the area between the old and the new squamo-columnar junctions.

The squamo-columnar junction exists between the squamous epithelium of the vagina and ectocervix and the columnar epithelium of the endocervix. With age, metaplasia occurs, transforming columnar cells to squamous cells and thereby advancing the squamo-columnar junction proximally toward the
endocervix. The area between the original junction and the new junction is the transformation zone.

**PAP SMEAR**

A cytologic screening test for cervical neoplasia

**Technique**

- A speculum is placed in the vagina to expose the uterine cervix (no digital exams or lubricants in the vagina prior to the Pap).
- Cells are scraped from the ectocervix with a spatula, then from the endocervix using an endocervical brush.
- The cells are smeared on a glass slide, fixative spray is applied, and the cells are examined.

**Success Rate of Pap**

- Decreases incidence and mortality rate of invasive cervical cancer by 90%
- 80% sensitivity
- 99% specificity

**Indications for Pap Smear**

According to the American College of Obstetricians and Gynecologists (ACOG) (1989) recommendations:

- Every woman should have a Pap smear (and pelvic exam) annually after age 18 or after onset of sexual activity.
- If three consecutive Pap smears and pelvic exams 1 year apart are normal, the screening interval can be lengthened.
- Lengthening is not recommended if the patient or her sexual partner has more than one other sexual partner.

**Microscopic Analysis of Pap Smear**

Cytologic analysis of cells taken from a Pap smear will indicate cervical dysplasia if there is:

- Clumping of chromatin
- Decreased cytoplasm resulting in a higher nucleus/cytoplasm ratio

**Classification of Pap Smear Abnormalities**

Remember, Pap smear gives information about cervical cytology. Two different systems exist that describe the possible findings of a Pap smear:
1. Modern Classification System A.K.A. CIN (cervical intraepithelial neoplasia): Describes the degree of abnormality of the cells.

2. Bethesda system (SIL, squamous intraepithelial lesion): Describes three things: (1) the adequacy of the Pap test performed, (2) the degree of abnormality, and (3) a description of the cells.

**Modern Classification vs. Bethesda System**

The following chart correlates the Bethesda staging with the CIN staging. All the terms are possible results of a Pap smear.

<table>
<thead>
<tr>
<th>Modern Classification System (CIN)</th>
<th>Bethesda Staging</th>
</tr>
</thead>
<tbody>
<tr>
<td>Squamous lesions: Normal</td>
<td>Normal</td>
</tr>
<tr>
<td>Atypical cells, possible inflammatory</td>
<td>Reactive cellular changes</td>
</tr>
<tr>
<td>CIN I—mild dysplasia: Neoplastic cells confined to lower one third of epithelium (60% spontaneously regress)</td>
<td>Atypical squamous cells of undetermined significance (ASCUS)</td>
</tr>
<tr>
<td>CIN II—moderate dysplasia: Involvement of two thirds of epithelium (43% regress)</td>
<td>Low-grade squamous intraepithelial lesion (LGSIL)</td>
</tr>
<tr>
<td>CIN III—severe dysplasia (carcinoma in situ): Involvement up to the basement membrane of the epithelium (33% regress, 12% advance to invasive cancer)</td>
<td>High-grade squamous intraepithelial lesion (HGSIL)</td>
</tr>
<tr>
<td>Glandular lesions: Atypical glandular cells</td>
<td>Squamous cell carcinoma</td>
</tr>
<tr>
<td>Squamous cell carcinoma</td>
<td>Squamous cell carcinoma</td>
</tr>
</tbody>
</table>

**Pap Smear Findings and Workup**

- ASCUS—repeat Pap every 4 to 6 months until three consecutive negative smears.
- AGCUS—repeat Pap or perform biopsy.
- LGSIL—the majority regress or persist without regression, so either repeat Pap every 4 to 6 months or perform colposcopy with endocervical curettage (ECC).
- HGSIL—colposcopy with ECC.
COLPOSCOPY WITH CERVICAL BIOPSY AND ECC

Definition

Low-magnification microscopic viewing with green filter light of cervix, vagina, and vulva

Indications

Abnormal finding on Pap smear:
- HGSIL and sometimes LGSIL
- Any other suspicious lesions

Procedure

1. Speculum is inserted for visualization of the cervix.
2. Acetic acid is applied. Acetic acid dehydrates cells and causes precipitation of nucleic proteins in the superficial layers. The neoplastic cells appear whiter because of higher nucleus/cytoplasm ratio.
3. Colposcopy: Then a low-power microscope (colscope) is used with green light to look for dysplasia. Signs of dysplasia include whiteness and abnormal vessels.
4. Cervical biopsy: Neoplastic and dysplastic areas are then biopsied under colposcopic guidance. Contraindications include acute PID or cervicitis. Pregnancy is NOT a contraindication.
5. ECC: A curette is then placed in the cervical canal to obtain endocervical cells for cytologic examination.

Information Provided by Colposcopy and ECC

If biopsy results or ECC is positive, cone biopsy or loop electrodiathermy excision procedure (LEEP)

CONE BIOPSY AND LEEP

Cone biopsy: A procedure performed in the operating room in which a cone-shaped biopsy is removed, including part of the endocervical canal
LEEP: A procedure performed in an office setting in which a small wire loop can be electrified to cauterize and remove a biopsy sample: Part of the endocervical canal is removed.
Indications for Cone Biopsy/LEEP

1. Inadequate view of transformation zone on colposcopy
2. Positive ECC
3. ± 2 grade discrepancy between colposcopic biopsy and Pap
4. Treatment for HGSIL
5. Treatment for adenocarcinoma-in-situ

LEEP as Treatment

LEEP can also be used to diagnose and treat CIN and VIN (vulvar intraepithelial neoplasia).

Guidelines for LEEP Treatment
- Never treat during pregnancy.
- Never treat without excluding invasive carcinoma.
- When treating, ablate entire transformation zone.
- Always excise keratinizing lesions.

CRYOTHERAPY

Cryotherapy is an outpatient procedure that uses a probe cooled with N₂O to −70°F to ablate lesions.

Cryotherapy Indications and Complications

Indications: Treatment of LGSIL or HGSIL only if it is a lesion completely visualized on colposcopic exam
Complications: Include discharge, failure of therapy for HGSIL

LASER THERAPY

Light Amplification by Stimulated Emission of Radiation (LASER): A high-energy photon beam generates heat at impact and vaporizes tissue.

Indications for Laser Therapy
1. Excision or ablation of CIN
2. Ablation during laparoscopic surgery (e.g., endometriosis)
Cervical Cancer

EPIDEMIOLOGY

Frequency
- Cervical cancer is expected to account for 12,800 new cancer cases in the United States in the year 2000.
- Cervical cancer is expected to account for 4,600 cancer deaths in the United States in the year 2000.

Age Affected
- Peak incidence between ages 45 and 55
- Fifteen percent of women develop it before age 30.
- Increasing percentage of women diagnosed before 20 years of age (perhaps due to early screening)

Race Prevalence
- More prevalent in African American (AA) women and urban Hispanic women than white women
- AA mortality rate = two times greater than whites

SYMPTOMS

Early Stages
- None
- Irregular/prolonged vaginal bleeding/pink discharge
- Postcoital bleeding (brownish discharge)

Middle Stages
- Postvoid bleeding
- Dysuria/hematuria

Advanced Stages
- Weight loss
- Bloody, malodorous discharge
- Severe pain, due to spread to sacral plexus

Cervical cancer is the third most common gynecologic malignancy (breast cancer is first; ovarian cancer is second).

Symptoms of cervical cancer become evident when cervical lesions are of moderate size; looks like "cauliflower."
DIFFERENTIAL DIAGNOSIS

- Eversions
- Polyps
- Papillary endocervicitis/papillomas

Tuberculosis, syphilitic chancres, and granuloma inguinale can also cause cervical lesions.

TYPES OF CERVICAL CANCER

Squamous Cell Cancer

- Accounts for 80% of cervical cancer

Types of Squamous Cell Carcinoma

- Keratinizing
- Nonkeratinizing:
  - Well-demarcated tumor-stromal borders
- Small-cell carcinoma:
  - Small, round, or spindle-shaped cell with poorly defined tumor-stromal borders

Adenocarcinoma

- Accounts for 10 to 20% of all invasive cervical cancers
- Arises from columnar cells lining the endocervical canal and glands
- Early diagnosis is difficult → 80% false-negative rate with Pap smear

Cancers Metastatic to Cervix by Direct Extension

Rectal
Intra-abdominal
Bladder
Endometrial

Occasionally (via hematogenous spread): Breast, lung

SITES OF DISTANT ORGAN METASTASES (IN ORDER OF FREQUENCY)

1. Lung
2. Liver
3. Bone
Clinical Staging of Invasive Cervical Cancer

Clinical staging of cervical cancer is important for prognosis and treatment.

Modes of Staging
- Pelvic and rectal exam (under anesthesia)
- Chest x-ray
- Liver function tests
- Evaluate genitourinary tract via intravenous pyelogram or computed tomography (CT) with intravenous contrast dye.
- Evaluate lymph node enlargements or abnormalities with external CT-guided biopsies.

Treatment of Invasive Cervical Cancer

- Radical surgery—radical hysterectomy with lymph node dissection
- Radiation therapy—high-dose delivery to the cervix and vagina, and minimal dosing to the bladder and rectum:
  - External beam whole pelvic radiation
  - Transvaginal intracavitary cesium—transvaginal applicators allow significantly larger doses of radiation to surface of cervix.

Treatment for Bulky Central Pelvic Disease

- Hysterectomy after radiation therapy
- Tumor cytoreduction:
  - Use of cytotoxic chemotherapy before definitive treatment with radiation or radical surgery

Recurrent Cervical Carcinoma

- Recurs within 2 to 3 years of primary treatment

Screening for Recurrent Cancer

Look for:
- Vaginal bleeding
- Hematuria/dysuria
- Constipation/melena
- Pelvic and leg pain
- Fistulas
- Sacral backache or pain in sciatic distribution
- Costovertebral angle and flank pain

High-Yield Facts

Radical hysterectomy requires removal of:
- Uterus
- Cervix
- Parametrial tissue
- Upper vagina
+ Pelvic lymphadenectomy from the bifurcation of the iliac vessels to the level of the inguinal ligament

Cervical Cancer
**Cause of Death**

- Uremia and pyelonephritis are major causes of death in cervical cancer.
- Found in 50% of patients

Excretory urogram can identify periureteral compression by tumor.

**Treatment of Recurrent Cancer**

- Patients may only be treated for cure if disease is confined to pelvis.
- Patients with central recurrence after radical hysterectomy are treated with radiation.
- Patients previously treated with radiotherapy are only treated by radical pelvic surgery.
- Chemotherapy:
  - Response rates higher with combination therapy
  - Most combinations include platinum.
  - Response rates = 50 to 70% for 4 to 6 months of life.

**CLEAR CELL ADENOCARCINOMA OF CERVIX**

- Incidence in women exposed in utero to diethylstilbestrol (DES) = 1:1000
- Who? Ages 16 to 27; median age = 19 years
- Overall survival rate—80%
- 5-year survival rate for stage I disease—> 90%

**Screening of DES-Exposed Women**

- Annual Pap smear
- Careful palpation of vaginal walls to rule out adenosis or masses

**Treatment**

- Similar to treatment of squamous cell carcinoma of cervix
- Preferred treatment is radical hysterectomy and pelvic lymph node dissection for stage I or IIA.
- Vaginectomy if vagina is involved

**Disease Recurrence**

- Most DES-related clear cell carcinomas recur ≤ 3 years of initial treatment.
- Pulmonary and supraclavicular nodal metastasis common → yearly screening chest x-ray recommended
<table>
<thead>
<tr>
<th>International Federation of Gynecologists and Obstetricians (FIGO) Stage</th>
<th>Description of Carcinoma</th>
<th>5-Year Survival Rate Post Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>In situ; intraepithelial carcinoma</td>
<td></td>
</tr>
<tr>
<td>I</td>
<td>Confined to cervix; preclinical</td>
<td></td>
</tr>
<tr>
<td>IA</td>
<td>Preclinical (Diagnosis only by microscopy)</td>
<td></td>
</tr>
<tr>
<td>IA-1</td>
<td>Minimal microscopic invasion of stroma: Max of 7-mm horizontal spread</td>
<td></td>
</tr>
<tr>
<td>IA-2</td>
<td>≤ 3-mm depth</td>
<td></td>
</tr>
<tr>
<td>IB</td>
<td>&gt; 3-mm to ≤ 5-mm depth from the base of the epithelium</td>
<td></td>
</tr>
<tr>
<td>IB-1</td>
<td>Clinical lesion ≤ 4 cm in diameter</td>
<td></td>
</tr>
<tr>
<td>IB-2</td>
<td>Lesion &gt; 4 cm in diameter</td>
<td></td>
</tr>
<tr>
<td>II</td>
<td>Carcinoma extends beyond cervix</td>
<td></td>
</tr>
<tr>
<td>II-1</td>
<td>Has not extended to pelvic wall</td>
<td></td>
</tr>
<tr>
<td>II-2</td>
<td>Involves upper two thirds of vagina, but not lower 2</td>
<td></td>
</tr>
<tr>
<td>III</td>
<td>Carcinoma extended to pelvic wall</td>
<td></td>
</tr>
<tr>
<td>III-1</td>
<td>No cancer-free space between the tumor and the pelvic wall (on rectal exam)</td>
<td></td>
</tr>
<tr>
<td>III-2</td>
<td>Tumor involves lower one third of vagina</td>
<td></td>
</tr>
<tr>
<td>IIIA</td>
<td>Does not involve pelvic wall</td>
<td></td>
</tr>
<tr>
<td>IIIB</td>
<td>Obvious parametrial involvement</td>
<td></td>
</tr>
<tr>
<td>IV</td>
<td>Carcinoma extends beyond true pelvis or Clinically involves mucosa of bladder or rectum</td>
<td>&lt; 15%</td>
</tr>
<tr>
<td>IVA</td>
<td>Spread to adjacent organs</td>
<td></td>
</tr>
<tr>
<td>IVB</td>
<td>Spread to distant organs</td>
<td></td>
</tr>
</tbody>
</table>
### TABLE 21-2. TNM Category Staging

<table>
<thead>
<tr>
<th>T</th>
<th>First Resection of Primary Tumor</th>
</tr>
</thead>
<tbody>
<tr>
<td>TX</td>
<td>Primary tumor cannot be assessed</td>
</tr>
<tr>
<td>T0</td>
<td>No evidence of primary tumor</td>
</tr>
<tr>
<td>T1</td>
<td>Confined to cervix</td>
</tr>
<tr>
<td>T2</td>
<td>Beyond cervix</td>
</tr>
<tr>
<td>T2a</td>
<td>No parametrium</td>
</tr>
<tr>
<td>T2b</td>
<td>Parametrial involvement</td>
</tr>
<tr>
<td>T3</td>
<td>Tumor extends to pelvic wall</td>
</tr>
<tr>
<td>T3a</td>
<td>Pelvic wall not involved</td>
</tr>
<tr>
<td>T3b</td>
<td>Pelvic wall involved</td>
</tr>
<tr>
<td>T4</td>
<td>Distant metastasis</td>
</tr>
<tr>
<td>T4a</td>
<td>Adjacent organs</td>
</tr>
<tr>
<td>T4b</td>
<td>Distant organs</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>N</th>
<th>Regional Lymph Nodes</th>
</tr>
</thead>
<tbody>
<tr>
<td>NX</td>
<td>Regional lymph nodes cannot be assessed</td>
</tr>
<tr>
<td>N0</td>
<td>No regional lymph node metastasis</td>
</tr>
<tr>
<td>N1</td>
<td>Regional lymph node metastasis</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>M</th>
<th>Distant Metastasis</th>
</tr>
</thead>
<tbody>
<tr>
<td>MX</td>
<td>Presence of distant metastasis cannot be assessed</td>
</tr>
<tr>
<td>M0</td>
<td>No distant metastasis</td>
</tr>
<tr>
<td>M1</td>
<td>Distant metastasis (excludes peritoneal metastasis)</td>
</tr>
</tbody>
</table>

### TABLE 21-3. Grading of Cervical Carcinoma

<table>
<thead>
<tr>
<th>Grade</th>
<th>Invasive Squamous Tumor</th>
<th>Adenocarcinoma</th>
</tr>
</thead>
<tbody>
<tr>
<td>X</td>
<td>Cannot be assessed</td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>Well differentiated</td>
<td>Small component of solid growth and nuclear atypia</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Mild to moderate</td>
</tr>
<tr>
<td>2</td>
<td>Moderately differentiated</td>
<td>Intermediate-grade differentiation</td>
</tr>
<tr>
<td>3</td>
<td>Poorly differentiated</td>
<td>Solid pattern</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Severe nuclear atypia predominate</td>
</tr>
<tr>
<td>4</td>
<td>Undifferentiated</td>
<td></td>
</tr>
</tbody>
</table>
GENERAL FACTS

An estrogen-dependant neoplasm that begins as proliferation of normal tissue: Over time, chronic proliferation becomes hyperplasia (abnormal tissue) and, eventually, neoplasia. Endometrial cancer is the most common gynecologic cancer. Most cases (> 75%) are diagnosed in postmenopausal women.

CLINICAL PRESENTATION

Abnormal bleeding is present in 90% of cases:
- Bleeding in postmenopausal women (classic)
- Meno/metrorrhagia (in premenopausal cases)
- Abnormal Pap smear: 1 to 5% of cases

Pap smears are not diagnostic, but a finding of AGCUS (abnormal glandular cells of unknown significance) leads to further investigation.

DIFFERENTIAL DIAGNOSIS OF POSTMENOPAUSAL BLEEDING

- Exogenous estrogens
- Atrophic endometritis/vaginitis
- Endometrial cancer
- Endometrial/cervical polyps

Etiologies of Endometrial Cancer

All etiologies (except radiation) result in chronic elevations in circulating levels of estrogen:
- Ovarian failure (i.e., polycystic ovarian disease [PCOD])
- Exogenous estrogens
- Estrogen-producing tumors (i.e., granulosa cell tumors)
- Liver disease (a healthy liver metabolizes estrogen)
- Previous radiation (leading to sarcomas)
Risk Factors

- Obesity
- Early menarche/late menopause
- Nulliparity
- PCOD
- Diabetes mellitus
- Hypertension
- Endometrial hyperplasia
- Tamoxifen treatment for breast cancer (increases risk two to three times)

Protective Factors

- Combined oral contraceptives
- Cigarette smoking
- Multiparity

Diagnosis of Endometrial Hyperplasia and Cancer

- Biopsy (gold standard)
- Pap smear (to evaluate cervical involvement)
- Endocervical curettage (specimens from endocervix and cervix must be examined separately to determine if there has been spread)

A positive finding would include endometrial hyperplasia or cancer.

Endometrial hyperplasia is a precancerous condition. Types include the following:

Simple (Cystic Hyperplasia Without Atypia)
- Glandular and stromal proliferation: 1 to 2% progress to cancer (this is the most differentiated and lowest risk of cancer)

Complex (Adenomatous Hyperplasia Without Atypia)
- Only glandular proliferation (both simple and complex are treated with progesterone)

Atypical
- Simple type of atypical
- Complex type of atypical
- Proliferation with cytologic atypia

Twenty-nine percent of atypical endometrial hyperplasias progress to cancer:
- Simple type is treated by hysterectomy.
- Complex type is treated like cancer.

Workup for Endometrial Cancer

After diagnosis of endometrial cancer is made, the following should be performed to evaluate for possible metastasis:
- Physical exam
Histologic Subtypes of Endometrial Cancer

- **Endometroid** (ciliated adenocarcinoma)—75 to 80%
- Papillary serous:
  - Poor prognosis
  - No history of elevated estrogen
  - More common in blacks
  - Acts like ovarian cancer
  - Presents late (stage IV)
- **Sarcomas** (covered below)

## STAGING OF ENDOMETRIAL CANCER

Staging is determined by the **extent of the tumor**. Therefore, **staging must be accomplished surgically**, not clinically, so the tumor can be visualized. This is always the first step in treatment.

<table>
<thead>
<tr>
<th>Stage</th>
<th>Description</th>
<th>Survival</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>IA—limited to endometrium</td>
<td>90% 5-year survival</td>
</tr>
<tr>
<td></td>
<td>IB—invasion &lt; one half of myometrium</td>
<td></td>
</tr>
<tr>
<td></td>
<td>IC—invasion &gt; one half of myometrium</td>
<td></td>
</tr>
<tr>
<td>II</td>
<td>IIA—endocervical glands only</td>
<td>70% 5-year survival</td>
</tr>
<tr>
<td></td>
<td>IIB—invasion of cervical stroma</td>
<td></td>
</tr>
<tr>
<td>III</td>
<td>IIIA—invasion of serosa and/or adnexa, and/or positive peritoneal cytology</td>
<td>40% 5-year survival</td>
</tr>
<tr>
<td></td>
<td>IIIB—invasion of vagina</td>
<td></td>
</tr>
<tr>
<td></td>
<td>IIIC—mets to pelvic/para-aortic lymph nodes</td>
<td></td>
</tr>
<tr>
<td>IV</td>
<td>IVA—invasion of bladder and/or bowel</td>
<td>10% 5-year survival</td>
</tr>
<tr>
<td></td>
<td>IVB—distant invasion, including intra-abdominal and/or inguinal lymph nodes</td>
<td></td>
</tr>
</tbody>
</table>

## GRADING

Grading is determined by the tumor **histology**:

- GI  Well differentiated—< 5% solid pattern
- GII Moderately differentiated—5 to 50% solid pattern
- GIII Poorly differentiated—> 50% solid pattern
TREATMENT

Basic treatment for all stages (surgical staging is always the first step):
- Total abdominal hysterectomy (TAH)
- Bilateral salpingo-oophorectomy (BSO)
- Nodal sampling
- Peritoneal washings

Adjuvant Therapy

After the above steps in treatment, adjuvant therapy depends on the stage.

Stages I–II  
**Brachytherapy** (intracavitary radiation)

Stages III–IV  
**External beam radiation**

**Hormone therapy:** Progestin therapy is often used as adjuvant hormonal therapy:
- If the cancer is progesterone receptor positive—70% have a 5-year survival.
- If the cancer is receptor negative—15 to 20% have a 5-year survival.

**Chemotherapy** is used only for cancers that recur outside the pelvis.
- Doxorubicin
- Cisplatin

UTERINE SARCOMA

Uterine sarcoma is classified separately from endometrial cancer:
- Presents as a rapidly enlarging mass with bleeding
- Not from fibroids (<1% of fibroids progress to cancer)
- Poor prognosis

Most cases are diagnosed with exploratory surgery for what was thought to be a uterine myoma (fibroid).

Types

- Leiomyosarcoma (LMS)
- Mixed mesodermal (MMD)
- Endometrial stromal sarcoma (ESS)

Diagnosis

- ≥ 10 mitosis/high-power field
- Usually diagnosed from specimen sent after hysterectomy
- Staged just like endometrial cancer

Treatment

- Surgical (TAH/BSO, nodes, washings)
- Plus adjuvant:
  - LMS—doxorubicin and cisplatin
  - MMD—ifosfamide and cisplatin
  - ESS—progestin therapy

HIGH-YIELD FACTS

Endometrial Cancer

- Side effects:
  - Doxyrubicin—cardiotoxicity
  - Cisplatin—nephrotoxicity

- Ifosfamide can cause hemorrhagic cystitis.
Ovarian Cancer

There are two basic histologic types of ovarian cancer:
- Epithelial
- Nonepithelial

**EPIDEMIOLOGY**
- Second most common gynecologic malignancy
- Fifth most common cancer for women
- The deadliest gynecologic malignancy
- Seventy percent of patients are diagnosed as stage III or IV.
- 1 in 70 lifetime risk

**EPITHELIAL CELL OVARIAN CANCER**

Ovarian cancer usually refers to epithelial cell type.

**Histologic Subtypes of Epithelial Ovarian Cancer**

Five subtypes arising from epithelial tissue:
- Serous 40%
- Endometroid 15%
- Mucinous 15%
- Undifferentiated 15%
- Clear cell 5%

**Typical Clinical Presentation**

Signs/symptoms are usually from metastasis. Ovarian cancer typically spreads by exfoliation of cancerous cells into the peritoneal fluid. The peritoneal fluid carries it to other structures in the abdomen.
Signs and Symptoms
- Pelvic mass
- Abdominal mass (“omentum caking”) (widening abdominal girth)
- Pleural effusion (dyspnea)
- Ascites
- Ventral hernia (due to ↑ intra-abdominal pressure)

CA-125
CA-125 is a tumor marker elevated in 80% of cases. It is useful in tracking the progression of the disease and the response to treatment.

Risk Factors
- Advanced age
- Family history
- Nulliparity
- Talc powder, high-fat diet, fertility drugs (data inconclusive on these)

Protective Factors
- Prolonged breast feeding
- Oral contraceptives
- Multiparity
- Reproductive surgery

Hereditary Ovarian Cancer Syndromes
Five to 10% of cases occur in association with genetically predisposed syndromes called hereditary ovarian cancer syndromes. There are three types:

1. Breast–ovarian cancer syndrome: It involves cancer of the breast and ovary and is linked to the BRCA-1 gene, is autosomal dominant, is seen in younger women.
2. Lynch II syndrome—hereditary nonpolyposis colon cancer (HNPCC): It involves sites that may include breast, ovaries, uterus, and colon.
3. Site-specific ovarian cancer: It accounts for < 1% and has extremely strong genetic link. Usually two or more first-degree relatives have the disease.

Ovarian Cancer Workup
1. As with any pelvic mass, the first step of evaluation is ultrasound.
2. Definitive identification of adnexal mass by laparoscopy/laparotomy follows.

Screening Recommendations
- Women with standard risk (fewer than two first-degree relatives with ovarian cancer): No routine screening recommended.
- Women with high risk (two or more first-degree relatives with ovarian cancer): Genetic testing and counseling.
If testing shows one of the hereditary syndromes, perform:
- Annual CA-125
- Annual transvaginal ultrasound
- Annual pelvic exam

**STAGING**

Ovarian cancer is staged surgically, not clinically.

<table>
<thead>
<tr>
<th>Stage</th>
<th>Description</th>
<th>Survival (5-year)</th>
</tr>
</thead>
</table>
| I     |—tumor limited to ovaries
IA—one ovary, capsule intact
IB—both ovaries, capsules intact
IC—tumor on ovary surface, capsule ruptured, ascites with malignant cells, or positive peritoneal washings | > 90% |
| II    |—pelvic spread
IIA—involvement of uterus/tubes
IIB—involvement of other pelvic structures
IIC—IIB or IIB plus tumor on ovary surface, capsule ruptures, ascites with malignant cells, or positive peritoneal washings | 70% |
| III   |—spread to the abdominal cavity
IIIA—positive abdominal peritoneal washings
IIIB—< 2-cm implants on abdominal peritoneal surface
IIIC—> 2-cm implants on abdominal peritoneal surface and/or positive retroperitoneal or inguinal nodes | 25% |
| IV    |—distant metastasis
Parenchymal liver/spleen spread
Pleural effusion, skin or supraclavicular nodes | 5% |

**TREATMENT**

Surgery is used to get rid of as much of the tumor as possible, as well as to biopsy like sites of spread. This always includes total abdominal hysterectomy/bilateral salpingo-oophorectomy and often includes lymph node sampling, omentectomy, and bladder and bowel resection. Debulking is the attempt to remove as much of the primary and metastatic tumor sites as possible and is employed in advanced disease.

**Postop Management**

First-line chemotherapy: Paclitaxel and cisplatin or paclitaxel and carboplatin:

Stage I–II  
**Only chemotherapy** if stage I/IIC or high-grade tumor

Stage III–IV  
**Chemotherapy,** plus:
- Radiation if residual tumor < 2 cm
- Interval debulking if tumor > 2 cm (interval debulking means additional surgery after chemotherapy)
Poor Prognostic Indicators
- Short disease-free interval
- Mucinous or clear cell tumor
- Multiple disease sites
- High CA-125

**NONEPITHELIAL OVARIAN CANCER**
These account for roughly 10% of ovarian cancers.

**Histologic Types**
- Germ cell—8% of all ovarian cancers; include teratomas, dysgerminomas, choriocarcinomas
- Gonadal-stromal—1% of all ovarian cancers; include granulosa-theca cell tumors, Sertoli- Leydig tumors

**OVARIAN GERM CELL TUMORS (GCTs)**
Eight percent of ovarian cancers are GCTs. GCTs arise from totipotential germ cells that normally are able to differentiate into the three germ cell tissues. Ninety-five percent are benign.

**Clinical Presentation**
- Abdominal pain with rapidly enlarging palpable pelvic/abdominal mass
- Acute abdomen
- Fever
- Vaginal bleeding
- Usually found in children or young women

**Types of Ovarian GCTs**
**Dysgerminoma (Most Common)** (arises from totally undifferentiated totipotential germ cells)
- Affects women in teens to early 20s
- 20% bilateral
- 20% associated with pregnancy
- LDH is the tumor marker.

**Endodermal Sinus Tumor** (arises from extraembryonic tissues)
- 20% of GCTs
- Most aggressive GCT
- Characteristic Schiller-Duval bodies
- AFP is the tumor marker.

**Immature Teratoma** (arises from embryonic tissues)
- 20% of GCTs
- Mixture of cells representing all three germ layers

**Embryonal and Choriocarcinoma (arise from trophoblasts)**
- Rare
- Tumors may cause sexual precocity or abnormal uterine bleeding.
- β-hCG is the tumor marker.

Signs and symptoms of GCTs are from the primary tumor, not mets (unlike epithelial ovarian cancer).
Mixed GCTs
- 10% of GCTs
- Dysgerminoma and endodermal sinus tumor is the most common combination.
- LDH, AFP, and β-hCG may be elevated.

Treatment of Ovarian GCTs
- Surgery:
  - Unilateral adnexectomy and complete surgical staging
- Adjuvant chemotherapy:
  - Recommended for all but stage I, grade I immature teratoma

BEP Therapy | Side Effects
--- | ---
Bleomycin | Pulmonary fibrosis
Etoposide | Blood dyscrasias
Cisplatin | Nephrotoxicity

Prognosis of Ovarian GCTs
Prognosis is generally good because most are discovered early. Five-year survival is 85% for dysgerminomas, 75% for immature teratomas, and 65% for endodermal sinus tumors.

Ovarian Sex Cord–Stromal Tumors
One percent of ovarian cancers: They arise from the sex cords of the embryonic gonad before they differentiate into male or female. They are functional tumors that secrete estrogen or testosterone. They usually affect older women.

Types of Sex Cord–Stromal Tumors
- Granulosa–Theca Cell Tumor
  - Secretes estrogens that can cause feminization, precocious puberty, or postmenopausal bleeding
  - Association with endometrial cancer
  - Inhibin is the tumor marker.
- Sertoli–Leydig Cell Tumor
  - Secretes testosterone
  - Presents with virilization, hirsutism, and menstrual disorders as a result of the testosterone
  - Testosterone is the tumor marker.

Treatment of Ovarian Sex Cord–Stromal Tumors
- Surgical Treatment
  - TAH/BSO
  - Unilateral oophorectomy in young women with low-stage/grade neoplasia
- Adjuvant Therapy
  - Data are inconclusive, but chemotherapy and radiation play a small role at present.
Fallopian cell carcinomas usually are adenocarcinomas. They spread through the peritoneal fluid in a similar fashion to ovarian cancer. It is very rare and can affect any age.

**Classic Presenting Triad**
- Pain
- Vaginal bleeding
- Leukorrhea

Many are diagnosed during a laparotomy for other indications.

**Hydrops tubae perfluens** is the pathognomonic finding, defined as cramping pain relieved with watery discharge.

**Staging, Treatment, and Prognosis**
- All similar to ovarian cancer

---

**TABLE 23-1. Ovarian Tumors and Their Serum Markers**

<table>
<thead>
<tr>
<th>Ovarian Tumor</th>
<th>Serum Tumor Marker</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dysgerminoma</td>
<td>LDH</td>
</tr>
<tr>
<td>Endodermal sinus tumor</td>
<td>AFP</td>
</tr>
<tr>
<td>Embryonal and choriocarcinoma</td>
<td>Beta-hCG</td>
</tr>
<tr>
<td>Epithelial ovarian tumor</td>
<td>CA-125</td>
</tr>
<tr>
<td>GCT</td>
<td>Inhibin</td>
</tr>
<tr>
<td>Sertoli–Leydig cell tumor</td>
<td>Testosterone</td>
</tr>
</tbody>
</table>

---

Fallopian cell carcinoma is the least common gynecologic malignancy.

In any postmenopausal bleeding or discharge that cannot be explained by endometrial biopsy, fallopian cell carcinoma should be considered.
VULVAR INTRAEPITHELIAL NEOPLASIA (VIN)

Dysplastic lesions of the vulva that have potential to progress to carcinoma: Etiology is unknown, although human papillomavirus (HPV) has been implicated because of similarity in pathology and often concomitant presence of cervical intraepithelial neoplasia (CIN).

Risk Factors
Like cervical cancer, vulvar cancer risk factors include HPV types 16, 18, 31, and 33, and the precancerous lesions are classified as intraepithelial neoplasia (termed VIN as opposed to CIN).

Presentation
Pruritus and/or irritation (recent or long-standing), raised white lesions

Diagnosis
- Biopsy
- Colposcopic exam (must include cervix, vagina, perineal and perianal skin)

Staging
As in cervical dysplasia, VIN is based on degree of epithelial spread:
- VIN I—involvement of < ½ epithelium.
- VIN II—involvement of > ½ epithelium
- VIN III—full-thickness involvement (carcinoma-in-situ)

Treatment
Treatment is according to the size of the lesion:
- Small, well-circumscribed VIN → wide local excision
- Multifocal lesions → laser vaporization
- Extensive lesions → vulvectomy
VULVAR CANCER

Vulvar cancer is a relatively rare gynecologic cancer (4 to 5% of all gynecologic cancers) and can arise as carcinoma of various types:
- Squamous (90%)
- Adeno
- Basal
- Melanoma
- Metastasis

Most often found in women 60 to 70 years old

Signs and Symptoms
- Pruritus (most common)
- Ulceration
- Mass (often exophytic)
- Bleeding

Risk Factors
Same as vulvar dysplasia (HPV, HSV-II, LGV, pigmented moles, and poor hygiene)

Diagnosis
Biopsy of the suspicious lesion

Staging

<table>
<thead>
<tr>
<th>Stage</th>
<th>Description</th>
<th>Survival</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>&lt; 2-cm tumor, no spread</td>
<td>&gt; 90%</td>
</tr>
<tr>
<td>II</td>
<td>&gt; 2-cm tumor, no spread</td>
<td>&gt; 90%</td>
</tr>
<tr>
<td>III</td>
<td>Spread to unilateral nodes or vagina or anus or lower urethra</td>
<td>Survival rates correlate to number of positive nodes: 1 node ≈ 85%; ≥ 3 nodes ≈ 15%</td>
</tr>
<tr>
<td>IVa</td>
<td>Mucosa, bilateral nodes</td>
<td>Survival &lt; 10%</td>
</tr>
<tr>
<td>IVb</td>
<td>Spread to upper urethra, rectal</td>
<td></td>
</tr>
<tr>
<td>V</td>
<td>Distant mets</td>
<td></td>
</tr>
</tbody>
</table>

Treatment

Stages I–II
Radical vulvectomy and lymphadenectomy (wide local excision is sometimes possible for certain small lesions < 1 cm)

Stages III–IV
As above, plus removal of affected organs and adjunct radiation therapy
VAGINAL CANCER

- Vaginal cancer is a rare gynecologic malignancy (2% of gynecologic cancers).
- Usually presents in postmenopausal women
- Most common type is squamous cell carcinoma (others types are the same as vulvar cancer types).

Signs and Symptoms
- Ulcerated mass
- Exophytic mass
- Bleeding
- Asymptomatic

Diagnosis
Biopsy of suspicious lesion

Staging
Stage I: Limited to vaginal mucosa
Survival = 75%

Stage II: Beyond mucosa but not involving pelvic wall
Survival = 70%

Stage III: Pelvic wall involvement
Survival = 35%

Stage IV: Involvement of bladder, rectum, or distant mets
Survival < 15%

Treatment
Stages I–II
Surgical resection and radiation

Stages III–IV
Radiation only

Adenocarcinoma of the vagina often correlates with in utero diethylstilbestrol exposure; these patients often present young.
DEFINITION OF GTN

Gestational trophoblastic neoplasias are neoplasms arising from placental syncytiotrophoblasts and cytotrophoblasts.

The four tumors are:
- Hydatidiform mole (complete or partial)
- Invasive mole
- Choriocarcinoma
- Placental site trophoblastic tumor

HYDATIDIFORM MOLE

Complete Mole
A placental (trophoblastic) tumor forms when a maternal ova devoid of DNA is “fertilized” by the paternal sperm:
- **Karyotype:** Most have karyotype 46XX, resulting from sperm penetration and subsequent DNA replication. Some have 46XY, believed to be due to two paternal sperms simultaneously penetrating the ova.
- **Epidemiology:** Incidence is:
  - 1 in 1,500 pregnancies in the United States
  - 1 in 200 in Mexico
  - 1 in 125 in Taiwan

Partial Mole
A mole with a fetus or fetal parts. Women with partial (incomplete) molar pregnancies tend to present later than those with complete moles:
- **Karyotype:** Usually 69XXY, and contains both maternal and paternal DNA
- **Epidemiology:** 1 in 50,000 pregnancies in the United States
Invasive Mole

A hydatidiform mole that invades the myometrium: It is by definition malignant, and thus treatment involves complete metastatic workup and appropriate malignant/metastatic therapy (see below).

Histology of Hydatidiform Mole

- Trophoblastic proliferation
- Hydropic degeneration (swollen villi)
- Lack/scarcity of blood vessels

Signs and Symptoms

- Passage of vesicles (look like grapes)
- Preeclampsia < 20 weeks
- Abnormal painless bleeding in first trimester

Diagnosis

- hCG > 100,000 mIU/mL
- Absence of fetal heartbeat
- Ultrasound- “snowstorm” pattern
- Pathologic specimen—grapelike vesicles
- Histologic specimen (see above)

Treatment of Complete or Partial Moles

- Dilation and curettage (D&C) to evacuate and terminate pregnancy
- Follow-up with the workup to rule out invasive mole (malignancy):
  - Chest x-ray (CXR) to look for lung mets
  - Liver function tests to look for liver mets
  - Weekly hCG level: The hCG level should decrease and return to normal within 2 months. If the hCG level rises, does not fall, or falls and then rises again, the molar pregnancy is considered malignant, and metastatic workup and chemotherapy is necessary.
  - Contraception should be used during the 1-year follow-up.

Metastatic Workup

CXR, computed tomography (CT) of brain, lung, liver, kidneys

Treatment (For Nonmetastatic Molar Preganacies)

- Chemotherapy—methotrexate or actinomycin-d (as many cycles as needed until hCG levels return to normal)
  or
- Total abdominal hysterectomy + chemotherapy (fewer cycles needed)
Treatment for metastatic molar pregnancy is the same as for choriocarcinoma (see below)

**CHORIOCARCINOMA**

An epithelial tumor that occurs with or following a pregnancy (including ectopic pregnancies, molar pregnancies, or abortion):

- **Histopathology:** Choriocarcinoma has characteristic sheets of trophoblasts with extensive hemorrhage and necrosis, and unlike the hydatidiform mole, choriocarcinoma has no villi.
- **Epidemiology:** Incidence is about 1 in 40,000 pregnancies.

**Diagnosis**

- Increased hCG
- Absence of fetal heartbeat
- Uterine size/date discrepancy
- Specimen (sheets of trophoblasts, no villi)

As with invasive mole and malignant hydatidiform mole, a full metastatic workup is required when choriocarcinoma is diagnosed.

**Treatment of Nonmetastatic Choriocarcinoma and Prognosis**

- Chemotherapy—methotrexate or actinomycin-d (as many cycles as needed until hCG levels return to normal)
  or
- Total abdominal hysterectomy + chemotherapy (fewer cycles needed)

Remission rate is near 100%.

**Treatment of Metastatic Choriocarcinoma, Metastatic Invasive Mole, or Metastatic Hydatidiform Mole**

Treatment is determined by the patient’s risk (high or low) or prognostic score.

**Prognostic Group Clinical Classification**

- **Low risk:**
  - hCG < 100,000 IU/24-hr urine or < 40,000 mIU/mL serum
  - Less than 4 months from antecedent pregnancy event or onset of symptoms to treatment
  - No brain or liver metastasis
  - No prior chemotherapy
  - Pregnancy event is not a term pregnancy.

- **High risk:** Opposite of above (i.e., hCG > 100,000 IU/24-hr urine, more than 4 months from pregnancy, brain or liver mets, etc.)
### World Health Organization (WHO) Prognostic Scoring System

<table>
<thead>
<tr>
<th>Risk Factor</th>
<th>0</th>
<th>1</th>
<th>2</th>
<th>4</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Age (years)</strong></td>
<td>≤ 39</td>
<td>&gt; 39</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Pregnancy</strong></td>
<td>H. mole</td>
<td>Abortion</td>
<td>Term</td>
<td></td>
</tr>
<tr>
<td><strong>Interval from pregnancy event to treatment (in months)</strong></td>
<td>&lt; 4</td>
<td>4–6</td>
<td>7–12</td>
<td>&gt; 12</td>
</tr>
<tr>
<td><strong>hCG (IU/mL)</strong></td>
<td>&lt; $10^3$</td>
<td>$10^3$–$10^4$</td>
<td>$10^4$–$10^5$</td>
<td>$&gt; 10^5$</td>
</tr>
<tr>
<td><strong>ABO blood group</strong></td>
<td>O × A</td>
<td>A × O</td>
<td>B</td>
<td>AB</td>
</tr>
<tr>
<td>(female × male)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Number of metastases</strong></td>
<td>1–4</td>
<td>5–8</td>
<td>&gt; 8</td>
<td></td>
</tr>
<tr>
<td><strong>Site of metastasis</strong></td>
<td>Spleen</td>
<td>GI</td>
<td>Brain</td>
<td></td>
</tr>
<tr>
<td>Kidney</td>
<td>Liver</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Size of largest tumor (cm)</strong></td>
<td>3–5</td>
<td>&gt; 5</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Prior chemotherapy agent</strong></td>
<td>Single</td>
<td>Multiple</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Scores are added to give the prognostic score.

### Treatment According to Score/Prognostic Factors

<table>
<thead>
<tr>
<th>Risk</th>
<th>Therapy</th>
<th>Remission Rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Low risk (score ≤ 4)</td>
<td>Single-agent therapy (methotrexate)</td>
<td>90 to 99%</td>
</tr>
<tr>
<td>Intermediate risk (score 5 to 7)</td>
<td>Multiple-agent therapy (MAC therapy—methotrexate, actinomycin, and cyclophosphamide)</td>
<td>≈ 50%</td>
</tr>
<tr>
<td>High risk (score ≥ 8)</td>
<td>Multiple-agent therapy (EMACO therapy—etoposide, MAC, and vincristine)</td>
<td></td>
</tr>
</tbody>
</table>
PLACENTAL SITE TROPHOBLASTIC TUMOR (PSTT)

PSTT is a rare form of GTN. It is characterized by infiltration of the myometrium by intermediate trophoblasts, which stain positive for human placental lactogen. Unlike other GTN, hCG is only slightly elevated.

Treatment

Total abdominal hysterectomy: Prognosis is poor if there is tumor recurrence or metastasis.
PELVIC INFLAMMATORY DISEASE (PID)

Definition
Inflammation of the female upper genital tract (uterus, tubes, ovaries, ligaments) caused by ascending infection from the vagina and cervix

Common Causative Organisms
- Neisseria gonorrhoeae
- Chlamydia trachomatis
- Escherichia coli, Bacteroides

Diagnosis
Physical Exam
- Abdominal tenderness
- Adnexal tenderness
- Cervical motion tenderness

Lab Results and Other Possible Exam Signs
+/- Fever
Gram-positive staining
Pelvic abscess
Elevated white count
Purulent cervical discharge

Laparoscopy
This is the “gold standard” for diagnosis, but it is usually employed only in cases unresponsive to medical treatment.

Risk Factors
- Multiple sexual partners
- New sex partner(s)
- Unprotected intercourse
- Concomitant history of sexually transmitted disease

HIGH-YIELD FACTS IN
Sexually Transmitted Diseases and Vaginitis

PID affects 10% of women in reproductive years.

Rarely is a single organism responsible for PID, but always think of chlamydia and gonorrhea first.

Requirement for diagnosis of PID:
1) Abdominal tenderness
2) Adnexal tenderness
3) Cervical motion tenderness
Positive lab tests are not necessary for diagnosis.

Chandelier sign—when you touch the cervix, there is so much pain that she jumps to the chandelier.
Criteria for Hospitalization

- Pregnancy
- Peritonitis
- Gastrointestinal (GI) symptoms (nausea, vomiting)
- Abscess (tubo-ovarian or pelvic)
- Uncertain diagnosis

Treatment

Inpatient
Cefotetan + doxycycline (preferred for chlamydia)
Clindamycin + gentamicin (preferred for abscess)

Outpatient
Ofloxacin + metronidazole
Ceftriaxone + doxycycline (preferred for chlamydia (because of doxycycline))

Sexual partners are treated also.

GONORRHEA

An infection of the urethra, cervix, pharynx, or anal canal, caused by the gram-negative diplococcus, *Neisseria gonorrhoeae*

Presentation

- Asymptomatic
- Dysuria
- Endocervicitis
- Vaginal discharge
- Pelvic inflammatory disease (PID)

Diagnosis

- Culture in Thayer–Martin agar (gold standard)
- Gonazyme (enzyme immunoassay)

Treatment

Ceftriaxone
or
Ciprofloxacin + doxycycline
or
Azithromax

Treat partners.
**CHLAMYDIA**

Chlamydia is an infection of the genitourinary (GU) tract, GI tract, conjunctiva, nasopharynx, caused by Chlamydia trachomatis, an obligate intracellular bacteria.

**Presentation**

There are numerous serotypes of chlamydia generally speaking. Serotypes A–K cause more localized GU manifestations and the L serotypes a systemic disease (lymphogranuloma venereum).

**SEROTYPES A–K**

Serotypes A–K of Chlamydia trachomatis can have the following presentation:
- Asymptomatic
- Mucopurulent discharge
- Cervicitis
- Urethritis
- PID
- Trachoma—conjunctivitis resulting in eyelash hypercurvature and eventual blindness from corneal abrasions
- Fitz-Hugh–Curtis syndrome

**SEROTYPES L1–L3**

Serotypes L1–L3 of Chlamydia trachomatis cause lymphogranuloma venereum. This is a systemic disease that can present in several forms:
- Primary lesion—painless papule on genitals
- Secondary stage—lymphadenitis
- Tertiary stage—rectovaginal fistulas, rectal strictures

**Diagnosis**

- Microimmunofluorescence test (MIF)—measures antichlamydia immunoglobulin M (IgM) titers. Titer > 1:64 is diagnostic.
- Isolation in tissue culture
- Enzyme immunoassay

**Treatment**

Doxycycline or azithromycin/erythromycin

---

**SYPHILIS**

Syphilis is an infection caused by the spirochete Treponema pallidum.

**Presentation**

Syphilis has various stages of manifestation that present in different ways:
- Primary syphilis—painless hard chancre of the vulva, vagina, or cervix (or even anus, tongue, or fingers), usually appearing 1 month after exposure; Spontaneous healing after 1 to 2 months
- Secondary syphilis—generalized rash (often palms and soles), condyloma lata, mucous patches with lymphadenopathy, fever, malaise, usu-
ally appearing 1 to 6 months after primary chancre: Spontaneous regression after about 1 month
- Tertiary syphilis—presents years later with skin lesions, bone lesions (gummas), cardiovascular lesions (e.g., aortic aneurysms), central nervous system (CNS) lesions (e.g., tabes dorsalis).

**Diagnosis**
- Screening is done via rapid plasma reagin (RPR) or Venereal Disease Research Laboratory (VRDL). These are nonspecific and can give positive results for many conditions.
- Treponemal test (FTA-ABS) is a very specific test, performed if RPR is positive.
- Visualization of spirochetes on darkfield microscopy is an additional test available.

**Treatment**
- Penicillin G for all stages, though in differing doses
- Doxycycline, if penicillin allergic

**Genital Herpes**
- Infection caused by herpes simplex virus type 1 (HSV-I) in 85% of cases, and by HSV-II in 15% of cases
- HSV is a DNA virus.
- Fifteen percent of adults have antibodies to HSV-II, most without history of infection.

**Presentation**
Patients with herpes can be asymptomatic, in addition to the following:
- **Primary infection:** Painful multiple vulvar vesicles, associated with fever, lymphadenopathy, malaise, usually 1 to 3 weeks after exposure
- **Recurrent infection:** Recurrence from viral stores in the sacral ganglia, resulting in a milder version of primary infection including vesicles.
- **Initial primary infection:** This is defined as initial infection by HSV-II in the presence of preexisting antibodies to HSV-I. The preexisting antibodies to HSV-II can make the presentation of HSV-I milder.

**Major Risks**
- Cervical cancer
- Neonatal infection

**Diagnosis**
- Gross examination of vulva for typical lesions
- Cytologic smear—multinucleated giant cells (Tzanck test)
- Viral cultures
Treatment

Treatment for HSV is palliative and not curative.
- Primary outbreak—acyclovir
- Recurrent infection—one half original dose of acyclovir
- Pregnancy—acyclovir during third trimester

HUMAN IMMUNODEFICIENCY VIRUS (HIV) AND ACQUIRED IMMUNE DEFICIENCY SYNDROME (AIDS)

HIV is an RNA retrovirus and causes AIDS. The virus infects CD-4 lymphocytes and other cells and causes decreased cellular immunity.

Presentation

Initial infection: Mononucleosis-like illness occurring weeks to months after exposure—fatigue, weight loss, lymphadenopathy, night sweats. This is followed by a long asymptomatic period lasting months to years.
AIDS: Opportunistic infections, dementia, depression, Kaposi’s sarcoma, wasting

Risk Factors
- Intravenous drug use
- Blood transfusions between 1978 and 1985
- Prostitution
- Multiple sex partners/unprotected sex
- Bisexual partners

Diagnosis
- Enzyme-linked immunosorbent assay (ELISA)—detects antibodies to HIV. It is sensitive but not as specific.
- Western blot—done for confirmation if ELISA is positive. It is very specific.
- Polymerase chain reaction (PCR)—an alternative means of testing

Treatment

Two antiretroviral agents plus one protease inhibitor has been common treatment.

HUMAN PAPILLOMAVIRUS (HPV)

HPV causes genital warts (condylomata acuminata):
- Subtypes 6 and 11 are not associated with cervical or penile cancer.
- Subtypes 16, 18, 31, and 33 are associated with cervical and penile cancer.

Presentation

Warts of various sizes (sometimes described as cauliflower-like) on the external genitalia, anus, cervix, or perineum
Diagnosis
- Warts are diagnosed by visualization.
- Cervical dysplasia caused by HPV infection is screened via Pap smear.

Treatment
- Condylomata acuminata are treated with cryosurgery, laser ablation, or trichloroacetic acid.
- See cervical dysplasia chapter for treatment of cervical dysplasia.

CHANCROID

Presentation
Chancroid presents as a papule on external genitalia that becomes a painful ulcer (unlike syphilis, which is painless) with a gray base. Inguinal lymphadenopathy also is possible.

Etiology
Haemophilus ducreyi

Diagnosis
Gram stain of ulcer or inguinal node aspirate showing gram-negative rods

Treatment
Ceftriaxone, erythromycin, or azithromycin

PEDICULOSIS PUBIS (CRABS)

Presentation
Pruritus in genital area from parasitic saliva

Etiology
Pediculosis is a parasite.

Diagnosis
Visualization of crabs, history of pruritus

Treatment
Permethrin cream or Lindane shampoo

VAGINITIS

Definition
Vaginitis is inflammation of the vagina, often resulting in increased discharge and/or pruritus, and usually caused by an identifiable microbe (see Table 26-1).
Etiology

- Antibiotics—destabilize the normal balance of flora
- Douche—raises the pH
- Intercourse—raises the pH
- Foreign body—serves as a focus of infection and/or inflammation

There are several common organisms that cause vaginitis: Bacterial (Gardnerella), Candida, and Trichomonas. The distinguishing features are described with the following characteristics.

Diagnostic Characteristics

- Clinical characteristics
- Quality of discharge
- pH—secretions applied to test strip reveal pH of discharge.
- “Whiff” test—combining vaginal secretions with 10% KOH: Amines released will give a fishy odor, indicating a positive test.
- Microscopic findings

| TABLE 26-1. Vaginitis |
|-----------------------|-----------------|-----------------|-----------------|
| Physiologic (Normal)  | Bacterial Vaginosis | Candidiasis | Trichomoniasis |
| Clinical Complaints  | None            | Malodorous discharge, especially after menses, intercourse | Pruritus, erythema, edema, odorless discharge, dyspareunia | Copious, frothy discharge, malodorous, pruritus, urethritis |
| Quality of Discharge | Clear or white, no odor | Homogenous gray or white, thin, sticky | White, “cottage cheese-like” | Green to yellow, sticky, “bubbly” or “frothy” |
| pH                   | 3.8—4.2         | > 5.5         | 4—5             | 5—6.5           |
| Microscopic Findings | Epithelial cells Normal bacteria include mostly *Lactobacillus*, with *Staphylococcus epidermidis*, *Streptococcus*, as well as small amounts of colonic flora | Visualize with saline Clue cells (epithelial cells with bacteria attached to their surface) | Bacteria include *Gardnerella* (*Haemophilus*) and/or *Mycoplasma* | In 10% KOH Budding yeast and pseudohyphae | In saline Motile, flagellated, protozoa |
| “Whiff” Test         | Negative (no smell) | Positive (fishy smell) | Negative | Positive or negative |
| Treatment            | Oral or topical *metronidazole* or topical *clindamycin* | Oral, topical, or suppository *imidazole* (or other various antifungals) | Oral *metronidazole* (Note: *Metronidazole* has potential disulfiram-like rxn and has a metallic taste) |
| Treat Sexual Partners? | Not necessary | Not necessary | Yes |
TOXIC SHOCK SYNDROME

See Figure 26-1.

Suspect TSS

Are at least 3 different organ systems (listed) involved?

- mucous membranes
- GI
- liver
- renal
- skin
- cardiac
- muscular
- hematologic
- skin rash
- fever > 38.9° C
- CNS

If criteria not met, pursue alternative diagnoses.

1) Assess hemodynamics.
2) Replace volume and electrolytes.
3) Intravenous antibiotics
   A) Anti-staph beta-lactam (e.g., nafcillin 1–2 g q4h)
   B) Clindamycin
   C) Vancomycin

Any potential site for *Staphylococcus aureus*? (Infection or colonization)

Male
   Surgical wound, trauma site, nasal, etc.

Female
   Vaginal, tampon, contraceptive sponge, or others (listed in male)

Positive
   Remove any FB*; culture site and blood

* Foreign body

FIGURE 26-1. Toxic shock syndrome (TSS) workup.
Vulvar Dystrophies

Vulvar dystrophies are a group of disorders characterized by various pruritic, white lesions of the vulva. Lesions must be biopsied to rule out malignancy.

Lichen Simplex Chronicus (LSC)

LSC is a hypertrophic dystrophy caused by chronic irritation resulting in the raised, whitened appearance of hyperkeratosis. Lesions may also appear red and irritated due to itching. Microscopic examination reveals acanthosis and hyperkeratosis.

Lichen Sclerosis

An atrophic lesion characterized by paperlike appearance on both sides of the vulva and epidermal contracture leading to loss of vulvar architecture: Microscopic examination reveals epithelial thinning with a layer of homogenization below and inflammatory cells.

Treatment of Vulvar Dystrophies

- Steroid cream (hydrocortisone)
- Diphenhydramine at night to prevent itching during sleep

Psoriasis

Psoriasis is a common dermatological condition that is characterized by red plaques covered by silver scales. Although it commonly occurs over the knees and/or elbows, lesions can be found on the vulva as well. Pruritus is variable.

Treatment

- Steroid cream
- Coal tar with ultraviolet light therapy or topical vitamin D
VESTIBULITIS

Inflammation of the vestibular glands that leads to tenderness, erythema, and pain associated with coitus (insertional dyspareunia and/or postcoital pain): Etiology is unknown. Although the affected area turns white with acetic acid under colposcopic examination, these lesions are not dysplastic.

Treatment
- Temporary sexual abstinence
- Trichloroacetic acid
- Xylocaine jelly for anesthesia
- Surgery—if lesions are unresponsive to treatment, vestibulectomy is possible, though with risk of recurrence.

CYSTS

Bartholin’s Abscess
Bartholin’s abscesses occur when the main duct draining Bartholin’s gland is occluded, which usually occurs due to infection. Inflammatory symptoms generally arise from infection and can be treated with antibiotics.

Treatment
- Incision and drainage and marsupialization (suturing the edges of the incised cyst to prevent reocclusion)
  or
- Ward catheter (a catheter with an inflatable tip left in the gland for 10 to 14 days to aid healing)

Sebaceous Cysts
Sebaceous cysts occur beneath the labia majora (rarely minora) when sebaceous gland ducts are occluded. Besides the palpable, smooth mass, patients are generally asymptomatic. Infection or other complications can be treated with incision and drainage.

Hidradenomas
Hidradenomas (apocrine sweat gland cysts) also occur beneath the labia majora as a result of ductal occlusion. These cysts tend to be more pruritic than sebaceous cysts. They are also treated by incision.

Other Rare Cysts
- Cyst of canal of Nuck: A hydrocele (persistent processus vaginalis), contains peritoneal fluid
- Skene’s duct cyst: Ductal occlusion and cystic formation of the Skene’s (paraurethral) glands
INFESTATIONS

Pthirus pubis
Crab lice ("crabs") are blood-sucking parasites that are transmitted through sexual activity or fomites. Adults lay eggs, which hatch into the lice that cause intense itching.

DIAGNOSIS
A magnifying glass will aid in revealing small brown lice and eggs attached to hair shafts.

TREATMENT
Treat with Permethrin cream or Kwell shampoo (contraindicated in pregnant or lactating women), as well as washing all garments.

Sarcoptes scabei
“Scabies” are also parasitic infections (more contagious) spread by person-to-person contact or via fomites. Patients may present with papular and/or vesicular eruptions on genitals or extremities, as well as with intractable itching. Close observation reveals that the source of itching is the site where adult parasites have burrowed into skin and laid eggs. Adults, larvae, or eggs may be seen.

TREATMENT
Kwell cream or lotion from the neck down, overnight. Crotamiton is applied similarly in pregnant/lactating women and children under 10 years of age.
Menopause

DEFINITIONS

- **Menopause** is the final menstruation marking the termination of menses (defined as 6 months of amenorrhea).
- Menopause is preceded by the *climacteric* or perimenopausal period, the multiyear transition from optimal menstrual condition to menopause.
- The postmenopausal period is the time after menopause.

FACTORS AFFECTING AGE OF ONSET

- Genetics
- Smoking (decreases age by 3 years)
- Chemo/radiation therapy

PHYSIOLOGY DURING THE PERIMENOPAUSAL PERIOD

Oocytes Die

- Women’s immature eggs, or oocytes, begin to die precipitously and become resistant to follicle-stimulating hormone (FSH), the pituitary hormone that causes their maturation.
- **FSH levels rise** for two reasons:
  1. Decreased inhibin (inhibin inhibits FSH secretion; it is produced in smaller amounts by the fewer oocytes)
  2. Resistant oocytes require more FSH to successfully mature, triggering greater FSH release.

Ovulation Becomes Less Frequent

Women ovulate less frequently, initially one to two fewer times per year and, eventually, just before menopause, perhaps once every 3 to 4 months. This is due to shortened follicular phase. The luteal phase does not change.

HIGH-YIELD FACTS IN Menopause

- Average age of menopause in the United States is about 51 years.
- Cigarette smoking is the only factor shown to significantly reduce age of menopause (3 years).
- FSH levels double to ≈ 20 mIU/mL in perimenopause and triple to ≈ 30 in menopause.
Estrogen Levels Fall

Estrogen (estradiol-17β) levels begin to decline, resulting in hot flashes (may also be due to increased luteinizing hormone [LH]). Hot flashes usually occur on the face, neck, and upper chest and last a few minutes, followed by intense diaphoresis.

**PHYSIOLOGY DURING THE MENOPAUSAL PERIOD**

- Levels of androstenedione fall, a hormone that is primarily produced by the follicle.
- Ovaries increase production of testosterone, which may result in hirsutism and virilism.
- Decrease in estradiol level and decrease in estrone level
- FSH and LH levels rise secondary to absence of negative feedback.

The most important physiological change that occurs with menopause is the decline of estradiol-17β levels that occurs with the cessation of follicular maturation. Table 28-1 lists the organ systems affected by those decreased estradiol levels.

### TABLE 28-1.

<table>
<thead>
<tr>
<th>Organ System</th>
<th>Effect of Decreased Estradiol</th>
<th>Available Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cardiovascular</td>
<td>↑ LDL, ↓ HDL</td>
<td>HRT/ERT (see below) results in 50% reduction in cardiac death.</td>
</tr>
<tr>
<td></td>
<td>After two decades of menopause, the risk of myocardial infarction (MI) and coronary artery disease is equal to that in men.</td>
<td></td>
</tr>
<tr>
<td>Bone</td>
<td>Osteoporosis. Estrogen receptors found on many cells mediating trabecular bone maintenance (i.e., ↑ osteoblast activity, ↓ osteoclast activity)</td>
<td>HRT/ERT, Calcitonin, Etidronate (a bisphosphonate osteoclast inhibitor), Calcium supplementation 50% reduction in death from hip fracture with normal estrogen levels</td>
</tr>
<tr>
<td>Vaginal mucous membranes</td>
<td>Dryness and atrophy, with resulting dyspareunia, atrophic vaginitis</td>
<td>HRT/ERT pill or cream</td>
</tr>
<tr>
<td>Genitourinary</td>
<td>Loss of urethral tone, dysuria</td>
<td>HRT/ERT</td>
</tr>
<tr>
<td>Psychiatric</td>
<td>Lability, depression</td>
<td>HRT/ERT</td>
</tr>
<tr>
<td>Neurologic</td>
<td>Preliminary studies indicate there may be a link between low levels of estradiol and Alzheimer’s disease.</td>
<td>HRT/ERT</td>
</tr>
<tr>
<td>Hair and skin</td>
<td>Skin—less elastic, more wrinkled</td>
<td>HRT/ERT pill or cream</td>
</tr>
</tbody>
</table>
TREATMENT OF THE ADVERSE EFFECTS OF MENOPAUSE

Hormone replacement therapy (HRT) or estrogen replacement therapy (ERT) has been shown to counteract the complications of estradiol loss listed in Table 28-1.

**Estrogen Replacement Therapy**

ERT = estrogen only: Indicated in women status post hysterectomy

**Hormone Replacement Therapy**

HRT = estrogen + progesterone: The progesterone component is needed to protect the endometrium from constant stimulation and resultant increase in endometrial cancer. It is indicated for women who still have their uterus.

**Risks of HRT/ERT**

- Increase incidence in breast cancer
- Increase incidence in endometrial cancer (ERT only)
- Thromboembolism
- Cholecystitis/cholelithiasis

Risks can be reduced by beginning therapy years after menopause and/or treatment for only a few years.

**Contraindications to HRT/ERT**

- Unexplained vaginal bleeding
- Breast carcinoma (relative, not absolute, contraindication)
- Metastatic endometrial carcinoma
- Liver disease
- History of thromboembolic disease
- History of MI (ERT/HRT has not shown to be effective in cardioprotection after an MI has occurred)

**High-Yield Facts**

Menopause

- Estrogen creates a hypercoagulable state due to increased production of hepatic coagulation factors.

- HRT possibly increases the risk of breast cancer, but it definitely decreases the risk of coronary artery disease. Consider the following in assessing the risks and benefits of HRT:
  - **Breast cancer** is the most common female malignancy, accounts for about 50,000 deaths/yr.
  - **Coronary artery disease** is the most common cause of mortality, accounts for about 500,000 deaths/yr.
ANATOMY OF PELVIC FLOOR SUPPORT

Several crucial structures make up the support of the female pelvic floor. Disturbance of any of the following can result in prolapse:

- Bony structure
- Broad and round ligaments
- Endopelvic fascia
- Pelvic diaphragm
- Urogenital diaphragm
- Perineum

PROLAPSE

Prolapse is the downward displacement of an organ from its normal position. There are several types.

Types of Prolapse

Prolapses can be classified according to the location of the protruding structure: Anterior, apical, and posterior.

**Anterior**

- Cystocele (bladder)—see Figure 29-1
- Cystourethrocele

![Cystocele](image)

FIGURE 29-1. Cystocele.

Apical
  - Uteroceles
  - Vaginal prolapse

Posterior
  - Rectocele—see Figure 29-2
  - Enterocele (intestine)—see Figure 29-3

Grading of Prolapse

<table>
<thead>
<tr>
<th>Organ displacement</th>
<th>Grade</th>
</tr>
</thead>
<tbody>
<tr>
<td>To the level of the ischial spines</td>
<td>Grade I</td>
</tr>
<tr>
<td>Between ischial spines and introitus</td>
<td>Grade II</td>
</tr>
<tr>
<td>Within introitus</td>
<td>Grade III</td>
</tr>
<tr>
<td>Past introitus</td>
<td>Grade IV</td>
</tr>
</tbody>
</table>

Risk Factors for Prolapse

Many conditions can cause prolapse by disturbing the anatomical supports (childbirth), disrupting the innervations, or increasing the pressure load. The following are some examples:

- Increased load—obesity, cough (e.g., chronic obstructive pulmonary disease)
Loss of levator ani function—postpartum
Disturbance of parts—postsurgical
Loss of innervation—amyotrophic lateral sclerosis (ALS), paralysis
Loss of connective tissue—spina bifida, myelomeningocele

Signs and Symptoms of Prolapse
- Feeling of “pressure”
- Organ protrusion, especially upon exertion
- Incontinence
- Groin pain
- Dysspareunia
- Spotting

Symptom alleviation/exacerbation is often related to pelvic effort (i.e., better when prone, better in the morning, worse with standing, worse in evening).

Diagnosis
Diagnosis is made by direct visualization of prolapsed organ during complete pelvic examination: Patient should be examined in the standing position.

Treatment of Prolapse
- Asymptomatic Prolapse
  - Usually requires follow-up but no immediate intervention
  - Pelvic-strengthening exercises (i.e., Kegel maneuvers) and/or HRT/ERT may benefit.

- Symptomatic Prolapse
  Can be treated with a pessary or surgically

  **Pessary**
  A pessary is an object placed in the upper vagina designed to help maintain support of the pelvic organs. Types include:
  - Smith-Hodge—an oval ring
  - Doughnut (ring)
  - Inflatable
  - Gehring—U-shaped

Surgical Treatment
These are several types of surgical repairs for each type of prolapse.

**CYSTOCELE**
- **Kelly plication** (anterior vaginal repair)—endopelvic fascial reinforcement via vaginal approach
- **Lefort procedure/colpocleisis**—surgical obliteration of the vaginal canal
- **Burch/Marshall–Marchetti–Krantz** procedures—urethrovesical suspension via abdominal approach
- **Sling procedure**—elevation of bladder neck and urethra via vaginal and abdominal approaches

**RECTOCELE**
- **Posterior repair**—posterior vaginal wall reinforcement with levator ani muscles via vaginal approach
ENTEROCELE

Moschovitz repair—approximation of endopelvic fascia and uterosacral ligaments via abdominal approach to prevent an enterocele

UTERINE PROLAPSE

Hysterectomy—a uterine prolapse often occurs in conjunction with another prolapse, and so combined repairs are usually performed.

URINARY INCONTINENCE

Definition
Involuntary loss of urine that is a symptom of a pathological condition. Incontinence can be due to reversible or irreversible (but treatable) causes.

Reversible Causes of Urinary Incontinence
Delerium, infection, atrophic vaginitis, drug side effects, psychiatric illness, excessive urine production, restricted patient mobility, and stool impaction are reversible causes of urinary incontinence.

It is helpful to search out these easily correctable causes before moving on to the more expensive and invasive workup for the irreversible causes.

Irreversible Types of Urinary Incontinence

STRESS INCONTINENCE
Loss of urine (usually small amount) only upon increased intra-abdominal pressure (i.e., with coughing, laughing, exercise): Caused by urethral hypermotility and/or sphincter dysfunction that maintains enough closing pressure at rest but not with exertion

URGE INCONTINENCE
Sudden feeling of urgency followed by complete emptying of bladder: Caused by unopposed detrusor contraction

OVERFLOW INCONTINENCE
Constant dribbling +/- urgency with inability to completely empty the bladder: Caused by detrusor underactivity (due to a neuropathy) or urethral obstruction

MIXED INCONTINENCE
Combinations of above

Evaluation

History
Ask about aforementioned symptoms, medications, medical history (diabetes mellitus, neuropathies)
**Physical**

Pelvic exam: Check for cystoceles, urethroceles, and atrophic changes.
Rectal exam: Check for impaction, and rectocele; assess sphincter tone.
Neuro exam: Assess for neuropathy.

**Labs**

Urinalysis and culture to rule out urinary tract infection

**Q-Tip Test**

A cotton swab is placed in the urethra. The change in angle between the Q-tip and the woman’s body is measured upon straining. Normal upward change is < 30°, and a positive test is one with > 30° change. A positive test indicates stress incontinence.

**Cystometry**

Cystometry provides measurements of the relationship of pressure and volume in the bladder. Catheters that measure pressures are placed in the bladder and rectum, while a second catheter in the bladder supplies water to cause bladder filling. Measurements include residual volume, pressures at which desires to void occur, bladder compliance, flow rates, and capacity. Diagnoses: Stress, urge, and overflow incontinence.

**Urodynamic Studies**

A set of studies that evaluate lower urinary tract function. Studies may include cystometry (see above), bladder filling tests, cystoscopy, uroflowmetry leak-point pressure tests, to name a few. Can help diagnose all types of incontinence.

**Treatment**

**Stress Incontinence**

- Kegel exercises strengthen urethral muscles.
- Estrogen therapy
- Alpha-adrenergic drugs
- Surgical repair (usually Burch procedure or Kelly plication)

**Urge Incontinence**

- Medications:
  - Anticholinergics
  - Calcium channel blockers
  - Tricyclics
- Timed voiding: Patient is advised to urinate in prescribed hourly intervals before the bladder fills.
- Surgery is rarely used to treat urge incontinence.

**Overflow Incontinence**

Due to Obstruction
Relieve obstruction.
Due to Detrusor Underactivity
Treat possible neuro causes:
- Diabetes mellitus
- B₁₂ deficiency
This chapter focuses on women’s health, ages 13 through the postmenopausal years.

**HEALTH MAINTENANCE AND SCREENING TOOLS**

**Pap Smear**
- Yearly beginning at age 18 or when sexually active
- After three consecutive normal Paps in a healthy, low-risk female, screening may be done every 2 to 3 years.

**Manual Breast Exams**
- An annual breast exam should be performed on all women beginning at age 13.
- All women, especially by age 30, should perform self-breast exams once per month (e.g., premenopausal women should examine their breasts one week after their menstrual period).

**Mammography**
- Annually beginning at age 35 if there is family history of breast cancer
- Annually beginning at age 40 for all others

**Colon Cancer Screening**
- Fecal occult blood testing beginning at ages 40 to 50 years
- Sigmoidoscopy starting at age 50, every 5 years (if higher risk, start earlier)
- Colonoscopy every 10 years (especially if inflammatory bowel disease, colonic polyps, colon cancer, or a family history of familial polyposis coli, colorectal cancer, or cancer family syndrome)
Laboratory Testing

**THYROID-STIMULATING HORMONE (TSH)**

Test:
- At age 65 and older, check every 3 to 5 years
- Periodic screening (age 19 to 64) if strong family history of thyroid disease and if autoimmune disease

**CHOLESTEROL**

Test:
- Every 5 years beginning at age 20
- Every 3 to 5 years between ages 65 and 75

Periodic screening if:
- Familial lipid disorder
- Family history of premature coronary artery disease (CAD) (< 55 years)
- History of CAD

**LIPIDS**

Periodic screening if:
- Elevated cholesterol
- History of parent or sibling with blood cholesterol ≥ 240 mg/dL
- History of sibling, parent, or grandparent with premature (CAD) (< 55 years)
- Diabetes mellitus (DM)
- Smoker
- Obese

**FASTING GLUCOSE**

Test:
- Every 3 years beginning at age 45
- Every 3 to 5 years if:
  - Family history of DM (one first- or two second-degree relatives)
  - Obese
  - History of gestational DM
  - Hypertension
  - High-risk ethnic group

**Tuberculosis (TB) Skin Testing**

Recommended for:
- Regular testing for teens
- Human immunodeficiency virus-positive (HIV+) people should be tested regularly.
- Exposure to TB-infected person requires testing.
- Medically underserved/low-income populations

**Sexually Transmissible Infection Testing**

Recommended for:
- History of multiple sexual partners
- History of sex with a partner who has multiple sexual contacts
- Partner has a sexually transmitted disease (STD)
- History of STD
HIV Testing

Recommended for:
- Women seeking treatment for STDs
- History of prostitution/intravenous drug abuse
- History of sex with an HIV+ partner
- Women whose partners are bisexual
- Women transfused between 1978 and 1985
- Women in an area of high prevalence of HIV infection
- Women with recurrent genital tract disease
- Women < 50 years of age who have invasive cervical cancer
- Women who are pregnant or planning to become pregnant

Bacteriuria Testing/Urinalysis

- Periodically for women with DM and women ≥ 65 years of age
- During routine prenatal care

Immunizations

- Tetanus–diphtheria booster once between 13 and 16 years
- Tetanus–diphtheria booster every 10 years
- Measles, mumps, rubella (MMR) for all nonimmune women
- Hepatitis B vaccine for those not previously immunized
- Varicella vaccine if not immune
- Hepatitis A vaccine if at high risk
- Influenza vaccine annually beginning at age 55
- Give influenza vaccine prior to age 55 if:
  - Residents of chronic care facilities
  - Immunosuppression
  - Hemoglobinopathies
  - Women who will be in T2 or T3 during the endemic season
- Pneumococcal vaccine if 65 years of age or sooner if:
  - Sickle cell disease
  - Asplenia
  - Alcoholism/cirrhosis
  - Influenza vaccine risk factors

Preventive Health Information

Nutrition and Exercise

The issues of nutrition and body weight should be emphasized during the three major transitional periods in a woman’s life:

1. Puberty
2. Pregnancy
3. Menopause

One’s body weight is determined by three major factors:

1. Genetics and heredity, which control:
   - Resting metabolic rate
   - Appetite
   - Satiety
   - Body fat distribution
   - Predisposition to physical activity
2. Nutrition
3. Physical activity and exercise

GOALS

1. Maintain a healthy diet consisting of small frequent meals (i.e., four to six instead of two to three):
   - Utilize the Food Guide Pyramid as a tool in making food choices in daily life.
   - Adjust caloric intake for age and physical activity level:
     - As one ages, there is a decrease in resting metabolic rate and loss of lean tissue.
     - Older women who are physically active are less likely to lose lean tissue and can maintain their weight with higher caloric intake.

2. Physical activity during all stages of life should include exercise at moderate intensity for 30 minutes on most days of the week.

SUBSTANCE ABUSE

Alcohol

Women experience more accelerated and profound medical consequences of excessive alcohol than men (a phenomenon called "telescoping"):
- Cirrhosis
- Peptic ulcers that require surgery
- Myopathy
- Cardiomyopathy
- When combined with cigarette smoking → oral and esophageal cancers
- Fetal alcohol syndrome:
  - Teratogenic effects are dose related.
  - Includes growth retardation, facial anomalies, mental retardation

Cigarettes

- Linked to lung cancer and CAD
- Most common factor in chronic obstructive pulmonary disease
- Endocrine effects: Smokers reach menopause earlier and have increased risk of osteoporosis.
- Obstetric effects: Reduced fertility, increased rates of spontaneous abortion, premature delivery, low-birth-weight infants, reduced head circumferences
- Children who grow up exposed to secondhand smoke have higher rates of respiratory and middle ear illness.

SEAT BELT USE

- Deaths due to accidents are greatest in women ages 13 through 39.
- Accidents cause more deaths than infectious diseases, pulmonary diseases, diabetes, and liver and kidney disease.
- Motor vehicle accidents account for 50,000 deaths per year and > 4 to 5 million injuries per year.
- Seat belts decrease chance of death and serious injury by > 50%.
**SAFER SEX PRACTICES**

Improved and successful prevention of pregnancy and STDs by more adolescents requires counseling that includes:
- Encouragement to postpone sexual involvement
- Provision of information about contraceptive options, including emergency contraception and side effects of various contraceptive methods

**FEMALE SEXUAL RESPONSE AND SEXUAL EXPRESSION**

**Female Response Cycle**

**Consists of:**

- **Desire**
  - Begins in the brain with perception of erotogenic stimuli via the special senses or through fantasy

- **Arousal**
  - Clitoris becomes erect.
  - Labia minora become engorged.
  - Blood flow in the vaginal vault triples.
  - Upper two thirds of the vagina dilate.
  - Lubricant is secreted from the vaginal surface.
  - Lower one third of vagina thickens and dilates.

- **Plateau**
  - The formation of transudate (lubrication) in the vagina continues in conjunction with genital congestion.
  - Occurs prior to orgasm

- **Orgasm**
  - Rhythmic, involuntary, vaginal smooth muscle and pelvic contractions → pleasurable cortical sensory phenomenon (“orgasm”)

**Sexuality During Prenatal Through Childhood**

- **Resolution**
  - Sexual development begins prenatally when the fetus differentiates into a male or female.
  - Sexual behavior, usually in the form of masturbation, is common in childhood.
  - As children grow older, they are socialized into cultural emphases on privacy and sexual inhibition in social situations.
  - Between ages 7 and 8, most children engage in childhood sexual games, either same-gender or cross-gender play.

- **Adolescence**
  - Gender identity and sexual preferences begin to solidify as puberty begins.
Menstrual Cycle
The menstrual cycle can affect sexuality (i.e., in some women, there is a peak in sexual activity in the midfollicular [postmenstrual] phase).

Pregnancy
For some women, intercourse is avoided during pregnancy due to fear of harming the baby or a self-perception of unattractiveness.

Postpartum
- Women often experience sexual problems within the first 6 months of delivery.
- Problems may include:
  - Perineal soreness
  - Excessive fatigue
  - Disinterest in sex

Menopause
A decrease in sexual activity is most frequently observed.

Advancing age is associated with decreased:
- Intercourse frequency
- Orgasmic frequency
- Enjoyment of sexual activity:
  - Sexual enjoyment may also be decreased with the increased duration of the relationship and with the partner’s increasing age.

Decreased sexual responsiveness may be reversible if caused by reduction in functioning of genital smooth muscle tissue.

Psychosocially, middle-aged women often feel less sexually desirable.

Hormonal Changes
Estrogen decrease → decreased vaginal lubrication, thinner and less elastic vaginal lining

Estrogen decrease → depressive symptoms → decreased sexual desire and well-being

Disorders of Sexual Dysfunction
It is important to first clarify whether the dysfunction reported is:
- Lifelong or acquired?
- Global (across all partners) or situational?
General Evaluation Strategies

Differentiate between the following possible etiologies:
- Medical illnesses
- Menopausal status
- Medication use (antihypertensives, cardiovascular meds, antidepressants, etc.)

Rule out other psychiatric/psychological causes:
- Life content (stress, fatigue, relationship problems, traumatic sexual history, guilt)
- Major depression
- Drug abuse
- Anxiety
- Obsessive–compulsive disorder

General Management Strategies

- Medical illnesses need evaluation and specific treatment.
- Screen for and treat depression with psychotherapy or medication.
- Reduce dosages or change medications that may alter sexual interest (i.e., switch to antidepressant formulations that have less of an impact on sexual functioning such as bupropion [Wellbutrin] or nefazodone [Serzone]).
  or
- Combine buspirone (Buspar), an antianxiety agent, with a selective serotonin reuptake inhibitor to counteract the sexual side effects.
- Address menopause and hormonal deficiencies.

Sexual Desire Disorders

- **Hypoactive sexual desire disorder**—persistent or recurrent absence or deficit of sexual fantasies and desire for sexual activity
- **Sexual aversion disorder**—persistent or recurrent aversion to and avoidance of genital contact with a sexual partner

Sexual Arousal Disorder

- Partial or total lack of physical response as indicated by lack of lubrication and vasocongestion of genitals
- Persistent lack of subjective sense of sexual excitement and pleasure during sex

**Management**

- Treat decreased lubrication with KY Jelly or Astroglide.
- Menopausal symptoms may respond to oral or topical estrogen.
- Sildenafil (Viagra) may be helpful.
- Referral for psychosocial consultation or therapy if psychological issues exist

**HIGH-YIELD FACTS**

**Women’s Health**

- Sexual intercourse during pregnancy is NOT related to bacterial vaginosis or preterm birth in normal, healthy pregnancies. But there are certain obstetrical conditions in which coitus should be avoided (i.e., placenta previa, abruptio placentae, premature labor, and premature rupture of membranes).

- Little is known about how being a new mother affects sexual desire and response.

- Complaints of sexual arousal disorder are typically accompanied by complaints of dyspareunia, lack of lubrication, or orgasmic difficulty.

- Lack of orgasm during intercourse is considered a normal variation of female sexual response if the woman is able to experience orgasm with a partner using other, noncoital methods.
**Orgasmic Disorder**

Persistent delay or absence of orgasm

**Evaluation**

Differentiate between the following:

- Take sexual experience into account—women often become more orgasmic with experience.
- Physical factors that may interfere with neurovascular pelvic dysfunction (i.e., surgeries, illnesses, or injuries)
- Psychological and interpersonal factors are very common (i.e., growing up with messages that sex is shameful and men’s pleasure only).
- Partner’s lack of sexual skills

**Management**

For lifelong, generalized orgasmic disorder, there is rarely a physical cause. Treat with masturbation programs and/or sex therapy.

**Sexual Pain Disorders**

**Dyspareunia**

Recurrent genital pain before, during, or after intercourse

**Evaluation**

Differentiate between:

- Physical disorder
- Vaginismus
- Lack of lubrication

**Management**

- If due to vaginal scarring/stenosis due to history of episiotomy or vaginal surgery, vaginal stretching with dilators and massage
- If postmenopausal, vaginal estrogen cream to improve vaginal pliability
- Low-dose tricyclic antidepressants may be helpful.
- Pelvic floor physical therapy (Kegel exercises)
- Coital position changes

**Vaginismus**

Recurrent involuntary spasm of the outer third of the vagina (perineal and levator ani muscles) interfering with or preventing coitus

**Evaluation**

- Obtain history.
- Rule out organic causes (i.e., vaginitis, endometriosis, pelvic inflammatory disease, irritable bowel syndrome, urethral syndrome, interstitial cystitis, etc.).
- Examine the pelvis for involuntary spasm.
- Rule out physical disorder or other psychiatric disorder.
Management

- Treat organic causes.
- Psychotherapy
- Provide reassurance.
- Physical therapy (i.e., Kegel exercises, muscle relaxation massage, and gradual vaginal dilatation) (the woman controls the pace and duration)

**DOMESTIC VIOLENCE**

Domestic violence refers to a relationship in which an individual is victimized (physically, psychologically, or emotionally) by a current or past intimate or romantic partner.

**Recognition of the Occurrence of Domestic Violence**

- Injuries to the head, eyes, neck, torso, breasts, abdomen, and/or genitals
- Bilateral or multiple injuries
- A delay between the time of injury and the time at which treatment is sought
- Inconsistencies between the patient’s explanation of the injuries and the physician’s clinical findings
- A history of repeated trauma
- The perpetrator may exhibit signs of control over the health care team, refusal to leave the patient’s side to allow private conversation, and control of the victim.
- The patient calls or visits frequently for general somatic complaints.
- **In pregnant women:** Late entry into prenatal care, missed appointments, and multiple repeated complaints are often seen in abused pregnant women.

**Assessment**

See Table 30-1.

**TABLE 30-1. Abuse Assessment Screen**

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td>Have you ever been emotionally or physically abused by your partner or someone important to you?</td>
</tr>
<tr>
<td>2.</td>
<td>Within the last year, have you been hit, slapped, kicked, or otherwise physically hurt by someone?</td>
</tr>
<tr>
<td>3.</td>
<td>Since you’ve been pregnant, have you been hit, slapped, kicked, or otherwise physically hurt by someone?</td>
</tr>
<tr>
<td>4.</td>
<td>Within the last year, has anyone forced you to have sexual activities? Has anyone in the past forced you to have sexual activities?</td>
</tr>
<tr>
<td>5.</td>
<td>Are you afraid of your partner or anyone you listed above?</td>
</tr>
</tbody>
</table>


---

Menopause and sexual dysfunction:
- Menopause → vaginal atrophy and lack of adequate lubrication → painful intercourse → decreased sexual desire

Many antidepressants alter sexual response by increasing the availability of serotonin and decreasing dopamine.

Estrogen improves overall sense of well-being—probably secondarily improves sexual desire.
Reaction to Domestic Violence

- Listen in a nonjudgmental fashion, and assure the patient that it is not her fault, nor does she deserve the abuse.
- Assess the safety of the patient and her children.
- If the patient is ready to leave the abusive relationship, connect her with resources such as shelters, police, public agencies, and counselors.
- If the patient is not ready to leave, discuss a safety or exit plan and provide the patient with domestic violence information.
- Carefully document all subjective and objective findings. The records can be used in a legal case to establish abuse.

SEXUAL ASSAULT

Sexual assault occurs when any sexual act is performed by one person on another without that person’s consent.

Rape is defined as sexual intercourse without the consent of one party, whether from force, threat of force, or incapacity to consent due to physical or mental condition.

Rape-Related Post-Traumatic Stress Disorder (RR-PTSD)

A “rape-trauma” syndrome resulting from the psychological and emotional stress of being raped

SIGNS AND SYMPTOMS

Acute Phase
- Eating and sleep disorders
- Vaginal itch, pain, and discharge
- Generalized physical complaints and pains (i.e., chest pain, backaches, and pelvic pain)
- Anxiety/depression

Reorganization Phase
- Phobias
- Flashbacks
- Nightmares
- Gynecologic complaints

MANAGEMENT

Physician’s Medical Responsibilities
- Obtain complete medical and gynecologic history.
- Assess and treat physical injuries in the presence of a female chaperone (even if the health care provider is female).
- Obtain appropriate cultures.
- Counsel patient and provide STD prophylaxis.
- Provide preventive therapy for unwanted pregnancy.
- Assess psychological and emotional status.
- Provide crisis intervention.
- Arrange for follow-up medical care and psychological counseling.
Physician’s Legal Responsibilities
- Obtain informed consent for treatment, collection of evidence, taking of photographs, and reporting of the incident to the authorities.
- Accurately record events.
- Accurately describe injuries.
- Collect appropriate samples and clothing.
- Label photographs, clothing, and specimens with the patient’s name; seal and store safely.

TREATMENT

Infection Prophylaxis
- Gonorrhea, chlamydia, and trichomonal infections:
  - Ceftriaxone 125 mg IM + azithromycin 1 g PO in a single dose
  or
  - Doxycycline 100 mg PO bid for 7 days + metronidazole 2 g PO in a single dose
  - Offer the hepatitis B vaccine.
  - Administer tetanus–diphtheria toxoid when indicated.

Postcoital Regimen
- Combined estrogen–progestin pills: Ovral (50 ug ethinyl estradiol, 0.5 mg norgestrel): 2 tabs PO STAT, then 2 more tabs 12 hours later:
  - 75% effective
- Mifepristone (RU 486): A single dose of 600 mg PO:
  - 99.9% effective

ETHICS

It is the physician’s responsibility to:
- Determine the patient’s preferences.
- Honor the patient’s wishes when the patient can no longer speak for herself.

End of Life Decisions
- Advanced directives (living will and durable power of attorney for health care) allow patients to voice their preferences regarding treatment if faced with a potentially terminal illness.
- In the living will, a competent, adult patient may, in advance, formulate and provide a valid consent to the withholding/withdrawal of life-support systems in the event that injury or illness renders that individual incompetent to make such a decision.
- In the durable power of attorney for health care, a patient appoints someone to act as a surrogate decision maker when the patient cannot participate in the consent process.

Life-Sustaining Treatment

Any treatment that serves to prolong life without reversing the underlying medical condition.
Reproductive Issues

The ethical responsibility of the physician is:
- To identify his or her own opinions on the issue at hand
- To be honest and fair to their patients when they seek advice or services in this area
- To explain his or her personal views to the patient and how those views may influence the service or advice being provided

Informed Consent

A legal doctrine that requires a physician to obtain consent for treatment rendered, an operation performed, or many diagnostic procedures

Informed consent requires the following conditions be met:

1. Must be voluntary
2. Information:
   - Risks and benefits of the procedure are discussed.
   - Alternatives to procedure are discussed.
   - Consequences of not undergoing the procedure are discussed.
   - Physician must be willing to discuss the procedure and answer any questions the patient has.
3. The patient must be competent.

Exceptions

The following are certain cases in which informed consent need not be obtained:

1. Lifesaving medical emergency
2. Suicide prevention
3. Normally, minors must have consent obtained from their parents. However, minors may give their own consent for certain treatments, such as alcohol detox and treatment for venereal diseases.

Patient Confidentiality

The information disclosed to a physician during his or her relationship with the patient is confidential.

The physician should not reveal information or communications without the express consent of the patient, unless required to do so by law.

Exceptions

- A patient threatens to inflict serious bodily harm to herself or another person.
- Communicable diseases
- Gunshot wounds
- Knife wounds

Minors

When minors request confidential services, physicians should encourage minors to involve their parents.
Where the law does not require otherwise, the physician should permit a competent minor to consent to medical care and should not notify the parents without the patient's consent.

If the physician feels that without parental involvement and guidance the minor will face a serious health threat, and there is reason to believe that the parents will be helpful, disclosing the problem to the parents is equally justified.

### OFFICE HEALTH MAINTENANCE TESTS

<table>
<thead>
<tr>
<th>Starting Age</th>
<th>Test</th>
<th>How Often?</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age 13–16</td>
<td>Tetanus–diphtheria booster</td>
<td>Once</td>
</tr>
<tr>
<td>&gt; Age 16</td>
<td>Tetanus–diphtheria booster</td>
<td>Every 10 years</td>
</tr>
<tr>
<td>≥ Age 18 (or before if sexually active)</td>
<td>Pap</td>
<td>Annually</td>
</tr>
<tr>
<td></td>
<td>Manual breast exams</td>
<td></td>
</tr>
<tr>
<td></td>
<td>CBC, BUN, creatinine, hemoglobin</td>
<td>Periodically</td>
</tr>
<tr>
<td>≥ Age 20</td>
<td>Cholesterol</td>
<td>Every 5 years</td>
</tr>
<tr>
<td>≥ Age 40</td>
<td>Mammogram</td>
<td>Annually</td>
</tr>
<tr>
<td></td>
<td>Fecal occult blood testing</td>
<td></td>
</tr>
<tr>
<td>≥ Age 45</td>
<td>Fasting glucose</td>
<td>Every 3 years</td>
</tr>
<tr>
<td>≥ Age 50</td>
<td>Sigmoidoscopy or Colonoscopy if high risk</td>
<td>Every 5 years or Every 10 years</td>
</tr>
<tr>
<td>≥ Age 55</td>
<td>Influenza vaccine</td>
<td>Annually</td>
</tr>
<tr>
<td>≥ Age 65</td>
<td>TSH</td>
<td>Every 3–5 years</td>
</tr>
<tr>
<td></td>
<td>Cholesterol</td>
<td>Periodically</td>
</tr>
<tr>
<td></td>
<td>Urinalysis</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Pneumococcal vaccine</td>
<td>Once</td>
</tr>
</tbody>
</table>